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DEPRESSIVE SYMPTOMS AND SURVIVAL AMONG LUNG CANCER 
PATIENTS; BIOMARKERS AND POTENTIAL BENEFITS OF AN IPOD- AND 
MINDFULNESS-BASED INTERVENTION 
 
Chelsea J. Siwik, M.S. 
 
June 10, 2019 
 
Lung cancer patients experience high levels of distress, which commonly 
manifests as depressive symptoms. Importantly, depressive symptoms have demonstrated 
prognostic significance in cancer contexts, although the biological pathways by which 
depressive symptoms lead to poorer survival remain unclear and warrant greater 
attention. In addition to understanding the biological pathways by which depressive 
symptoms accelerate disease, identification of efficacious and effective psychological 
treatments for depressive symptoms are needed to improve both quality and quantity of 
life for cancer patients. Interventions that reduce depressive symptoms and improve 
downstream clinical outcomes are certainty needed; however, because many cancer 
patients face considerable burden, interventions that offer feasibility and accessibility are 
also desirable. Thus, this study has two primary aims: 1) to test the prognostic 
significance of depressive symptoms and explore the role of two biomarkers – cortisol 
and leukocyte telomere length (LTL) – as they relate to the depression-survival pathway 
and 2) to explore the ameliorative role of an iPod and mindfulness-based intervention on 





Non-small cell lung cancer patients (N = 67) who had received a diagnosis within 
five years were recruited to participate in the current study. Participants reported on 
depressive symptoms, provided a blood sample for LTL assessment, and collected home-
based saliva samples for cortisol assessment at both baseline and at a three-month follow-
up. Participants were invited to partake in an optional iPod and mindfulness-based pilot 
intervention that occurred between baseline and follow-up. The intervention involved 
listening to pre-recorded audio tracks adapted from the Mindfulness-based Stress 
Reduction program. A number of statistical tests, including ANCOVAs, hierarchical 
linear regressions, Cox Proportional Hazards regressions, and Kaplan-Meier analyses 
using the log rank test, were conducted to assess hypothesized relationships. Spearman’s 
rank-order correlations were used to assess theoretically derived control variables. 
Variables that were moderately related to outcomes (r > .3, < .5) were adjusted for.  
 Regarding Aim 1, results revealed only clinical, not sub-clinical levels of 
depression at baseline predicted shorter survival; ethnic minorities evidenced greater 
shortening of LTL; and contrary to expectation, an increase in LTL was associated with 
shorter survival. Regarding Aim 2, results revealed that the intervention was associated 
with an increase in depressive symptoms and LTL and shorter survival. Although an 
increase in depressive symptoms was initially observed to be associated with a decrease 
in LTL, upon closer examination, there was an interaction effect. Post-hoc analyses 
revealed that as depressive symptoms increased, LTL only shortened among patients who 






 Although results from the current investigation should be interpreted cautiously 
due to a number of limitations, these findings point to longer LTL as one potential 
biological explanation for the depression-survival relationship among lung cancer 
patients. Surprisingly, the less supported biomarker, LTL, as compared to cortisol, 
emerged as a potential link between depressive symptoms and shorter survival, a 
relationship that warrants continued attention and greater clarification. These results also 
cohesively suggest that the intervention was associated with poorer psychological and 
physical health and poorer clinical outcomes among this small sample of lung patients. 
Contrary to the intended and expected benefits of the pilot iPod- and mindfulness-based 
intervention, it yielded concerning negative associations that cannot be ignored. While a 
number of potential explanations for the current findings are discussed, elucidation of the 
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A cancer diagnosis and treatment are exceptionally stressful experiences that pose 
significant psychological and physical challenges. In addition to the acute stress of 
receiving a life-threatening diagnosis, patients must cope with treatment side effects and 
disruption of social and vocational roles (Andersen, Kiecolt-Glaser, & Glaser, 1994). 
Cancer-related stressors, such as fear of recurrence (Costanzo et al., 2007) and 
psychosocial symptoms (Harrington, Hansen, Moskowitz, Todd, & Feuerstein, 2010) can 
persist beyond treatment into survivorship, demonstrating the potentially profound and 
pervasive impact of on-going cancer-related stress over the course of a cancer journey. 
Lung Cancer 
In addition to stressors common to all cancers, lung cancer patients experience 
disease-specific challenges. Compared to other cancers, lung cancer grows rapidly, 
spreads quickly, and often remains undiagnosed until the disease has progressed to a later 
stage – an indicator of the extent of tumor growth and metastasis – that is a strong 
predictor of survival (Yang et al., 2005). Indeed, 65.1% of lung cancers are diagnosed at 
a late (III or IV) opposed to early (I or II) stage (Siegel, Ma, Zou, & Jemal, 2014). While 
the 5-year survival rate of lung cancer is estimated at 18%, those diagnosed at a later 
stage have a survival rate of less than 5%, and more than half of those with lung cancer 
die within the first year of their diagnosis (Henningfield & Adjei, 2017; Siegel, Miller, & 
Jemal, 2016). Despite efforts to improve diagnostic and treatment methods, the survival 
rate has remained relatively unchanged for the past three decades
	
 2 
(Siegel, Miller, & Jemal, 2018), suggesting there may be other prognostic factors that are 
currently unrecognized. Although immunotherapy, a newer, molecular targeted treatment, 
has demonstrate improvement to the median survival in a limited group of non-small cell 
lung cancer (NSCLC) patients, these therapies are, unfortunately, not available to many 
patients (Massarelli, Papadimitrakopoulou, Welsh, Tang, & Tsao, 2014). In addition to 
the aggressive nature of lung malignancy, lung cancer patients report experiencing high 
levels of disease-related stigma (LoConte, Else-Quest, Eickhoff, Hyde, & Schiller, 2008), 
as lung cancer is often perceived as a self-inflicted disease due to its strong association 
with smoking (Henningfield & Adjei, 2017). Thus, lung cancer patients are among the 
most distressed of all cancer patients (Carlson et al., 2004). 
Depression and Cancer 
Depression is a common psychological manifestation of stress in cancer contexts. 
Estimated at approximately 12.5% (Linden, Vodermaier, Mackenzie, & Greig, 2012), 
depression rates across cancer types exceed those among non-medically ill populations 
by four times (Lutgendorf & Andersen, 2015; Raison & Miller, 2003). Among lung 
cancer specifically, the prevalence of depression has been estimated between 11- 44% 
(Hopwood, Stephens, & Party, 2000; Massie, 2004), which is among the highest when 
compared to other cancers (Linden et al., 2012). Nonetheless, not all cancer patients 
become depressed and depressive symptoms are not explained by disease severity 
(Brown, Levy, Rosberger, & Edgar, 2003), indicating cancer-related stress confers risk 
for depression, but does not predict it (Raison & Miller, 2003). While sadness and other 
vegetative symptoms are common in cancer contexts, and although it can be difficult to 
tease apart (Fisch, 2004), patients with comorbid symptoms of depression suffer from 
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distinct and intensified symptoms that extend beyond typical adjustment and lead to 
marked impairment of functioning (Chochinov, 2001) that can affect treatment 
compliance and clinical outcomes.  
Depression and cancer survival. Mounting evidence points to depression as a 
predictor of shorter survival in cancer (Spiegel & Giese-Davis, 2003). Not only do meta-
analyses indicate depression is predictive of earlier mortality across a number of cancers 
(Satin, Linden, & Phillips, 2009), including lung (Pinquart & Duberstein, 2010), but in a 
different study, depressive symptoms were the most consistent psychological predictor of 
shortened survival compared to cancer-related distress, anxiety, mood, sense of control, 
and perception of physical health, even after controlling for demographic (e.g., age, 
gender) and medical (e.g., cancer site and stage, treatment status) factors (Brown et al., 
2003). Thus, depressive symptomology specifically appears to be a strong prognostic 
indicator of survival in cancer compared to other psychopathologies and distress more 
broadly (Brown et al., 2003), and some have identified depressive symptoms to be as 
important as traditional prognostic indictors of survival including stage at diagnosis and 
disease recurrence (Zimmaro et al., 2018). Furthermore, decreases in depressive 
symptoms obtained via psychosocial interventions have been linked to longer survival 
among breast cancer patients (Giese-Davis et al., 2011; Spiegel, Kraemer, Bloom, & 
Gottheil, 1989). In one randomized control trial (RCT) in metastatic breast cancer, after 
adjusting for medical factors, women with improved depressive symptoms lived almost 
twice as long over a 14 year span as women whose depressive symptoms worsened over 
the course of the year following study entry (Giese-Davis et al., 2011), demonstrating the 
magnitude of untreated depression in cancer contexts. Taken together, although a handful 
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of studies have reported a null association between depression and earlier cancer 
mortality (Spiegel & Giese-Davis, 2003), considerable evidence points to depressive 
symptoms as a predictor of shorter survival in cancer. 
Current gaps. First, despite abundant evidence demonstrating the prognostic 
nature of depressive symptoms across a number of cancers, the mechanisms by which 
depressive symptoms lead to shorter survival in cancer contexts remains unknown. 
Behavioral pathways, such as treatment noncompliance, have been examined as potential 
explanations for this relationship given that depression-related motivation deficits can 
inhibit patients from attending appointments. Indeed, depressed patients are more likely 
to experience breaks in treatment (DiMatteo, Lepper, & Croghan, 2000), which can lead 
to increased risk for earlier mortality (Fesinmeyer, Mehta, Blough, Tock, & Ramsey, 
2010). However, a recent study among head and neck cancer patients identified 
biological, opposed to behavioral, pathways as a significant mediator of the depression-
survival relationship (Zimmaro et al., 2018). In this study, depressive symptoms, 
measured prior to treatment onset, predicted shorter 2-year overall survival. Additionally, 
although depressive symptoms were associated with increased treatment disruption, 
treatment disruption did not mediate the depression-survival relationship, whereas 
treatment response – a dichotomous clinical biological indicator of treatment success – 
did. When entered simultaneously into survival models, depression remained a significant 
predictor, indicating treatment response partially mediated the depression-survival 
relationship. This recent investigation points to biological, opposed to behavioral 
mechanisms as an explanation for the depression-survival relationship. 
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Indeed, many biobehavioral reviews foundational for the field of psycho-
oncology have already proposed a number of biological pathways by which 
psychological distress, including depressive symptoms, may promote poorer cancer 
outcomes (Andersen et al., 1994; Antoni et al., 2006; Armaiz-Pena, Lutgendorf, Cole, & 
Sood, 2009; Eismann, Lush, & Sephton, 2010; Lutgendorf & Sood, 2011; Reiche, Nunes, 
& Morimoto, 2004; Sephton & Spiegel, 2003). Yet, no clear explanation for how 
depressive symptoms lead to shorter survival in cancer has been reported to date, 
necessitating continued effort. The majority of these seminal overviews emphasize the 
role of immune and neuroendocrine biomarkers given that substantial literature has 
demonstrated dysregulation of these systems in depressive and cancer contexts, both 
individually and jointly. However, few comprehensive biobehavioral reviews have 
integrated telomeres, a marker of cellular aging, and the majority of these reviews are 
largely all encompassing, such that they provide detailed explanations of the biological 
underpinnings associated with psychological stress and cancer broadly, but do not focus 
on depressive symptoms specifically. Given that Brown and colleagues (2003) 
demonstrated distinct forms of distress (e.g., depression) have unique effects on survival 
outcomes, broad stress models may not be adequately capturing meaningful, nuanced 
explanations for the depression-survival pathway. Thus, a more specific approach may be 
required to elucidate how depressive symptoms cause shorter survival in cancer.  
Second, despite growing evidence for the prognostic significance of depressive 
symptoms, the treatment of depressive symptoms remain under prioritized in cancer 
contexts. Although efforts to acknowledge and treat comorbid mental illnesses among 
cancer populations have certainly improved (Pirl, 2004), interventions that are both 
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efficacious and effective warrant continued attention to potentially improve both quality 
and quantity of life for cancer patients. Psychosocial interventions have demonstrated 
efficacy in decreasing depressive symptoms in cancer contexts, although less attention 
has been given to mindfulness-based interventions, especially compared to cognitive-
behavioral and supportive group approaches (Li, Fitzgerald, & Rodin, 2012). 
Mindfulness-based approaches, which foster attitudes of acceptance, detachment from an 
anticipated outcome, and emotion regulation by enhancing present moment awareness, 
warrant greater exploration given the lack of control, considerable uncertainty, and 
continual adjustment that accompanies cancer (Carlson et al., 2013). Additionally, given 
the considerable burden many cancer patients face, interventions that promote feasibility, 
through mobile and flexible formats, for example, are desirable. Thus, interventions that 
reduce depressive symptoms and prevent/ameliorate related downstream clinical 
consequences and promote feasibility in cancer populations remain a need. 
Therefore, the current study attempts to begin elucidating how depressive 
symptoms lead to shorter survival and how to efficaciously and effectively treat 
depressive symptoms and related outcomes among NSCLC patients via two primary 
aims: 1) test the prognostic significance of depressive symptoms and the role of two 
biomarkers – cortisol and leukocyte telomere length (LTL) – as they relate to the 
depression-survival pathway and 2) explore the ameliorative role of an iPod-based 
MBSR intervention on depressive symptoms and related outcomes. 
Aim 1: The Potential Role of Two Biomarkers in the Depression-Survival Pathway 
1) Cortisol. Cortisol, a glucocorticoid hormone, has many widespread biological 
functions, implicated in mood, emotional memory, and cognition (Keller et al., 2006). It 
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is both the end product of the hypothalamic-pituitary-adrenal (HPA) neuroendocrine 
stress response and a central communicator between the central nervous system (CNS) 
and the periphery that synchronizes biological function and initiate behavioral action. 
Cortisol secretion, therefore, occurs both in response to stressors and operates diurnally 
on a circadian schedule. 
The neuroendocrine stress response. When threat is detected, a downward 
cascade of biological reactions is initiated via the sympathetic nervous system and the 
HPA axis, resulting in the production of catecholamines and glucocorticoids (cortisol in 
humans), respectively (Sapolsky, Romero, & Munck, 2000). Activation of the HPA axis 
is initiated via secretion of corticotropin release hormone (CRH) from the paraventricular 
nucleus (PVN) of the hypothalamus. The pituitary gland is then stimulated and releases 
adrenocorticotropic hormone (ACTH), which travels via systemic circulation to the 
adrenal gland and stimulates the release of cortisol into the blood (Sapolsky et al., 2000). 
Because cortisol is the product of the neuroendocrine stress response, it is both a 
biomarker of acute and chronic stress, with particular sensitivity to uncontrollable and 
social-evaluative stressors (Dickerson & Kemeny, 2004).  
Although cortisol secretion is adaptive in response to a stressor, as it prepares an 
organism to endure threat (Armaiz-Pena et al., 2009), chronic production of cortisol can 
become maladaptive. Excessive cortisol production can cause desychronization of the 
HPA-axis and other cortisol-related biological systems, disrupting a number of biological 
functions (Pariante & Miller, 2001). Upon chronic exposure to cortisol, glucocorticoid 
receptors (GRs) become desensitized and negative feedback loops fail to regulate cortisol 
levels, eventually causing the system to become blunted. Because GRs are widely 
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distributed across the human body with dense concentrations in certain areas of the brain 
(Rosenfeld, Van Eekelen, Levine, & de Kloet, 1993), it is apparent cortisol has influence 
on a number of diverse biological processes (Weiner, 1992), including neural, 
cardiovascular, immune, and metabolic functions (McEwen, 2008). Consequently, in 
addition to the considerable “wear and tear” chronic stress can ensue on the HPA axis, it 
can also cause widespread biological dysregulation with far reaching consequences, 
including greater risk for disease. For a comprehensive overviews of the extensive inner 
workings of a neuroendocrine response via the HPA axis, see McEwen (2000, 2008) and 
Miller et al. (2007). 
Circadian rhythms. In addition to production of cortisol in response to a stressor, 
cortisol secretion occurs rhythmically on a diurnal schedule (Halberg, 1960). In fact, it is 
becoming more evident that many biological functions in addition to cortisol production, 
such as sleep/wake cycles, cell proliferation, immune activity (Fu & Lee, 2003), DNA 
damage repair mechanisms (Innominato et al., 2014), and cell senescence (Fu & Kettner, 
2013), are regulated via an internal “clock.” This clock appears to function normally 
independent of external cues, but aligns closely with the Earth’s 24-hour rotation 
(Shostak, 2017). These biological circadian rhythms are believed to be evolutionarily 
advantageous as they allow the host’s physiology to naturally adapt to environmental 
surroundings. Although cortisol production is responsive to the environment, circadian 
rhythms allow the CNS to control biological function without taxing limited higher-level 
resources (i.e., conscious thought). Glucocorticoids are one of the primary mechanisms 
by which the suprachiasmatic nuclei (SCN; i.e., the central pacemaker or mammalian 
clock) of the CNS can communicate peripherally to coordinate important biological 
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functions (Innominato et al., 2014). Thus, cortisol secretion follows an endogenous 
diurnal rhythm to facilitate synchronization of these functions (Fu & Lee, 2003). For an 
extensive review on the mammalian central clock and how it coordinates peripheral 
systems, see Dibner et al. (2010). 
Cortisol profiles. Research has identified typical, healthy diurnal cortisol profiles 
as the following: highest levels in the morning upon waking, known as the cortisol 
awakening response (CAR), followed by tapering levels throughout the day, and lowest 
levels prior to sleep between 2100 – 2400 hours (Clow, Hucklebridge, Stalder, Evans, & 
Thorn, 2010). Therefore, steeper diurnal cortisol slopes are considered normal/healthy, 
whereas flattened slopes are aberrant, indicative of circadian and/or HPA dysregulation, 
and have been linked with poorer health outcomes. See Figure 1 for a depiction of a 
normal cortisol profile and a steep slope. Although cortisol rhythms tend to follow this 
daily pattern, cortisol secretion is influenced by a number of factors including exercise, 
sleep, and consumption of food, medication, and other substances (e.g., alcohol, tobacco, 
etc.). Daily mean diurnal cortisol is also influenced by these factors, and can be more 
challenging to interpret, as it is more inter-individually variable. While chronic 
production of cortisol and elevated mean cortisol levels at bedtime are considered 
aberrant, higher overall diurnal mean cortisol is more challenging to classify given that 
cortisol production is influenced by genetics (Ouellet-Morin et al., 2008). In other words, 
diurnal cortisol slope is a more stable marker of circadian rhythmicity as it reflects daily 
pattern, whereas overall diurnal mean cortisol is more susceptible to inter-individual 
variation. Thus, although elevated mean cortisol can be indicative HPA hyperactivity, it 
should be interpreted cautiously, as higher overall mean cortisol does not always reflect 
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aberration. Lastly, CAR, despite substantial discussion in depression literature, has 
significant methodological limitations (Clow, Thorn, Evans, & Hucklebridge, 2004) and 
its significance regarding health outcomes remains complex (Clow et al., 2004). 
Therefore, empirically supported markers of cortisol profiles – mean diurnal cortisol and 
diurnal cortisol slopes - will remain the focus of the current study.  
Taken together, cortisol has become a widely used, reliable biomarker of acute 
and chronic psychological stress (Hellhammer, Wust, & Kudielka, 2009), the 
neuroendocrine stress response (Riad-Fahmy, Read, & Walker, 1980), and systemic 
circadian coordination (Windle, Wood, Lightman, & Ingram, 1998) when assessed and 
interpreted correctly. Because the PVN receives neural input from the SCN, which 
controls the HPA axis and circadian coordination, respectively, the two systems are 
tightly linked (Clow et al., 2010). Thus, given the diagnostic hallmarks of depression, 
which include significant changes to metabolic function (e.g., appetite and sleep), it is not 
surprising abnormal cortisol profiles have been observed among depressed individuals. 
Additionally, because circadian rhythms are central to many biological processes 
including cortisol secretion and cell proliferation (Hrushesky, Lannin, & Haus, 1998), it 
is logical that desychronization of circadian cortisol rhythms has been observed in 
patients with cancer, a disease described by rapid and uncontrolled cell division. 
Depression and cortisol. Substantial literature has linked aberrant cortisol 
profiles and depression. Elevated cortisol was originally observed among depressed 
patients upwards of 50 years ago (Board, Wadeson, & Persky, 1957) and a significant 
number of experiments and subsequent reviews on the depression-cortisol association 
have confirmed HPA axis hyperactivity and diminished sensitivity of GR feedback loops 
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among depressed individuals (Burke, Davis, Otte, & Mohr, 2005; Herbert, 2013; Pariante 
& Miller, 2001). Approximately half of depressed individuals demonstrate an impaired 
recovery response to a dexamethasone suppression test (Gold et al., 1986), which is used 
to assess functioning of GR mediated feedback loops (see Carroll (1984) for a 
comprehensive description and overview). Despite inconsistent prevalence rates, Miller 
et al. (2007) reported a striking effect: depressed individuals have demonstrated cortisol 
levels one standard deviation greater than levels among non-depressed counterparts 
following a dexamethasone test, suggesting meaningful differences in GR-mediated HPA 
axis function.  
With respect to diurnal cortisol rhythms, a couple of small studies have reported 
abnormal circadian profiles – one among men suffering from an acute depressive episode 
(n = 11) compared to age-matched controls (n = 7; Linkowski et al. (1987), and another 
among individuals with MDD (n = 14) compared to individuals with PTSD (n = 15) and 
healthy men (n = 15; Yehuda, Teicher, Trestman, Levengood, and Siever (1996). Both of 
these studies, however, collected multiple samples of cortisol over one day, which has 
been shown to be an unreliable estimate (Segerstrom, Boggero, Smith, & Sephton, 2014). 
In a different study, approximately half of individuals with depression demonstrated 
elevated evening cortisol levels (Claustrat, Chazot, Brun, Jordan, & Sassolas, 1984), a 
marker of abnormal diurnal rhythmicity. Taken together, decades of research have 
identified hyperactivation and subsequent dysregulation of the HPA axis, measured 
through cortisol, as a hallmark of depression (Herbert, 2013; Jehn et al., 2006), although 
the evidence of disrupted diurnal rhythmicity is more limited. Consequently, depression 
has been hypothesized to be a result of chronic activation of the neuroendocrine stress 
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response (Pariante & Lightman, 2008). Despite consistent observation of aberrant cortisol 
in depression, the inconsistencies associated with the type of aberration (e.g., only 50% 
demonstrate elevated evening cortisol levels) are puzzling, but may be explained by 
methodological discrepancies in cortisol assessment. Alternatively, these inconsistencies 
may be indicative of subtypes of depression, as Bonanno’s longitudinal work has 
consistently identified distinct depressive trajectories (e.g., emergent post-event, chronic, 
depressed prior followed by improvement) following a host of stressful events including 
a spinal cord injury (Bonanno, Kennedy, Galatzer-Levy, Lude, & Elfström, 2012), 
bereavement (Galatzer-Levy & Bonanno, 2012), and a medical diagnosis (Morin, 
Galatzer-Levy, Maccallum, & Bonanno), all of which activate the HPA axis. Thus, 
greater exploration into the role of dysregulated cortisol profiles in different depressive 
contexts (e.g., cancer) warrants greater attention. 
The prognostic significance of cortisol in cancer. Miller et al. (2007) stated, 
“stressors that threaten physical integrity, involve trauma, and are uncontrollable,” much 
like cancer, “elicit a high, flat diurnal profile of cortisol secretion” (p. 25). Indeed, 
aberrant diurnal cortisol profiles marking circadian disruption have been linked to poorer 
clinical outcomes in cancer, including tumor development, disease progression (Eismann 
et al., 2010; Fu & Lee, 2003; Hrushesky et al., 1998; Mormont & Levi, 1997), and 
shorter survival in breast (Sephton, Sapolsky, Kraemer, & Spiegel, 2000), renal cell 
(Cohen et al., 2012), lung (Sephton et al., 2013), and ovarian (Schrepf et al., 2015) 
cancer. Although the number of studies examining cortisol and survival in cancer are 
limited, mounting evidence points to the prognostic significance of circadian-regulated 
neuroendocrine disruption in cancer. Because the circadian clock regulates diurnal 
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cortisol and important aspects of the cell cycle, disruption to its function appears to have 
profound influence on tumor development and the host’s survival. Indeed, experimental 
manipulation of circadian disruption of endocrine function has been shown to cause 
spontaneous tumor onset (Filipski et al., 2002; Fu & Lee, 2003) and accelerate growth 
(Sapolsky & Donnelly, 1985) in animal models. Despite the long held belief that the 
circadian clock suppresses tumors (Eismann et al., 2010; Fu & Kettner, 2013), more 
recent evidence suggests, in some circumstances, it may also promote tumorigenesis 
(Shostak, 2017), highlighting the vital, yet debated, role of circadian function on tumor 
behavior. Nonetheless, glucocorticoids have been shown to stimulate growth (Moran, 
Gray, Mikosz, & Conzen, 2000), increase the invasive potential (Sood et al., 2006), and 
inhibit tumor cell death (Volden & Conzen, 2013) in tumor microenvironments. Taken 
together, circadian clock regulated coordination of diurnal cortisol appears to play a 
central role to maintenance of healthy biological functioning on a systemic, cellular, and 
molecular level, and disruptions to this system have been linked to cancer onset, growth, 
and poorer survival. 
Depression and cortisol in cancer. Cortisol appears to be a biological correlate 
of depression and cancer (Pasquini & Biondi, 2007). Elevated bedtime cortisol has been 
associated with depressive symptoms (Lutgendorf et al., 2008) and shorter survival 
(Schrepf et al., 2015) in ovarian cancer patients. Dysregulated diurnal cortisol profiles 
have also been linked with greater vegetative depression, but not stress or distress, among 
ovarian cancer patients (Weinrib et al., 2010). Additionally, a decline in vegetative 
depressive symptoms reported by ovarian cancer patients six months post-surgery was 
associated with reductions in mean bedtime cortisol levels (Schrepf et al., 2013), 
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suggesting patients with improved psychological symptoms also experienced 
improvements in physiological health.  
Jehn et al. (2006) extended these findings beyond ovarian cancer by 
demonstrating greater dysregulation of diurnal cortisol among depressed compared to 
non-depressed cancer patients; although depression and disease status were not 
independent, suggesting the depression-cortisol association could be confounded by 
disease severity. In a different sample, however, depressed compared to non-depressed 
breast cancer patients had significantly lower mean waking cortisol levels at study entry, 
which could not be fully explained by disease status, suggesting a unique association 
between depression and circadian coordinated cortisol function independent of disease 
(Giese-Davis et al., 2006). In a unique study involving a dexamethasone suppression test, 
patients with both depression and cancer demonstrated high plasma cortisol levels 
following the test, indicating disrupted glucocorticoid-mediated feedback loops in the 
HPA axis (Musselman et al., 2001). Depressive symptoms were also correlated with 
plasma cortisol levels in this sample, suggesting HPA dysregulation increased with 
depression severity.  
 In contrast, Sephton and colleagues (2000) reported a null association between 
depressive symptoms and cortisol slopes, which are prognostic of survival, among a 
sample of metastatic breast cancer patients. In a later analysis using a subset of the same 
metastatic breast cancer sample, however, Sephton and colleagues (2009) reported an 
association between greater depressive symptoms and higher waking cortisol and 
“accentuated” cortisol slopes. While these findings are somewhat contrary to expectation 
as higher waking cortisol is typically interpreted as physiologically beneficial, this 
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relationship may be reflective of increases in HPA activity. Taken together, although 
these findings are somewhat inconsistent, majority of the positive associations between 
depression and cortisol were observed among ovarian cancer, whereas most null and 
contradictory findings were among breast cancer patients. Further, the number of studies 
examining depression and cortisol in cancer, let alone cancer survival, is surprisingly 
scarce. Even fewer studies report null or contradictory findings, making it difficult to 
deduce conclusions. Nonetheless, a comprehensive meta-analytic review of 80 studies 
that examined associations between diurnal cortisol slopes and 12 different indices of 
mental and physical health indicated flatter diurnal cortisol slopes were associated with 
10 of the 12 health outcomes, which included depression and cancer, suggesting 
dysregulation of circadian markers correspond to poor downstream health outcomes 
(Adam et al., 2017). 
It is not surprising depressed cancer patients experience earlier mortality (Pinquart 
& Duberstein, 2010; Satin et al., 2009) Theoretically, cancer patients with comorbid 
depression experience compounded cortisol dysregulation, both depression-driven HPA 
axis disruptions as well as aberrations in diurnal cortisol rhythmicity that have been 
linked with tumors. A comprehensive review on the interaction of circadian clock 
regulated cortisol profiles and HPA axis systems by Nadar and collegues (2010) provided 
evidence that the two systems are highly interrelated biologically and that the central 
circadian clock system dictates activity of the HPA axis. It remains intriguing, however, 
that the cortisol aberrations observed in depressed individuals appears to be HPA-related, 
whereas the aberrations associated with cancer seem to reflect dysregulation in diurnal 
cortisol rhythmicity. Thus, although cortisol is a clear correlate of depression and cancer, 
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the nuanced biological underpinnings of the aberrations in cortisol profiles observed 
across conditions are complex and should be interpreted thoughtfully.  
Cortisol and the depression-survival relationship. All together, the literature 
indicates a complex interaction between depressive symptoms, aberrant cortisol profiles, 
and survival in cancer contexts, although the directionality of the relationship between 
depression and cortisol remains unknown. Because the temporal onset of HPA 
dysregulation in depression remains unclear, elucidation of these relationships in the 
context of illness, especially an illness strongly linked to aberrations in cortisol profiles, 
is a challenge. While the role of genetics will be central in clarifying these relationships, 
further examination of these stress factors offer opportunity to begin understanding such 
relationships.  
Dysregulated cortisol profiles have been proposed as a mediator of the 
depression-survival relationship (Cohen et al., 2012; Eismann et al., 2010; Sephton et al., 
2003). Cohen and colleagues (2012) replicated the association between both depressive 
symptoms and aberrant cortisol profiles with shorter survival among renal cell carcinoma 
patients. When controlling for diurnal cortisol rhythms, the strength of the association 
between depressive symptoms and survival time was substantially reduced, suggesting 
aberrant cortisol profiles may have partially mediated the depression-survival 
relationship. However, because the authors reported a null association between 
depressive symptoms and cortisol and did not report if the main effect of cortisol or the 
interaction between depression and cortisol were statistically significant, the analytic 
approach was not clear and did not seem to meet updated criteria for mediation (Chmura 
Kraemer, Kiernan, Essex, & Kupfer, 2008). Further, it is unlikely the authors included 
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the interaction term in the Cox regression models, which is another criterion of mediation 
outlined in the MacArthur approach (Chmura Kraemer et al., 2008). This is problematic 
because it is unclear if depressive symptoms and aberrant cortisol profiles were “working 
together” to cause earlier mortality or if cortisol is truly serves as an explanation for how 
depressive symptoms lead to shorter survival (Kraemer, Stice, Kazdin, Offord, & Kupfer, 
2001), warranting prospective analysis following more rigorous statistical criteria. 
Nonetheless, Cohen and colleagues (2012) only reported partial, opposed to full 
mediation, suggesting other biological processes may also be contributing to this 
pathway. Indeed, substantial literature has already demonstrated a central role of the 
immune system in the intersection of depression, neuroendocrine function, and cancer 
(Costanzo, Sood, & Lutgendorf, 2011; Lutgendorf & Andersen, 2015; Reiche et al., 
2004), yet no evidence exists to date suggests immune markers explain the depression-
survival relationship. A more recent, yet growing body of evidence (discussed below) 
suggests telomeres, typically extracted from leukocytes, may be an important biomarker 
of psychological stress, including depressive symptoms, and clinical outcomes in cancer 
as well. Although empirical exploration continues to unravel the underlying complexities 
of telomere biology, emerging evidence suggests telomeres are intertwined with tumor 
onset and growth, and therefore, survival. Thus, the current study aims to expand on 
current biobehavioral literature by integrating a newer, less amalgamated biomarker – 
telomere length – that holds promise as a contributor to the depression-survival 
relationship. 
2) Telomere length (TL). Telomeres are DNA-based protein structures capping 
the ends of chromosomes that serve to maintain cellular integrity and stability 
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(Blackburn, Epel, & Lin, 2015). Upon each cell division, telomeric DNA is lost, resulting 
in cumulative shortening of telomeres over time; a process that determines how fast cells 
age and when they die (Rivera-Tavarez, 2017). Thus, the slow, cumulative shortening of 
telomeres over the course of the lifespan is consistent with typical, healthy aging; 
however, the loss of TL can be accelerated by environmental factors such as chronic 
stress (Epel et al., 2004), an effect that is observable as early as intrauterine life 
(Entringer et al., 2011), and is inconsistent with typical, healthy aging as it is considered 
premature. Indeed, stress has been experimentally shown to accelerate telomere attrition 
in animal models (Haussmann & Heidinger, 2015; Kotrschal, Ilmonen, & Penn, 2007). 
Therefore, the lifetime decline in TL is influenced by a host of elements including 
genetics, developmental and environment factors, and physiology (e.g., oxidative stress 
exposure; Blackburn (2001). Telomeres are also under control of a biological (mitotic) 
clock, although timing of this clock is related to previous number of cell replications, 
rather than diurnal circadian rhythmicity (von Zglinicki, 2002). Nonetheless, telomeric 
processes including cell proliferation (Fu & Lee, 2003), DNA damage repair mechanisms 
(Innominato et al., 2014), and programmed cell death, or senescence (Fu & Kettner, 
2013), are all regulated via an internal biological “clock,” demonstrating biological 
parallels between cortisol and telomeric function. 
When telomeres become “too short,” the cell initiates a DNA damage response – 
it stops dividing or dies – causing cellular changes that can permanently inhibit tissue 
replacement and subsequent wide-spread genomic instability (Augustine, Maitra, & Goel, 
2017). Cells are only able to divide a finite number of times, known as the Hayflick limit 
(Hayflick, 1965), and when cells approach the limit, they become senescent (Blackburn, 
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2000). The underlying biological role of senescence is to prevent growth arrest (McHugh 
& Gil, 2017), and cells become senescent via two pathways: programmed (naturally 
occurring) and premature stress-induced (Bielak-Zmijewska, Mosieniak, & Sikora, 
2017). Cell senescence is biologically beneficial as it limits excessive cell proliferation 
(e.g., tumor progression) since cells are unable to replicate under such conditions. In 
contrast, cell senescence has been identified as a cause of age related disease, such as 
cancer (McHugh & Gil, 2017), and experimental ablation of senescent cells in mice has 
been shown to extend health (Baker et al., 2011) and life (Baker et al., 2016) by delaying 
onset of age-related pathologies.  
Consistent with other biological systems, when functioning properly in a state of 
homeostasis, cell division is seamless, balanced between cell proliferation and 
senescence. However, stressors commonly disturb homeostasis. The body elicits 
biological responses in response to stress in an attempt to restore equilibrium, a process 
known as allostasis – fluctuations in biological processes to meet the demands of external 
pressures (McEwen & Stellar, 1993). Just as the release of cortisol is adaptive in response 
to perceived stress, but can become maladaptive when chronically activated, cell 
senescence adaptively counterbalances cell proliferation, but can also become 
problematic when the system is strained, telomeres shorten rapidly, and cells become 
senescent prematurely. Telomere shortening and cell senescence are therefore natural 
biological processes that seem to become maladaptive when they occur prematurely at an 
accelerated rate as a result of an unbalanced system, potentially caused by stress. Thus, 
telomeres appear to be yet another biomarker of how “stress gets under the skin” and can 
lead to poorer health. Indeed, aged, senescent cells have been linked with tumor 
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progression and appear to support cancer cell proliferation (Krtolica, Parrinello, Lockett, 
Desprez, & Campisi, 2001), factors that influence the host’s survival. 
Fortunately, telomeres are maintained and can be lengthened by the enzyme 
telomerase, which serves to balance terminal DNA loss during cell proliferation 
(Blackburn, 2000). Without telomerase, cells would continuously divide and shorten at an 
accelerated rate, leading to widespread, premature cell senescence and greater risk of age-
related diseases including cancer and earlier mortality (Blackburn et al., 2015). Although 
telomeres are maintained and lengthened via telomerase, which is required for eukaryotic 
survival, there appears to be a delicate balance between the two and their related 
processes (Blackburn, 2001). Recent work by Margalef and colleagues (2017) 
demonstrated telomerase can compromise cell replication and contribute to telomere 
shortening under certain conditions, highlighting the complex molecular relationship 
between TL and telomerase that is not yet fully understood. The complexity of this 
relationship is further complicated by the fact that telomerase is not the only determinant 
of TL, as growing evidence suggests other biological processes including oxidative stress 
and inflammation can also accelerate TL shortening (von Zglinicki, 2002; Wolkowitz et 
al., 2011).  
Despite the need for elucidation of the interactions between TL attrition during 
cell division, TL maintenance via telomerase, and cell senescence both in and out of 
allostatic contexts, the past two decades of research have identified TL as a robust 
biomarker of cellular aging. When controlling for chronological age, which accounts for 
only 10% of TL variation (Blackburn et al., 2015), and other risk factors, shorter TL has 
been shown to predict all-cause mortality (Needham et al., 2015; Rode, Nordestgaard, & 
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Bojesen, 2015). Demonstrated by within-pair twin analyses, Bakaysa and colleagues 
(2007) evidenced twins with shorter telomeres had a three times greater risk of dying 
compared to co-twins with longer telomeres (Bakaysa et al., 2007), suggesting TL may 
account for all-cause mortality in older age even when controlling for developmental and 
genetic influence. Given that TL has been crowned the biomarker of cellular aging, and 
that both depression and cancer have been conceptualized as age-related diseases 
(Herrmann, Pusceddu, März, & Herrmann, 2018; Lindqvist et al., 2015), it makes sense 
TL has been linked to both depression and cancer independently; however, these 
relationships have rarely been explored simultaneously. In fact, Elizabeth Blackburn, a 
Nobel Prize recipient, and colleagues (2015), have explicitly encouraged further 
exploration into the interaction between psychological distress, telomeres, and disease, as 
they are likely “powerful” and remain relatively “unexplored” (p. 1197). Thus, to adhere 
to the scope of the current investigation, the relationships between depression, TL, and 
cancer will be reviewed briefly. For more comprehensive, detailed reviews, see Lindqvist 
et al. (2015) and Manoliu, Bosch, Brakowski, Brühl, and Seifritz (2018) for a review on 
depression and TL, and Gunes, Avilla, and Rudolph (2017) and Herrmann et al. (2018) 
for a review on TL and cancer.  
Depression and TL. According to Schutte and Malouff’s (2015) relatively recent 
meta-analysis, only 25 studies have examined depression and TL, which is considerably 
less than the existent literature examining the association between depression and 
cortisol. Nonetheless, a growing body of evidence demonstrates a link between 
psychological stress, depressive symptoms, and TL. Simon et al. (2006) demonstrated 
individuals with mood disorders (MDD and bipolar with and without comorbid anxiety) 
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had significantly shorter leukocyte telomere length (LTL) compared to aged-matched 
controls. The three mood disorders were grouped together as significant differences in TL 
were not observed between them, likely due to power restrictions (n = 15). Nonetheless, 
the authors reported a striking effect among the depression-only group: telomere attrition 
represented approximately 10 years of accelerated aging compared to healthy controls, 
demonstrating clinical opposed to statistical significance. Further, Vakonaki and 
colleagues (2018) recently reviewed the current empirical evidence on the relationship 
between psychological illness (schizophrenia, depression, and anxiety) and TL and 
concluded that majority of studies report shorter TL among patients with a psychological 
disorder. Taken together, it seems mental health disparities broadly are linked with 
shorter telomeres. 
 Furthermore, Hartmann and colleagues (2010), among others, have provided 
evidence of an association between depression and shorter TL, independent of other 
mood disorders. A prospective study showed depression predicted shorter LTL at a two-
year follow-up compared to age-matched controls when controlling for potential 
confounds including sex, smoking status, activity, physical health, and body mass index 
(Vance et al., 2018). Further, a relatively recent meta-analysis involving over 21,040 
individuals and 32 studies reported those with depression had 71% greater odds of having 
shorter TL (Schutte & Malouff, 2015). Although the reported effect size of this meta-
analysis was small (r = - .12), the results reflect a difference of approximately 97 
chromosomal base pairs. This finding is meaningful because the minimum TL required to 
maintain stability in human leukocytes is 3.81kb (Lin et al., 2014), demonstrating that a 
small change in TL can have a significant impact despite small statistical magnitude 
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(Blackburn et al., 2015). Further, a more recent meta-analysis reported a moderate to 
large effect size between depression and shorter LTL among 5,369 individuals (Hedge’s 
g = -.55; Darrow et al. (2016). Nonetheless, not all studies reported a significant 
association between depression and TL. In a recent review, Lindqvist et al. (2015) 
evidenced just under half of the included studies (4 out of 11) reported no significant 
differences in LTL between depressed and non-depressed individuals. Additionally, of 
the studies that did reported a significant difference, the effect size ranged from .04 to .98 
with a mean of .41, suggesting that as TL continues to become integrated into inter-
disciplinary research, standardization of assessment procedures need to be established 
and communicated. 
A number of additional inconsistencies regarding the depression-TL relationship 
have been reported. For instance, Schutte and Malouff’s meta-analysis (2015) suggested 
cross sectional associations between depression and TL were stronger than longitudinal 
relationships, which is puzzling, but could explain why a recent prospective study did not 
see a relationship between depression and shorter LTL at an 11-year follow-up among 
1,250 middle aged female nurses (Chang et al., 2018). In contrast, a dose-response 
relationship between depression duration and severity and shorter TL over a four year 
span was observed by Verhoeven et al. (2014), and Wolkowitz et al. (2011) have reported 
proportionally shorter LTL among individuals with a lifetime history of MDD, especially 
when untreated. However, Hartman et al. (2010) and Vance et al. (2018) reported their 
results indicated duration, symptom severity, and treatment did not differentially 
influence TL. Taken together, although a majority of studies report an association 
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between depression and shorter TL (Lindqvist et al., 2015), the strength as well as a 
number of factors related to the relationship remain unclear.  
The prognostic significance of TL in cancer. Given the fundamental role of 
telomere biology during cell proliferation and that cancer is defined as the uncontrolled 
division of cells, it is not surprising telomeres have exploded in cancer research over the 
past two decades (Blackburn, Greider, & Szostak, 2006). Telomeres appear to be shorter 
in cancer cells than cells from normal tissue (Hastie et al., 1990; Heaphy et al., 2010; 
Nakamura et al., 2000; Odagiri et al., 1994), and shorter cancer tissue telomeres have 
been linked with advanced disease, accelerated disease progression, metastasis, and 
poorer survival (Heaphy et al., 2013; Herrmann et al., 2018). Current hypotheses posit 
that as telomeres from cancer cells shorten rapidly and near senescence, telomerase 
facilitates indefinite cell division in an attempt to re-stabilize telomeres, which ultimately 
leads to a state of “immortalization” (Augustine et al., 2017). As such, overexpression of 
telomerase has been observed in 90% of cancer cells and experimentally induced 
inhibition of telomerase limited the number of cancer cell divisions (Kim et al., 1994). It 
has therefore been hypothesized that depletion of telomerase in tumor microenvironments 
would eliminate the cell’s ability to excessively proliferate, although experiments have 
revealed the opposite – eventual loss of telomere function among cells depleted of 
telomerase led to greater tumor progression (De Lange & Jacks, 1999). This research 
indicates that the disruption of the delicate balance between cell division (telomere 
shortening) and telomerase in the tumor microenvironment appears to activate 
tumorigenesis, although the specific timing and mechanisms of this process remain 
unclear (Hackett & Greider, 2002). See Gunes et al. (2017) for an extensive review on 
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telomeric biology and tumors. Taken together, although elucidation of telomeric biology 
in tumor environments continues to unfold, it is becoming clear that telomeres play a 
central role in tumor onset and progression, and therefore, survival in cancer. 
Peripheral TL has also been identified as a prognostic marker in cancer. Typically 
measured as a mean from leukocytes, shorter LTL has been linked to increased risk (Ma 
et al., 2011; Shao et al., 2007; Wentzensen, Mirabello, Pfeiffer, & Savage, 2011; Willeit 
et al., 2010; Wu et al., 2003), earlier mortality (Wentzensen et al., 2011; Willeit et al., 
2010), and shorter survival (Callahan et al., 2017; Renner, Krenn-Pilko, Gruber, 
Herrmann, & Langsenlehner, 2018; Valls, Piñol, Reñé, Buenestado, & Viñas, 2011; 
Weischer et al., 2013; Zhang, Chen, et al., 2015) across a number of cancer types, and a 
few reviews have demonstrated a robust relationship between shorter TL and shorter 
cancer survival. For instance, in one longitudinal study (N = 47,102), shorter LTL was 
associated with reduced survival across multiple cancer types at a 20-year follow-up 
(Weischer et al., 2013). A meta-analytic review by Wentzensen and colleagues (2011) 
involving 25 studies demonstrated patients with shorter TL had higher risk of incidence 
and mortality across a number of cancer types, although the strength and consistency of 
these relationships may have been driven by stronger effects among specific cancers. 
This analysis only included two studies in lung cancer, evidencing a clear 
underrepresentation of this disease type. Lastly, a more recent meta-analysis involving 33 
studies by Zhang and colleagues (2015) supported the association between shorter TL 
and poorer cancer survival (n = 11,429). However, their analysis included studies that 
collected TL from both tumor tissue and blood, which is problematic given the distinct 
biological underpinnings of peripheral telomeres and telomeres collected from tumor 
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microenvironments. Nonetheless, similar to the findings reported by Wentzensen and 
colleagues (2011), upon examination of disease-specific associations between TL and 
survival, Zhang et al (2015) reported variation in the strength of the relationship across 
cancer types, pointing to the importance of examining these relationships in disease-
specific contexts. Of the 27 studies examining overall survival included in the analysis, 
only one study was among lung cancer patients, further demonstrating the need for 
greater inclusion of lung cancer samples in future investigations. 
Consistent with these meta-analytic findings, Callahan and et al. (2017) reported 
shorter LTL predicted shorter disease-specific survival in renal cell carcinoma, but noted 
strong effects among stage-I patients, indicating prognostic significance of LTL early in 
the disease. Puzzling and contradictory findings by Svenson and et al. (2008) 
demonstrated longer TL was prognostic of disease-specific survival among breast cancer 
patients with advanced disease. Others have also reported null and contradictory 
associations between TL and cancer risk (Hou, Zhang, Gawron, & Liu, 2012; Yuan et al., 
2018), although fewer have reported these associations with survival outcomes. Despite 
these discrepancies, promising evidence points to a relatively robust relationship between 
shorter systemic TL and shorter survival in cancer, although this relationship has yet to 
be examined in lung cancer. 
Depression and TL in cancer. TL appears to be an important biomarker in both 
depressed and cancer populations, although only two studies have examined them 
simultaneously, neither of which were among lung cancer. One of the studies, conducted 
among a large sample of bladder cancer patients (n = 464), reported current depressive 
symptoms, both independently and combined with shorter TL, were associated with 
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shorter survival (Lin et al., 2015). The authors reported shorter TL was a stronger 
predictor of survival than depressive symptoms, but the differences were negligible. In 
this sample, patients with depressive symptoms and shorter TL had a 4-times greater risk 
for mortality and shorter disease-free survival compared to patients without depressive 
symptoms and longer TL, suggesting TL accounted for some of the variance explaining 
the depression-survival relationship. However, the authors reported no association 
between depressive symptoms and TL, thus mediation analysis criteria was not met. The 
only other study examining depression and TL in cancer was conducted by Sharpley et al. 
(2018), but survival was not included in the analysis. In this sample of prostate cancer 
patients, irritability, but not depression (both measured via the PHQ-9 depression 
questionnaire), was associated with shorter TL. The authors suggested that because 
depression is typically characterized by irritability opposed to sadness in males these 
results are not unexpected. Although only two studies have examined depression and TL 
in cancer, the results are promising for the possibility that TL may partially explain the 
depression-survival relationship.  
Integration of TL into psychobiological cancer models. There is paucity of 
telomere biology in current biobehavioral cancer models despite mounting evidence 
demonstrating a robust effect of stress on TL (Shalev et al., 2013; Starkweather et al., 
2014), a biomarker that appears to play a central role in tumor onset and progression and 
has been linked to shorter cancer survival. Nonetheless, there have been some attempts to 
integrate telomeres into stress-aging models (Epel, 2009; Epel & Prather, 2018; 
Wolkowitz, Epel, Reus, & Mellon, 2010). Although the causal association between 
psychological stress/depressive symptoms and telomere attrition remains unknown, Epel 
	
 28 
(2009) provided compelling evidence for the downstream effects of chronic stress on 
cortisol disruption and subsequent telomere attrition. In contrast, Wolkowitz and 
colleagues’ (2010) model postulates stress-related biomarkers (e.g., cortisol and TL) 
precede psychiatric and medical symptoms. Although longitudinal and experimental 
studies among humans and animals have demonstrated psychological and experimentally 
induced stress, respectively, can lead to telomere attrition (Epel et al., 2004; Hau et al., 
2015; Herborn et al., 2014; Kotrschal et al., 2007), this does not translate directly to 
psychological illness, such as depression. While Chen et al. (2007) provided evidence for 
depression’s shortening effect on TL, and the majority of the literature suggests 
depressive symptoms precede telomere attrition, Gotlib and colleagues (2015) provided 
evidence suggesting the opposite. The authors demonstrated that at-risk females aged 10 
– 14 whose mothers have depression had significantly shorter telomeres compared to 
peers who did not have a familial risk for depression. These associations were not 
assessed longitudinally, but demonstrated the possibility that telomere attrition could 
have a role in the onset of depression rather than just a consequence. Taken together, 
although it is known psychiatric disorders including depression predict shorter TL, it 
remains unclear if the telomeric shortening process precedes onset of certain disorders 
(Epel & Prather, 2018). Therefore, greater exploration of this association is needed. 
Biological Interplay Between Cortisol and TL. Manipulation of glucocorticoids 
in animal models has helped establish the causal effect of cortisol on TL. In one study, 
experimental exposure to corticosterone, the main glucocorticoid in many species, 
resulted in significantly shorter telomeres during the “late life” phase in seabirds 
compared to controls (Herborn et al., 2014). In a different study, following one year of 
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experimental exposure to stressors during adulthood (intended to mimic experience of 
chronic stressors typical in humans), stress-exposed birds had shorter TL than non-
stressed controls (Hau et al., 2015), although no differences in glucocorticoids were 
observed. These findings further demonstrate the impact of stress on TL, but also the 
possibility that chronic stress may burden cellular aging systems prior to and potentially 
independent of endocrine systems. However, because there are considerable differences 
in stress appraisal and biological processes between non-mammals and humans, the 
generalizability of these findings is limited. Reductions in leukocyte telomerase, implying 
reductions in telomere maintenance, however, have been observed in humans following 
experimental exposure to cortisol (Choi, Fauce, & Effros, 2008). Taken together, 
although the results of these studies demonstrate glucocorticoid cause telomere attrition 
in animal models, the opposite effect is still possible, as the effect of telomere attrition on 
glucocorticoids has not been reported to date. 
Cortisol and TL and the depression-survival relationship. Decades of research 
have evidenced strong associations between depressive symptoms, cortisol profile 
aberrations, and shorter survival in cancer patients. Although TL is a relatively new 
biomarker, supported by far less research and associated with greater uncertainties, 
evidence for associations between these constructs and shorter TL also exists. Certainty, 
fewer investigations have examined depressive symptoms, telomeres, and survival in 
cancer simultaneously, but of the studies that have, lung cancer is markedly 
underrepresented. The causality of the relationships between depressive symptoms and 
each of the two biomarkers remains unconfirmed, yet the integration of depression and 
cancer literature adequately supports the plausibility that aberrant cortisol profiles and 
	
 30 
shorter TL could play a role in the pathway linking depressive symptoms and shorter 
survival in cancer. Thus, it is proposed cortisol profiles, a biomarker of circadian 
coordinated neuroendocrine function, and TL, a biomarker of cellular aging, help explain 
how depressive symptoms lead to shorter survival in lung and other cancers. 
While the elucidation of biological explanations for the depression-survival 
relationship in lung and other cancers is needed, cancer patients with untreated 
depression continue to suffer from poorer quality and quantity of life, pointing to the 
need for efficacious and effective psychosocial interventions. Despite more recent 
improvements in efforts to acknowledge and treat comorbid mental illnesses among 
cancer populations, continued efforts are warranted as they have the potential to mitigate 
the unpleasant experience of depressive symptoms and related downstream clinical 
consequences. Mindfulness-based interventions (MBIs) broadly and Mindfulness-based 
Stress Reduction (MBSR) in particular, have demonstrated promise for reducing 
psychological and biological aspects of stress in cancer populations, although fewer 
studies have examined their role in reducing depressive symptoms and related outcomes. 
Aim 2: Mindfulness-based Interventions in Cancer Contexts 
Since Jon Kabat-Zinn (1982) introduced the first MBI, known as the MBSR 
program, to chronic pain patients at the University of Massachusetts Medical Center in 
1979, the use of MBIs in western health settings has advanced at an accelerated rate (R. 
A. Baer, 2003). Rooted in Buddhist philosophy, mindfulness has been described as 
“paying attention in a particular way: on purpose, in the present moment, and 
nonjudgmentally” (Kabat-Zinn (1994), p. 4). A skill that is typically obtained through 
meditative practice – “the intentional self-regulation of attention from moment to 
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moment” (Kabat-Zinn, 1982), p.34)  – these philosophies and skills, stemming largely 
from Kabat-Zinn’s seminal work, have been adapted into a host of health-related 
interventions. Referred to as the “third wave” of therapy (Hayes, 2004), MBI’s have been 
adapted to reduce symptoms of distress in traditional psychotherapeutic settings as well 
as in medical contexts.  
Despite differences between them, MBI’s, including MBSR, are largely centered 
on acceptance without judgment, practice without attachment to an outcome, and an 
intention to enhance the mind-body connection in order to regain a degree of control over 
one’s well being. Unlike other stress-reducing strategies, such as problem-focused 
coping, which involves direct attempts to change a stressor (Lazarus & Folkman, 1984), 
mindfulness-based strategies are detached from the expectation for things to be different 
via an attitude of acceptance. These theoretical pillars resonate with many aspects of 
chronic illness, including cancer, given that illness typically sources a lack of control and 
considerable uncertainty and requires continual adjustment (Carlson et al., 2013). As 
such, MBSR has been adapted specifically for cancer patients by Carlson and colleagues 
(2010), a program referred to as mindfulness-based cancer recovery (MBCR), 
demonstrating the applicability of mindfulness in cancer contexts.  
The traditional, manualized MBSR program developed by Kabat-Zinn is an 8-
week group intervention that meets weekly for approximately two and a half hours to 
provide participants with instruction, practice, and discussion of mindfulness and 
mindfulness-based skills (e.g., walking, standing, eating, body scan). In addition to 
meditation practices, to obtain “detached self-observation” (Kabat-Zinn (1982), p. 34) 
hatha yoga is included to enhance bodily sensations and strengthen the mind-body 
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connection. Participants are also asked to practice at least 45 minutes per day, six days 
per week between in-person weekly group meetings, and are encouraged to participate in 
a day log (~6 hour) retreat toward the end of the program. For an extensive description of 
the structure and content of the MBSR program, see Kabat-Zinn (1982). Taken together, 
the format of MBSR and MBCR, which mirrors the format of MBSR closely, requires 
considerable commitment and in-person attendance. 
Effectiveness of MBSR in Cancer. Certainly, the in-person group format of 
these interventions likely fosters benefit, potentially in the form of a sense of 
connectedness (Carlson, 2013), social support, and accountability; however, the 
commitment in-person interventions require limits feasibility for some patients, 
particularly those with greater burden and fewer resources. A focus group conducted 
among a small group of lung cancer patients (N = 11) designed to discuss perceptions of 
MBIs identified the following barriers to participation: transportation and financial 
issues, limits to physical functioning, lack of interest, feeling overwhelmed with new 
appointments/obligations, cognitive changes including forgetfulness, and time 
commitment (Lehto & Wyatt, 2013). Further, as MBSR has recently been described as “a 
phenomenon of wealthy white western women” (Carlson, 2018), it is plausible group-
based MBIs may not be appealing to individuals who do not fall into those 
sociodemographic categories.  
To start addressing these barriers, Zernicke and colleagues (2013) conducted an 
online MBCR program to promote feasibility. Although this program reported a small 
(20%) drop out rate, confirming feasibility for this program in mobile format, this 
intervention preserved the group component by requiring a set virtual meeting time each 
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week. Participants essentially formed an online classroom environment equipped with an 
instructor. Thus, this study largely maintained the structure of traditional MBSR despite 
being accessible remotely via a website. Although the intervention demonstrated 
significant improvements in mood disturbance and stress symptoms, it did not shed light 
on whether group participation is an active component or if these changes can be 
achieved through mobile platforms that forego a group commitment. Of the 1,800 
patients invited to participate, only 180 expressed interest with a final enrollment of 62, 
warranting further exploration into the potential benefits of a mobile MBSR program that 
delivers core components (e.g., meditation practice), but does not require group 
involvement.  
Lengacher and colleagues (2018) recently piloted the efficacy and feasibility of an 
iPad-based MBSR(CR) intervention that eliminated the group component among a small 
sample (N = 15) of breast cancer survivors. Results from the study revealed statistically 
significant improvements in psychological and somatic symptoms of depression with a 
large effect size (d = 0.85), in addition to a host of other symptom improvements. 
Additionally, patients described the iPad intervention as “convenient and easy to use,” 
and approximately 87% of the enrolled participants completed the program (p. 527). 
Although a small pilot, this study provides preliminary evidence for the efficacy and 
feasibility of mobile MBSR intervention that forgo the group, face-to-face components.  
Efficacy of MBSR in Cancer. Depressive symptoms. Although the active 
components and mechanisms by which MSBR enhances one’s ability to cope with 
disease, the optimal “prescribed” amount and the optimal intervention time point remains 
unknown (Dobkin & Zhao, 2011; Hunt, Al-Braiki, Dailey, Russell, & Simon, 2018), 
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MBSR has demonstrated efficacy in reducing psychological distress and depressive 
symptoms in cancer contexts (Dobkin & Zhao, 2011; Lengacher et al., 2018; Shennan, 
Payne, & Fenlon, 2011). Two separate meta-analyses that examined the efficacy of 
MBSR interventions among breast cancer patients demonstrated significant 
improvements in depressive symptoms (Huang, He, Wang, & Zhou, 2016; Zainal, Booth, 
& Huppert, 2013); d = 0.575). In contrast, a more recent meta-analysis indicated MBSR 
efficaciously reduced depressive symptoms for all cancers patients except for breast 
cancer (Zhang, Wen, et al., 2015). These contradictory results are somewhat puzzling, 
especially given that the majority of MBI studies have been conducted among breast 
cancer samples.  
Further, although the majority of studies report improvements to stress symptoms 
broadly, some report no improvements to depressive symptoms specifically. For instance, 
in one RCT among cancer patients with varied types of cancers, MBSR did not 
demonstrate a significant reduction in depressive symptoms at a 6-month follow-up 
(Bränström, Kvillemo, & Moskowitz, 2012). In this study, however, the majority of 
patients (86%) had received their diagnosis over a year from study participation, 
suggesting MBSR interventions may be most efficacious when conducted closer to 
diagnosis. Taken together, some of the inconsistent findings regarding MBSR’s effects 
on depressive symptoms may stem from variation in cancer types, assessment time 
frames, and intervention time points in the cancer trajectory (e.g., at diagnosis versus in 
survivorship), necessitating further investigation into the effects of MBSR’s on 
depressive symptom among patients who suffer from cancers other than breast, including 
lung, and at time points more proximal to the intervention.  
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Cortisol. In addition to reducing psychological aspect of stress, MBIs and MBSR 
have demonstrated some, although more mixed, evidence for the efficacy of improving 
aspects of physical health (Ledesma & Kumano, 2009). Although, few interventions to 
date have examined the efficacy of MBSR on markers of cortisol in cancer contexts, 
some evidence exists. For example, Lengacher and colleagues (2012) reported a 
significant reduction in cortisol levels from pre-MBSR following week one and three of 
the 6-week intervention among a sample of advanced (stage III or IV) cancer patients, 
which included lung malignancies (20% of the sample). Although there were no 
significant differences in cortisol levels pre- and post-intervention, only at week one and 
three during the intervention, the authors reported cortisol levels were much lower 
(roughly half) from pre to post, differences that may have been undetected due to a small 
sample size (N = 26). Similarly, Branstrom and colleagues (2013) did not observe effects 
of the MBSR intervention on cortisol at a 3- and 6-month follow-up among women with 
different cancers, but the authors observed a moderating intervention effect – patients that 
participated in the intervention with initially low levels of waking cortisol demonstrated 
an increase whereas those with initially high levels of waking cortisol demonstrated a 
decrease at the 3-month follow-up. Although the implications of these findings are 
somewhat ambiguous, these results suggest MBSR may have the potential to regulate 
aberrant HPA-axis activity, whether initially hyper- or hypo-active.  
Similarly, Carlson and colleagues (2004) reported no changes in diurnal mean 
cortisol or cortisol slope among early staged (I or II) breast and prostate cancer patients 
(N = 59) following an MBSR intervention. However, they did observed fewer elevations 
in evening cortisol post-intervention as well as shifts in abnormal cortisol secretion 
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patterns from an inverted V shape (highest levels in the afternoon) to a V shape (lowest 
levels in the afternoon), reflecting a shift toward more regulated diurnal cortisol profiles. 
Interestingly, upon re-assessment at 6- and 12-months post-intervention (N = 33), a linear 
decrease in overall diurnal mean cortisol, mostly driven by decreases in evening levels, 
was observed across time points (Carlson, Speca, Faris, & Patel, 2007), indicative of a 
healthier diurnal cortisol profile. In a different RCT comparing the effects of an MBCR 
intervention to a group, emotion-focused intervention (SET) and a one-day stress 
management control condition among breast cancer survivors, cortisol slopes were 
maintained in both treatments compared to the control condition, whose slopes became 
flatter (Carlson et al., 2013). Although these results did not demonstrate unique effects of 
MBSR on cortisol profiles, it highlights the potential for decline in neuroendocrine 
function when cancer patients forego psychosocial interventions. Taken together, the 
evidence for the efficacy of MBSR interventions on regulation of cortisol profiles 
remains both mixed and convoluted, but seem to suggest MBSR interventions may delay, 
rather than improve dysregulation of neuroendocrine function that tends to accompany 
tumor progression. However, the majority of studies examining these effects have been 
conducted primarily among certain cancers (i.e., breast) among earlier stages of disease, 
warranting greater attention to other malignancies, especially those typically diagnosed at 
later stages, such as lung. 
TL. Despite the relatively recent surge of both TL and MBIs in stress and cancer 
research, nearly no studies to date have examined them simultaneously. While somewhat 
greater attention has been directed toward the effects of MBIs on TL in non-clinical 
samples (Epel, Daubenmier, Moskowitz, Folkman, & Blackburn, 2009) and has 
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demonstrated some efficacy for lengthening telomeres (Conklin et al., 2018; Hoge et al., 
2013), limited studies have been conducted in and out of cancer populations. One non-
mindfulness-based intervention (phone counseling) among cervical cancer survivors 
reported a moderating effect of decreased distress with increased TL, indicating TL is 
potentially modifiable via psychosocial interventions following reduction in 
psychological distress (Biegler, Anderson, Wenzel, Osann, & Nelson, 2012). The only 
study that has examined the effects of an MBI on TL in cancer contexts to date was 
conducted by Carlson and colleagues (2015). Building on the parent RCT described 
above (Carlson et al., 2013), a sample of distressed breast cancer survivors were 
randomized to the MBCR, SET, or a one-day stress management control condition. 
Results revealed no significant differences in TL between groups post intervention. 
Similar to the cortisol findings, however, there was a trend observed between the 
intervention groups and the control condition – TL in either intervention group (MBCR 
or SET) was maintained, whereas TL decreased among control condition patients. While 
the differences were not statistically significant and the long-term effects were not 
reported, these results point to the possibility that MBSR could contribute to TL 
maintenance (lack of a decrease) over the course of a 3-month intervention period, 
although further investigation is needed. 
The only other intervention study in cancer that examined TL was conducted by 
Ornish and colleagues (2013). The intervention consisted of a host of comprehensive 
lifestyle changes in diet, activity, social support, and stress management, which included 
elements of MBSR (i.e., yoga-based stretching, breathing, meditation, progressive 
relaxation) among low-risk prostate cancer patients that had opted to undergo 
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surveillance opposed to typical treatment. Results from a 5-year follow-up demonstrated 
a significant increase in TL among the intervention group and a decrease in TL among 
the control group, although it is unclear if the improvements stemmed from the stress 
management component or were driven by other aspects of the intervention. Taken 
together, the potential benefits of an MBI on TL among cancer patients remains relatively 
unexplored despite considerable evidence demonstrating psychological distress has 
shortening effects on TL, a biological mechanism that has important implications in 
tumor development and progression. Although the evidence is scarce, MBSR may be one 
avenue to target depressive symptoms and downstream consequences, including TL. 
Survival. Although debated extensively for some time, psychological 
interventions have demonstrated efficacy for improving survival time among cancer 
patients (Andersen et al., 2008; Spiegel et al., 1989). Reviewed comprehensively by 
Spiegel (2011) and Antoni (2013), a number of studies have established compelling 
evidence to conclude psychosocial interventions can foster benefit by enhancing quality 
and quality of life for cancer patients. Despite being one of the most distressed cancer 
type populations (Carlson et al., 2004), the effects of a psychosocial intervention, 
including an MBI, on survival have yet to be tested among lung cancer patients. The 
majority of psychosocial interventions have been rooted in cognitive behavioral therapy 
(CBT) or functioned as an emotional support group and have largely been conducted 
among breast cancer patients/survivors (Antoni, 2013), necessitating greater attention to 




Taken all together, evidence suggests that cancer patients experience high levels 
of distress and depressive symptoms, which have demonstrated prognostic significance in 
cancer contexts. Although the biological pathways by which depressive symptoms lead to 
poorer survival currently remain unclear, evidence points to the dysregulation of 
circadian coordinated neuroendocrine function and cellular aging processes, which can be 
assessed by markers of cortisol and TL, respectively. Current literature points to the need 
for greater exploration into the role of these biological systems in the context of the 
depression-survival relationship. Nonetheless, knowing that depressive symptoms worsen 
both quality and quantity of life in cancer contexts, interventions that efficaciously and 
effectively reduce depressive symptoms that offer feasibility and accessibility are a 
clinical priority. 
Study Aims 
The current study attempts to begin elucidating how depressive symptoms lead to 
shorter survival and how to efficaciously and effectively treat depressive symptoms and 
related outcomes among NSCLC patients. Thus, the primary aims of the current study are 
to 1) replicate the prognostic significance of depressive symptoms and explore the role of 
two biomarkers – cortisol and leukocyte telomere length (LTL) – as they relate to the 
depression-survival pathway and 2) explore the ameliorative role of an iPod-based 
MBSR intervention on depressive symptoms and related outcomes among NSCLC 
patients. Specifically, regarding Aim 1, if depressive symptoms emerge as a significant 
predictor of shorter survival and are significantly associated with a biomarker (cortisol 
and LTL), then the association between the significant biomarker(s) and the depression-
survival pathway will be explored. Additionally, regarding Aim 2, if the iPod-based 
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MBSR intervention attenuates depressive symptoms, then the benefits of the intervention 
will be explored among biological and clinical outcomes. In accordance with the primary 
aims of this study, the following hypotheses are outlined below and visually presented in 
Figure 1. 
Hypotheses 
Aim 1. Hypothesis 1a. More depressive symptoms will predict shorter survival. 
Hypothesis 1b. More depressive symptoms will be associated with greater cortisol 
dysregulation (higher overall mean and bedtime cortisol and flatter diurnal cortisol 
slopes). 
Hypothesis 1c. More depressive symptoms will be associated with shorter LTL. 
Hypothesis 1d. If hypothesis 1a and 1b emerge as significant, then greater cortisol 
dysregulation will be associated with both depressive symptoms and shorter survival.  
Hypothesis 1e. If hypothesis 1a and 1c emerge as significant, then shorter LTL 
will be associated with both depressive symptoms and shorter survival.  
Aim 2. Hypothesis 2a. Participation in and use of the intervention will be 
associated with fewer depressive symptoms from baseline to follow-up. 
Hypothesis 2b. Participation in and greater use of the intervention will be 
associated with improved diurnal cortisol rhythmicity from baseline to follow-up. 
Hypothesis 2c. Participation in and greater use of the intervention will be 
associated with maintenance of LTL (lack of a decrease) from baseline to follow-up. 
Hypothesis 2d. Participation in and use of the intervention will be associated with 





Data were collected as part of a larger study investigating the prognostic 
significance of circadian disruption in lung cancer patients (University of Louisville IRB 
13.0508). 
Participants 
NSCLC patients were recruited from the James Graham Brown Cancer Center 
with the assistance and support of collaborating medical staff, such as oncologists and 
nurses. Eligible patients were diagnosed with non-small cell lung cancer within five years 
of study entry, were ages 18–85, resided within a 120-mile radius of the recruitment 
center, had no medical diagnosis likely to influence six-month survival, no immune-
compromising condition, and no recent history of psychiatric hospitalization or substance 
abuse. A total of 65 patients met inclusion criteria and consented. 
Procedure 
Recruitment. Recruitment personnel checked eligibility criteria using a 
standardized chart review. Following identification of eligible participants, collaborating 
physicians introduced patients to study personnel during their scheduled appointment. 
Recruitment personnel provided patients with an overview of the study, answered 
questions, and obtained informed consent from those willing to participate. All study 
procedures were conducted in accordance with University of Louisville Human Subjects 
Protection Program guidelines.  
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Baseline data collection. Participants received detailed instructions and materials 
for 10-day at home baseline data collection. Materials included a packet containing a 
battery of questionnaires to be completed in one sitting, a packet of daily questionnaires 
to be completed each morning and night over the course of the 10 days, and a salivary 
cortisol kit containing 20 salivettes. Prior to leaving the clinic, participants completed a 
blood draw for telomere length assessment conducted by a trained phlebotomist. Study 
personnel called participants mid-way through data collection (approximately day five) to 
check-in, provide reminders, and answer questions regarding data collection. Following 
the baseline data collection, study personnel collected materials from participants, 
compensated their efforts with a $100 Visa gift card, and re-introduced the iPod-based 
MBSR intervention in detail.  
iPod- and mindfulness-based pilot intervention. Study personnel introduced 
mindfulness to participants as a distress-reducing technique, invited participants to attend 
a bi-weekly drop-in mindfulness-based cancer support group, and provided participants 
with an iPod containing mindfulness audio tracks. The audio tracks were recorded by 
clinical psychologist and co-investigator, who is both knowledgeable and skilled in 
mindfulness practice. The tracks were based on the Mindfulness-based Stress Reduction 
(MBSR) program (Kabat-Zinn, 1982). Some of the tracks provide instructional narratives 
about the foundations of mindfulness, whereas others function as guided meditation on 
eating, breathing, listening, thinking, feeling and the body as a whole. A list of tracks is 
provided in Table 1. Participants that agreed to participate in the optional pilot 
intervention were taught how to use the device, and to enhance feasibility and adherence, 
patients were asked to listen to tracks of their choice for 30 minutes per day, five days per 
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week. Although the iPods documented which tracks were selected and completed, 
participants were also provided with a log to document listening behavior. Participants 
returned their iPods and listening logs at their  three month follow-up appointment. Over 
the course of the three month intervention, study personnel called to check-in, provide 
reminders, and answer questions about the intervention at approximately one and two 
months. Study personnel downloaded track data using iTunes software and returned the 
iPod to participants to compensate their intervention participation efforts. 
Follow-up data collection. Regardless of whether patients opted to participate in 
the intervention, they were asked to attend a  three month follow-up appointment at the 
Cancer Center. Similar to baseline data collection, participants were provided with 
instructions and materials for at home data collection, but for six instead of 10 days. 
Materials included a packet containing a battery of questionnaires to be completed in one 
sitting, a packet of daily questionnaires to be completed each morning and night over the 
course of the six days, and a salivary cortisol kit containing 12 salivettes. Participants 
provided another blood sample prior to leaving the clinic. Following follow-up data 
collection, study personnel met with participants to collect materials, provide them with a 
second $100 Visa gift card to compensate them for follow-up data collection efforts, and 
obtain feedback about the study.  
Salivary cortisol. Collection. Participants were asked to collect two saliva 
samples per day – one immediately upon waking and the other as close to bedtime as 
possible for 10 and six consecutive days of baseline and follow-up data collection, 
respectively, to enable calculation of diurnal cortisol profiles. The salivary cortisol kit 
that participants received for baseline and follow-up contained 20 and 12 “salivettes,” 
	
 44 
respectively. The salivettes were pre-labeled and arranged consecutively by day and time 
with space for participants to record their assigned study ID, the date, and the exact time 
that the sample was collected in sharpie. Salivettes were also color coordinated by 
collection time; salivettes to be collected at waking had yellow labels whereas bedtime 
salivettes had blue labels to maximize likelihood of participants’ accuracy.  
To collect a sample, participants were instructed to remove the salivette cap, place 
the cotton swab in their mouth for approximately two minutes, or until the swab was fully 
saturated. While the cotton swab was in the participants’ mouths, they were advised to 
record their study ID, the date, and time of collection on the tube. Participants were then 
asked to spit the saturated cottons swab back into the salivette tube, replace the salivette 
cap, and store the sample in the refrigerator in the provided Ziploc bag. Participants were 
instructed to keep collected saliva samples in the refrigerator until materials were 
returned to study personnel. Participants were instructed not to put anything in their 
mouth – eat, drink, smoke, chew gum, brush their teeth, etc. – 30 minutes prior to 
collection a sample to minimize contamination of cortisol. The importance of collecting 
morning samples immediately upon waking, recording the exact time that the sample was 
collected, and reporting any deviations from the protocol was explained to participants by 
study personnel. To enhance adherence and accuracy, participants were advised to keep 
the salivary cortisol kit next to their bedside. The daily questionnaire packet participants 
were asked to complete each morning and night contained detailed instructions for saliva 
collection and space to record deviations from the protocol as needed.  
Assay. Once study materials were returned, saliva samples remained in the 
refrigerator until they were prepared to be assayed. The majority of the samples were 
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prepped within a few days of collection of the last sample, although no samples were 
prepped beyond one month of the at home collection of the last sample. Saliva samples 
were centrifuged for 15 minutes at 453 g at 25°C. Samples were then aliquoted into 
microcentrifuge tubes and stored at -80°C until they were assayed. Cortisol levels were 
then assed using an enzyme-linked immunoabsorbent assay (ELISA; Salimetrics, Inc., 
State College, PA). Assay sensitivity was 0.007 µg/dL. The average inter-assay and intra-
assay coefficients of variation (CV) were under 10% for both the low and high control. 
Leukocyte telomere length (LTL). Collection. Blood samples were collected in 
K2 EDTA purple top tubes during baseline and follow-up appointments at the Cancer 
Center and were kept on ice until they were transferred to the laboratory by study 
personnel. At the laboratory samples were centrifuged at 1300 RCF for 10 minutes at 
4°C. The layer of plasma on top of each tube was transferred via pipet into 3-5 (volume 
dependent) 1.5 mL microcentrifuge tubes that were kept on ice. The remaining cell pellet 
(red blood cell + white blood cell) at the bottom of each tube was also transferred via 
pipet into 3-5 (volume dependent) 1.5 mL microcentrifuge tubes that were kept on ice. 
All tubes were then frozen immediately at -80°C. This procedure did not exceed two 
hours from the blood draw.  
Following completion of data collection, a total of 107 (67 baseline and 40 
follow-up) frozen blood cell pellet samples were packed and shipped from the University 
of Louisville to Dr. Elizabeth Blackburn’s laboratory at the University of California San 
Francisco. Shipping procedures adhered to the University of Louisville’s Department of 
Environmental Health and Safety protocol. Grant funds were used to compensate Dr. Jue 
Lin of Dr. Blackburn’s Laboratory, who conducted telomere length assays using an 
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adapted protocol (Lin et al., 2010) from methodology originally outlined by Cawthon 
(2002).  
Assay. The following methodological description of the assay process was 
provided by Dr. Lin, “A telomere (T) primer and single copy gene (S) primer pair were 
prepared. The primers used for the telomere polymerase chain reaction (PCR) were 
tel1b [5'-CGGTTT(GTTTGG)5GTT-3'], used at a final concentration of 100 nM, 
and tel2b [5'-GGCTTG(CCTTAC)5CCT-3'], used at a final concentration of 900 nM. The 
primers used for the single-copy gene (human beta-globin) PCR were 
hbg1 [5'GCTTCTGACACAACTGTGTTCACTAGC-3'], at a final concentration of 300 
nM, and hbg2 [5'-CACCAACTTCATCCACGTTCACC-3'], at a final concentration of 
700 nM. The final reaction mix contained 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 200 
mM each dNTP; 1% DMSO; 0.4x Syber Green I; 22 ng E. coli DNA per reaction; 0.4 
Units of Platinum Taq DNA polymerase (Invitrogen Inc.) per 11 µl reaction; ~6ng of 
genomic DNA. Tubes containing 26, 8.75, 2.9, 0.97, 0.324 and 0.108ng of a reference 
DNA (a commercial genomic DNA from pooled leukocytes from Roche Diagnostics 
Corporation, Indianapolis, IN) are included in each PCR run so that the quantity of 
targeted templates in each research sample can be determined relative to the reference 
DNA sample by the standard curve method. The same reference DNA was used for all 
PCR runs. 
The telomere thermal cycling profile consisted of cycling for telomeric (T) PRC: 
96°C for 1 minute; denature at 96°C for 1 second, anneal/extend at 54°C for 60 seconds, 
with fluorescence data collection for 30 cycles and cycling for single copy gene (S) PCR: 
96°C for 1 minute; denature at 95°C for 15 seconds, anneal at 58°C for 1 second, extend 
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at 72°C for 20 seconds, 8 cycles; followed by denature at 96°C for 1 second, anneal at 
58°C for 1 second, extend at 72°C for 20 seconds, hold at 83°C for 5 seconds with data 
collection for 35 cycles. 
To control for inter-assay variability, 8 control DNA samples are included in each 
run. In each batch, the T (telomeric) /S (single copy gene) ratio of each control DNA is 
divided by the average T/S ratio for the same DNA from 10 runs to get a normalizing 
factor. This is done for all 8 samples and the average normalizing factor for all 8 samples 
is used to correct the participant DNA samples to get the final T/S ratio. The T/S ratio for 
each sample will be measured twice. When the duplicate T/S value and the initial value 
vary by more than 7%, the sample will be run the third time and the two closest values 
were reported. The average CV for this study was 2.4%.” 
Survival data. An electronic chart review was conducted on February 15th, 2019 
at the Cancer Center, which revealed a survival rate sufficient for analysis (46.3%; Bland 
and Altman (2004). The date of death was recorded and entered into SPSS for any 
participant who had passed away. It is expected, that as of the cut off date (2/15/19), 
survival data may lag behind actual data by approximately six months. 
See Figure 3 for a visual depiction of the phases of the study when variables of 
interest were collected. 
Measures 
Demographic and medical variables. Medical and demographic variables were 
gathered via self-report and confirmed through medical chart review and are summarized 
in Table 2. Smoking history was quantified as ‘pack years,’ which reflects the product of 
number of packs of cigarettes per day by years of smoking. 
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Depressive symptoms. The packet of questionnaires completed by participants 
during baseline and follow-up data collection included the Center for Epidemiological 
Studies – Depression (CES-D; Radloff (1977), which was used to measure depressive 
symptoms. The CES-D is composed of 20 items that assess depressive symptoms over 
the past week on a four-point scale ranging from “rarely or none of the time (less than 
one day)” and “most of all of the time (5-7 days).” The total score is comprised of the 
sum of the 16 depressive symptoms items and the reverse score of the four positive affect 
items. Scores greater than 16 indicate risk for clinical depression. The CES-D is a 
commonly used measure of depressive symptoms among medically ill populations, 
including cancer. Among breast cancer patients, the CES-D has demonstrated high 
internal consistency (Cronbach α = 0.85), adequate test-retest reliability, and construct 
validity (Hann, Winter, & Jacobsen, 1999). In the present study, internal consistency was 
acceptable and good at baseline and follow-up (Cronbach α = .77; .83), respectively.  
Cortisol. Salivary cortisol was collected at two time points over the course of 10 
days based on empirically driven recommendations for reliable between-person cortisol 
estimates for calculation of diurnal cortisol slope (Segerstrom et al., 2014). However, to 
lessen the burden and increase likelihood of participation, follow-up cortisol data 
procedures were reduced to six days of at home collection. After samples were assayed, 
the CV was checked. 





Data preprocessing.  Data preparation and analyses were conducted using SPSS 
v25.0 (SPSS IBM, Armonk, NY, 2017). Data was entered by two research assistants 
separately in independent datasets and subsequently compared to ensure accuracy.  
Data reduction and scoring.  Sample characteristics. Characteristics of the 
sample were determined by calculating frequency, percentage, and mean data on 
demographic and medical factors and are provided in Table 2. 
Depressive symptoms. Summary scores were calculated for the CES-D assessed 
at baseline and follow-up. For less than 50% of data missing from the CES-D, missing 
data points were replaced using the mean of other responses. If a participant missed more 
than half of the questionnaire, missing data was not replaced.  
Cortisol. Raw cortisol data consisted of an exact collection time from the saliva 
collection tubes and a laboratory-generated cortisol value (µg/dl) from the assay. Sample 
collection times reported by subjects were checked and corrected using wrist-worn 
actigraphy data, which was collected for aims of the parent study. Cortisol samples 
collected more than 15 minutes after waking (as determined by the actigraphy data) were 
excluded. Raw cortisol values were log-transformed to adjust for positive skew. Diurnal 
mean cortisol values were calculated for waking, bedtime, and overall mean using log-
transformed values for each individual. Cortisol values were also regressed on collection 
time to calculate a diurnal cortisol slope for each individual (Sephton, 2000; Sephton et 
al., 2013). The regression of 20 values (waking and bedtime collected over 10 days) and 
12 values (waking and bedtime collected over six days) were calculated for baseline and 
follow-up, respectively. The unstandardized beta (slope of the regression) represents the 
diurnal salivary cortisol slope (Kraemer et al., 2006). Diurnal slopes are typically 
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negative with higher values indicative of flattened slopes. Thus, three indicators of 
diurnal cortisol included in analyses included: 1) log-transformed overall mean, 2) log-
transformed bedtime mean, and 3) diurnal slope using log-transformed values. Waking 
mean will be excluded as a variable in the analysis as it has not previously demonstrated 
distinct associations with depression or survival in cancer, whereas overall mean (Board 
et al., 1957), bedtime mean (Schrepf et al., 2015), and slope (Sephton et al., 2013) have. 
Intervention. Because the intervention was a pilot, presented as optional, and 
lacked a randomized control group, participants’ participation status was coded as 
participated (n = 25) or not (n = 42). Using the data logged by the iPod and downloaded 
by study personnel following the intervention, variables indicating total listening time 
and total number of tracks listened to were created. Prior to calculation of variables, the 
listening log that participants completed by hand was used to crosscheck the data 
recorded by the device.  
Survival. A categorical variable (yes/no) indicating whether the patient had died 
(all cause mortality) as of February 15, 2019 was created. The amount of time (in days) 
from date of study entry to date of death was calculated for patients who had died. For 
living patients, this tracking variable reflects the number of days from study entry to the 
cessation of tracking on February 15th, 2019. Survival or tracking time (in days) was also 
calculated from each participant’s date of diagnosis to either date of death or the date of 
tracking cessation (e.g., February 15, 2019). 
Analytic approach. The overall analytic approach followed the MacArthur 
approach (Chmura Kraemer et al., 2008) and recommendations outlined by Kraemer and 
colleagues (2001). Prior to regression analysis, all continuous independent and control 
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variables (e.g., age at diagnosis) were median centered and binary control variables (e.g., 
sex) were effects coded (i.e., -1/2, +1/2) to improve interpretation and minimize error 
(Kraemer & Blasey, 2004).  
Theoretically derived control variables were identified for each dependent 
variable. A data driven approach was then taken to test the contribution of each proposed 
variable using Spearman’s rank-order correlations. According to Kraemer and colleagues 
(2001) indicators that are only associated with the dependent variable should be entered 
into the first step of the model as a covariate, whereas indicators that are associated with 
both the independent and the dependent variable should be entered into the first step of 
the model as a ‘proxy’ with the independent variable and the interaction between the two. 
‘Proxy risk factors’ are risk factors, but are correlates of the independent variable, an 
association that should be accounted for according to Kraemer et al. (2001). This 
approach was taken for the current analysis. Thus, the association between each 
theoretically derived covariate and the independent and dependent variable was examined 
prior to the proposed analysis. Indicators were included in the model if they demonstrated 
a strong enough relationship with the dependent and/or independent variable (effect size 
> 0.3) to ensure contribution without increasing risk of multicollinearity (effect size < 
0.5). Additionally, because the intervention was not randomized, intervention 
participation status (yes/no) was also tested as a covariate in all models that included a 
longitudinal variable.  
Preliminary analysis. Data were explored and tested for assumptions of 
parametric data, including tests for normality, significant outliers, linearity, and 
homoscedasticity (Field, 2013). All variables were examined for outliers; scores greater 
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than four standard deviations from the mean were assessed for removal prior to analysis. 
Scatterplots, boxplots, histograms, and Predicted probability (P-P) plots were examined 
for each continuous variable. Skewness and kurtosis statistics were calculated for 
continuous variables by dividing the statistic by the standard error. Those that failed to 
meet assumptions by visual inspection or by z-skewness values outside of the 95% 
confidence interval (values > 1.96) were assessed for transformation. Variables were 
transformed according to the parameters provided by Field (2013). All transformed 
variables were re-assessed for assumptions prior to analysis.  
Additional assumptions were checked prior to conducting ANCOVA tests. To 
confirm the independence of the covariate and treatment effect, independent-samples t-
tests were conducted between the independent variable and the covariant to ensure that 
the covariate was independent of the treatment effect. As a part of the analysis, the 
Levine’s test was used as a preliminary assessment of the homogeneity of regression 
slopes analysis. 
All other assumptions for survival statistical tests (i.e., Kaplan-Meier using log 
rank and Cox Proportional Hazards regressions) were confirmed prior to running 
analyses.  
Primary analysis. In addition to examining each hypothesized association 
including constructs assessed at baseline, to examine change in constructs over time 
(from baseline to follow-up), a within-subjects regression coefficient analysis was 
conducted on depressive symptoms, markers of cortisol, and LTL for each participant. In 
other words, for each participant, the slope of change (from baseline to follow-up) and 
intercepts were calculated for depressive symptoms, markers of cortisol, and LTL. Each 
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variable (e.g., depressive symptoms) was regressed on collection time points – baseline 
and follow-up – to calculate a slope of change (the unstandardized beta) using a linear 
regression. Thus, the calculated slope represents a change (e.g., in depressive symptoms) 
over the intervention period for each participant, regardless of participation status. The 
intercept value was entered as a covariate to control for baseline individual differences.  
Regarding loss to follow-up, analyses were first conducted with the available 
data. Analyses were subsequently conducted handling missing data using the intent-to-
treat principles outlined by Lachin (2000). Following these principles, baseline values 
were used to replace missing values at follow-up, resulting in a slope of zero (i.e., no 
observed change).  
Covariates. Spearman’s rank-order correlations were used to assess the 
contribution of theoretically derived indicators in cancer samples for each independent 
and dependent variable. Theoretically derived and tested indicators of survival, 
depression, and markers of cortisol included: disease stage, age, age at diagnosis, sex, 
prior/current treatment (chemotherapy/radiotherapy), and tobacco history in pack-years. 
Theoretically derived and tested indicators of LTL included: disease stage, age, age at 
diagnosis, sex, prior/current treatment (chemotherapy/radiotherapy), tobacco history in 
pack-years and ethnic minority status. Results from these analyses were used to 
determine inclusion of covariates in the subsequent analyses (see Tables 3 – 5).  
Aim 1. Hypothesis 1a. Baseline. To test the prognostic value of baseline 
depressive symptoms on survival calculated from the date of study entry and the date of 
diagnosis two separate two-tailed Cox Proportional Hazards regressions were conducted. 
Sex was entered into the first step of the model as a covariate on survival calculated from 
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study entry (Table 3). Each model was run with and without intervention participation 
status included as a covariate. 
Slope of change and intent-to-treat principles. To test the prognostic value of 
change in depressive symptoms on survival calculated from the date of study entry and 
the date of diagnosis, two separate two-tailed Cox Proportional Hazards regressions were 
conducted. Sex was entered into the first step of the model as a covariate on survival 
calculated from study entry (Table 3). Each model was run with and without use of the 
intervention included as a covariate. The same analyses were subsequently conducted 
using intent-to-treat principles outlined by Lachin (2000); i.e., baseline values were used 
to replace missing values at follow-up, resulting in a slope of zero (i.e., no observed 
change), resulting in a total of eight regressions. 
Hypothesis 1b. Baseline. To test the baseline association between depressive 
symptoms and markers of diurnal cortisol profiles (overall mean, bedtime mean, and 
diurnal slope), separate hierarchical linear regressions were conducted. Each marker of 
cortisol was tested as the outcomes in separate models. Age at study entry and age at 
diagnosis were entered into the first step of two separate models as a covariate on 
bedtime mean cortisol (Table 4).  
Slope of change and intent-to-treat principles. To test the association between 
change in depressive symptoms and change in cortisol profiles (overall mean, bedtime 
mean, and diurnal slope), separate hierarchical linear regressions were conducted. Each 
marker of cortisol was tested as the outcome in separate models. Each model was run 
with and without use of the intervention included as a covariate. The same analyses were 
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subsequently re-conducted using intent-to-treat principles outlined by Lachin (2000), 
resulting in a total of 12 regressions. 
 Hypothesis 1c. Baseline. To test the association between depressive symptoms 
and LTL assessed at baseline, a hierarchical linear regression was conducted. Age at 
diagnosis was entered into the first step of the model as covariate (Table 5).  
Slope of change and intent-to-treat principles. To test the association between 
change in depressive symptoms and change in LTL, a hierarchical linear regression was 
conducted. Minority status was entered into the first step of the model as covariate (Table 
5). The model was run with and without use of the intervention included as a covariate. 
The same analyses were subsequently re-conducted using intent-to-treat principles 
outlined by Lachin (2000), resulting in a total of four regressions. 
Hypothesis 1d. Because the proposed conditions were not met (see results of 
hypothesis 1a and 1b), hypothesis 1d (i.e., if hypothesis 1a and 1b emerge as significant, 
then greater cortisol dysregulation will be associated with both depressive symptoms and 
shorter survival) was not examined. 
Hypothesis 1e. Because the proposed conditions were only partially supported 
independent of the intervention (see results of hypothesis 1a), hypothesis 1e (i.e., if 
hypothesis 1a and 1c emerge as significant, then shorter LTL will be associated with both 
depressive symptoms and shorter survival) was not examined as proposed. However, as a 
part of the post-hoc analysis to elucidate results that emerged following the analysis of 
hypothesis 2c, the prognostic significance of LTL was ultimately examined. 
Aim 2. Because the intervention was a pilot, not randomized, an exploratory 
analysis was conducted to elucidate baseline group differences between patients who 
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participated in the intervention and those who did not. Demographic and medical factors 
were compared between the two groups using independent samples t-tests, Chi-square 
tests, and Mann-Whitney U tests to elucidate potential confounding continuous, 
dichotomous, and categorical variables, respectively. Results from these analyses were 
used to determine inclusion of covariates in the subsequent analyses (see Table 6). 
Hypothesis 2a. Participation. To test if participation in the intervention (yes/no) 
was associated with a change in depressive symptoms, an ANCOVA was conducted. 
Both chemotherapy treatment status at baseline (yes/no; Table 6), and the intercept from 
the within-subjects regression coefficient analysis (to control for individual differences at 
baseline) were entered as covariates. The same analyses were subsequently re-conducted 
using intent-to-treat principles outlined by Lachin (2000), resulting in a total of two 
ANCOVAs. Levene’s tests were used to test the assumption of homogeneity of variances.  
Use of the intervention. Among those who completed the intervention, to test if 
greater participation (total listening time and total number of tracks listened to) was 
associated with a change in depressive symptoms, separate hierarchical linear regressions 
were conducted. The same analyses were subsequently conducted using intent-to-treat 
principles outlined by Lachin (2000), resulting in a total of four regressions.  
Hypothesis 2b. Participation. To test if participation in the intervention (yes/no) 
was associated with a change in markers of cortisol (overall mean, mean bedtime, and 
diurnal cortisol slope), separate ANCOVAs were conducted. Chemotherapy treatment 
status at baseline (yes/no; Table 6) and the intercept from the within-subjects regression 
coefficient analysis (to control for individual differences at baseline) were entered as 
covariates in each model. The same analyses were subsequently conducted using intent-
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to-treat principles outlined by Lachin (2000), resulting in a total of six ANCOVAs. 
Levene’s tests were used to test the assumption of homogeneity of variances. 
Use of the intervention. Among those who completed the intervention (n = 25), to 
test if greater participation (total listening time and total number of tracks listened to) was 
associated with a change in markers of cortisol (overall mean, mean bedtime, and diurnal 
cortisol slope), separate hierarchical linear regressions were conducted. The same 
analyses were subsequently conducted using intent-to-treat principles outlined by Lachin 
(2000), resulting in a total of 12 regressions. 
Hypothesis 2c. Participation. To test if participation in the intervention (yes/no) 
maintained LTL, an ANCOVA was conducted. Chemotherapy treatment status at 
baseline (yes/no; Table 6) and the intercept from the within-subjects regression 
coefficient analysis (to control for baseline differences) were entered as covariates. The 
same analyses were subsequently conducted using intent-to-treat principles outlined by 
Lachin (2000), resulting in a total of two ANCOVAs. Levene’s tests were used to test the 
assumption of homogeneity of variances. 
Use of the intervention. Among those who completed the intervention, to test if 
greater participation (total listening time and total number of tracks listened to) was 
associated with change in LTL, two hierarchical linear regression was conducted. The 
same analyses were subsequently conducted using intent-to-treat principles outlined by 
Lachin (2000), resulting in a total of four regressions.  
Hypothesis 2d. Participation. To test if participation in the intervention (yes/no) 
was associated with survival time calculated from date of study entry and date of 
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diagnosis, two separate Kaplan-Meier analyses (Kaplan & Meier, 1958) using the log 
rank test were conducted.  
Use of the intervention. Among those who completed the intervention, to test if 
greater participation (total listening time and total number of tracks listened to) was 
associated with survival time calculated from study entry and date of diagnosis, four 
separate two-tailed Cox Proportional Hazards regressions were conducted. In models 
with survival calculated from study entry as the outcome, sex was entered into the model 
as a covariate (Table 3). 
Post-hoc analysis. Aim 1. Hypothesis 1a. Baseline. To determine if clinically 
significant depressive symptoms at baseline predicted overall survival, the sample was 
split between participants who endorsed clinically significant levels of depression (score 
> 16 on the CES-D, n = 29) and those who did not (score < 16 on the CES-D, n = 30). 
Two separate Kaplan-Meier analyses using log rank tests were conducted to test if 
survival distributions calculated from study entry and date of diagnosis differed between 
those who endorsed experiencing clinically significant depressive symptoms and those 
who did not. 
Hypothesis 1b. Baseline. To determine if clinically significant depressive 
symptoms were associated with markers of cortisol dysregulation (higher overall mean 
and bedtime cortisol and flatter diurnal cortisol slopes), the sample was split between 
participants who endorsed clinically significant levels of depression (score > 16 on the 
CES-D) and those who did not (score < 16 on the CES-D), and separate hierarchical 
linear regressions were conducted. Each marker of cortisol was tested in a separate 
model. The covariates that emerged as significantly associated with bedtime mean 
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cortisol (age at baseline and age at diagnosis; Table 4) were included in the models with 
bedtime mean cortisol as the outcome.  
Hypothesis 1c. Baseline. To determine if clinically significant depressive 
symptoms were associated with LTL, the sample was split between participants who 
endorsed clinically significant levels of depression (score > 16 on the CES-D) and those 
who did not (score < 16 on the CES-D), a hierarchical linear regression was conducted. 
The covariate that emerged as significantly associated with LTL (age at diagnosis; Table 
5) was included in the model. 
Hypothesis 1c. Slope of change and intent-to-treat principles. To elucidate 
findings that emerged as significant following primary analysis of hypothesis 1c, an 
interaction term between change in depressive symptoms and minority status (yes/no) 
was calculated. A hierarchical linear regression was conducted to re-assess the 
association between change in depressive symptoms and change in LTL including the 
same covariates that were included in the model initially (primary analysis) of hypothesis 
1c (minority status (Table 5) and participation in the intervention (yes/no) in addition to 
the interaction term. 
Aim 2. Hypothesis 2a. Participation. To elucidate the findings that emerged as 
significant following the primary analysis of hypothesis 2a, an interaction term between 
participation in the intervention (yes/no) and chemotherapy treatment status at baseline 
(yes/no) was calculated. An ANCOVA was conducted to re-assess the association 
between the intervention and change in depressive symptoms using intent-to-treat 
principles. The same covariates were included as the primary analysis (the intercept from 
the within-subjects regression coefficient analyses and chemotherapy treatment status at 
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baseline) in addition to the interaction term. The Levene’s test was assessed to test the 
assumption of homogeneity of variances. 
Use of the intervention. In an attempt elucidate results that emerged contrary to 
hypotheses following primary analysis of hypothesis 2a, subsequent post-hoc analysis 
were conducted using variables reflective of intervention use (i.e., total listening time and 
total number of tracks listened to).  
Among those who participated in the intervention (n = 25), total listening time 
and total number of tracks listened to were median split to create two groups: low and 
high use of the intervention. Two separate independent-samples t-tests were conducted to 
determine if change in depressive symptoms following intent-to-treat principles differed 
between low versus high use of the intervention.  
Among those who participated in the intervention, variables were created to 
capture use of didactic (i.e., instructional) and practice tracks. For each participant, the 
average total amount of time that didactic and practice tracks were listened to was 
calculated. Similarly, for each participant, the total number of tracks that were 
categorized as didactic and practice were calculated. Unexpectedly, separate linear 
regressions could not be conducted using didactic track variables (total time and total 
number of tracks listened to) due to a low sub-sample size (n = 2). Thus, separate linear 
regressions were conducted to test the association between total amount of listening time 
and number of tracks listened to for practice tracks and change in depressive symptoms 
following intent-to-treat principles. 
Finally, the total listening time and total number of times that the practice track 
titled, “Awareness of the breath” (11minutes and 5 seconds in length) was listened to was 
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examined using separate linear regressions to test the association with change in 
depressive symptoms following intent-to-treat principles. 
Hypothesis 2c. Participation. An independent-samples t-test was conducted to 
elucidate the findings that emerged following primary analysis of hypothesis 2b, which 
demonstrated that there was a significant difference in baseline diurnal cortisol slope 
between the two groups (those who participated in the intervention versus those who 
declined).  
Hypothesis 2c. Participation. To elucidate findings that emerged following 
primary analysis of hypothesis 2c, an ANCOVA was conducted to examine the 
association between the intervention (yes/no) and change in LTL with an interaction term 
between participation intervention status and chemotherapy treatment status at baseline. 
The model adjusted for baseline differences in LTL (the intercept from the within-
subjects analysis) and chemotherapy treatment status at baseline (yes/no; Table 6). 
Cox Proportional Hazard regressions were conducted to examine the prognostic 
value of LTL with and without adjusting for intervention participation status (yes/no). 
Separate models including survival calculated from date of study entry and date of 
diagnosis were conducted. 
Despite being considerably underpowered, a hierarchical linear regression was 
subsequently conducted to examine the association between change in depressive 
symptoms and change in LTL with an interaction between change in depressive 
symptoms and the intervention after controlling for minority status (yes/no; Table 5).  
Hypothesis 2d. Use of the intervention. In an attempt elucidate results that 
emerged contrary to hypothesis 2d, subsequent post-hoc analysis were conducted using 
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variables capturing intervention use (i.e., total listening time and total number of tracks 
listened to).  
Similar to hypothesis 2a, among those who participated in the intervention, total 
listening time and total number of tracks listened to were median split to create two 
groups: low and high use of the intervention. Kaplan-Meier analysis using log rank tests 
were conducted to test if survival distributions calculated from study entry and date of 
diagnosis differed between low versus high use of the intervention. 
Among those who participated in the intervention, variables were created to 
capture use of didactic (i.e., instructional) and practice tracks. For each participant, the 
average total amount of time that didactic and practice tracks were listened to was 
calculated. Similarly, for each participant, the total number of tracks that were 
categorized as didactic and practice were calculated. Similar to hypothesis 2a, Cox 
Proportional Hazard regressions could not be conducted using didactic track variables 
(total time and total number of tracks listened to) due to a low sub-sample size (n = 2). 
Thus, total of four Cox Proportional Hazard regressions were conducted to test the 
association between total amount of listening time and number of tracks listened to for 
practice tracks and survival calculated from study entry and date of diagnosis.  
Finally, the total listening time and total number of times that the practice track 
titled, “Awareness of the breath” (11minutes and 5 seconds in length) listened to was 
examined using four Cox Proportional Hazard regressions to test potential associations 
with survival calculated from study entry and date of diagnosis. 
 Power analysis 
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G*Power version 3.1, previous studies, and an online power calculator (HyLown 
Consulting LLC) were all used to estimate the anticipated power of the proposed study 
aims based on final samples sizes: N = 67; n = 59, 58, 58, 57, and 64 for depressive 
symptoms, overall mean cortisol, mean bedtime cortisol, diurnal cortisol slope, and LTL, 
respectively. All power estimates were calculated with a 5% Type I error (α = .05). 
Aim 1. Hypothesis 1a. The estimated power for hypothesis 1a is based on a 
similar study that reported depression was a significant predictor of 6-month survival 
among 43 NSCLC patients, 13 of which experienced death, with a medium to large odds 
ratio of 5.30 (Pirl et al., 2008). These results suggest the current sample of 59 with 
approximately a 50% rate of death should attain adequate power. Further, based on the 
expectation of a hazards ratio of 2 in our sample of 57, the online power calculator 
(HyLown Consulting LLC) provided an estimated of .66. 
Hypothesis 1b – 1c. Small to large effect sizes have been reported between 
depressive symptoms and markers of cortisol. Large effect sizes between depression and 
higher afternoon cortisol (Cohen’s d = .83; (Burke et al., 2005) and overall mean cortisol 
(Cohen’s d = .60; (Stetler & Miller, 2011) have been reported among non-medically ill 
samples. Small to moderate effects (Cohen’s f  = .17) have been reported between 
depressive symptoms and higher evening cortisol in an ovarian cancer sample 
(Lutgendorf et al., 2008). Among non-medically ill participants, moderate effect sizes 
have been reported between depressive symptoms and shorter LTL (Hedge’s g = -.55; 
Darrow et al. (2016). No effect size estimates are available for depressive symptoms and 
TL in cancer contexts given that only two studies have examined these constructs among 
cancer populations, neither of which reported an effect size. Based on the expectation of a 
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small to large effect size on biological markers in our sample of 57, our power will range 
between .18 and .99. 
Aim 2. Hypothesis 2a. Medium to large effect sizes of an MBSR intervention on 
depressive symptoms have been reported among cancer patients in mobile (Cohen’s d = 
0.85; N = 15) and non-mobile (Cohen’s d = 0.56) formats, respectively (Lengacher et al., 
2018; Zhang, Wen, et al., 2015). Based on the expectation of a medium to large effect 
size on depressive symptoms in our sample of 59, our power will range between .17 and 
.99. 
Hypothesis 2b – 2c. Small effects of an MBSR intervention on cortisol slope (η2 = 
0.02) and medium effects on bedtime cortisol (η2 = 0.05) have been reported among 
breast cancer patients (Carlson et al., 2013); overall diurnal mean cortisol was not 
reported. A small to medium effect (η2 = 0.043) of an intervention involving components 
of MBSR on maintenance of TL has been reported among a breast cancer sample 
(Carlson et al., 2015). However, there are a limited number of studies that have examined 
the effects of an MBSR intervention on biological markers. Thus, it should be noted that 
the current investigation is exploratory opposed to confirmatory in nature. Nonetheless, 
based on the expectation of a small to medium effect of the intervention on biological 
outcomes in our sample of 57, our power will range between .06 and .99. 
Hypothesis 2d. The effects of MBSR or an MBI on survival have not been tested 
among cancer populations. A small effect of a psychological intervention involving a 
combination of stress reduction, problem solving, social support enhancing, and health 
behavior techniques on 11 year survival (HR = 0.44) has been reported, which indicated 
breast cancer patients who were randomized to the intervention were half as likely to die 
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from breast cancer (Andersen et al., 2008). Based on the expectation of a hazards ratio of 
2 in our sample of 67, the online power calculator (HyLown Consulting LLC) provided a 
power estimate of .66. Nonetheless, the proposed analyses are exploratory, not 






All of the independent-samples t-tests conducted to assess the independence of 
the treatment variable and the covariate assumption for the ANCOVA were not 
statistically significant; thus, the assumption was met for each analysis.  
Primary analysis 
Covariates. Results of the Spearman’s rank-order correlations are summarized in 
Tables 3 – 5. 
Aim 1. Hypothesis 1a. Baseline. Sex (female) emerged as significantly associated 
with longer survival calculated from study entry. No theoretically derived covariates were 
significantly associated with survival calculated from date of diagnosis. No theoretically 
derived covariates were significantly associated with the independent variable, depressive 
symptoms; therefore, no variables were entered as a ‘proxy’ (Table 3).  
 Contrary to hypotheses, after adjusting for participation in the intervention, although 
both Cox Proportional Hazards regression models emerged as significant (study entry: p 
= .018; date of diagnosis: p = .022), depressive symptoms assessed at baseline did not 
predict survival calculated from study entry or date of diagnosis. Participation in the 
intervention emerged as a significant predictor of shorter survival in both models 
calculated from study entry (P(Wald) = .017; hazard ratio, 0.396; 95% confidence 
interval [CI], .185 - .850) and date of diagnosis (P(Wald) = 0.021; hazard ratio, 0.405; 
95% confidence interval [CI], .188 - .870). Results are presented in Table 7.
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Slope of change and intent-to-treat principles. No indicators emerged as 
significantly associated with the independent variable, change in depressive symptoms 
(including intent-to-treat variables). Therefore, because sex emerged as significantly 
associated with longer survival calculated from study entry, it was again entered as a 
covariate in models with survival calculated from study entry at the outcome. No 
additional covariates were entered into models with survival calculated from date of 
diagnosis as the outcome. No models included a ‘proxy’ (Table 3).  
Contrary to hypotheses, change in depressive symptoms did not emerge as a 
statistically significant predictor of survival calculated from study entry or date of 
diagnosis following Cox Proportional Hazards regression analysis with or without use of 
the intervention included in the model. Results are summarized in Table 7.  
Loss to follow-up Cox Proportional Hazards regression analyses using intent-to-
treat principles yielded similar statistically non-significant associations between change 
in depressive symptoms and both measures of survival with and without the intervention 
included in the model. Although the overall model was again significant for survival 
calculated from study entry (p = .040), only participation in the intervention emerged as a 
significant predictor (P(Wald) = .021; hazard ratio, 0.400; 95% confidence interval [CI], 
.184 - .871. The model including survival calculated from date of diagnosis neared 
significance (p = .052), but only use of the intervention emerged as a significant predictor 
(P(Wald) =  0.020; hazard ratio, 0.391; 95% confidence interval [CI], .178 - .860). 
Results are summarized in Table 7. 
Hypothesis 1b. Baseline. In the anticipated direction, both older age at study entry 
and older age at diagnosis emerged significantly associated with increased bedtime mean 
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cortisol. No theoretically derived covariates were significantly associated with any other 
marker of cortisol. No theoretically derived covariates were significantly associated with 
the independent variable, depressive symptoms; therefore, no variables were entered as a 
‘proxy’ (Table 4). 
The regression conducted to assess the association between depressive symptoms 
and mean bedtime cortisol assessed at baseline while controlling for age emerged as 
significant, F(2,52) = 3.720, p = .031 and accounted for 12.5% variance. Only age was 
significantly associated with mean bedtime cortisol (p = .010) and accounted for 11.5% 
of the variance. Similarly, the regression used to assess the association between 
depressive symptoms and mean bedtime cortisol assessed at baseline while controlling 
for age at diagnosis emerged as nearly significant, F(2,52) = 3.133, p = .052 and 
accounted for 10.8% variance. Again, only age at diagnosis was significantly associated 
with mean bedtime cortisol (p = .017) and accounted for 8.3% of the variance. The 
association between depressive symptoms and both diurnal cortisol slope and overall 
mean cortisol assessed at baseline did not emerge as significant in the model. Results are 
summarized in Table 8. 
Slope of change and intent-to-treat principles. No theoretically derived covariates 
were significantly associated with any change in any of the markers of cortisol (including 
intent-to-treat variables; Table 4). Therefore, no additional theoretically derived variables 
were entered as a covariate or a ‘proxy’ in any of the models. 
Contrary to hypotheses, the hierarchical linear regressions conducted to assess the 
associations between change in depressive symptoms and change in markers of cortisol 
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(overall mean, bedtime mean, and diurnal slope) both with and without adjusting for the 
intervention did not emerge as significant. Results are summarized in Table 8.  
Loss to follow-up analyses using intent-to-treat principles similarly yielded no 
statistically significant associations between change in depressive symptoms and change 
in markers of cortisol. Results are summarized in Table 8.  
Hypothesis 1c. Baseline. Older age at diagnosis emerged as significantly 
associated with shorter LTL at baseline. No theoretically derived covariates were 
significantly associated with the independent variable, depressive symptoms; therefore, 
no variables were entered as a ‘proxy.’ Spearman’s rank-order correlations are 
summarized in Table 5. 
The regression conducted to assess the association between depressive symptoms 
and LTL at baseline while controlling for age at diagnosis emerged as significant, F(2,54) 
= 3.915, p = .026 ,and accounted for 12.7% variance. However, only age at diagnosis was 
significantly associated with TL (p = .015) and accounted for 9.1% of the variance. 
Slope of change and intent-to-treat principles.  As expected, minority status (non-
White participants) emerged as significantly associated with a more negative change 
(steeper slope) in LTL and was entered into the first step of the model as a covariate. 
Because minority status was not significantly associated with the independent variable, 
change in depressive symptoms, no variables were entered as a ‘proxy.’ Spearman’s 
rank-order correlations are summarized in Table 5. 
The regression conducted to assess the association between change in depressive 
symptoms and change in LTL while controlling for minority status emerged as 
significant, F(2,24) = 4.914, p = .016 and accounted for 29% of variance. Both minority 
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status (p = .012) and change in depressive symptoms (p = .029) were significantly 
associated with LTL. The regression controlling for both minority status and the 
intervention also emerged as significant, F(3, 23) = 4.930, p < .01 and accounted for 39% 
of variance. Both minority status (p = .015) and change in depressive symptoms (p < .01) 
were, again, significantly associated with LTL, but participation in the intervention did 
not significantly contribute to the model (Table 9). As demonstrated in Figure 4, the slope 
of change in depressive symptoms and change in LTL was negative. Consistent with 
hypotheses, as depressive symptoms increased over time (from baseline to follow-up) 
LTL decreased over time, and the LTL among minority participants was shorter than 
non-Hispanic White participants. 
No indicators, including minority status, were significantly associated with a 
change in LTL and following intent-to-treat principles; therefore, no covariates or proxies 
were included in the models. Loss to follow-up analyses using intent-to-treat principles 
yielded no statistically significant associations (Table 9). 
Aim 2. The Chi-square test between intervention status and current chemotherapy 
status revealed a significant difference between groups, X2(1, N = 59) = 3.845, p = .050. 
No other factors emerged as significant. Results of the exploratory analysis are presented 
in Table 6. 
Hypothesis 2a. Participation. After adjusting for baseline individual differences 
in depressive symptoms and chemotherapy treatment status at baseline, the intervention 
did not demonstrate statistically significant associations with change in depressive 
symptoms (Table 10). There was homogeneity of variances, as assessed by Levene's test 
of homogeneity of variance (p = .503). 
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Loss to follow-up ANCOVA analysis using intent-to-treat principles yielded a 
statistically significant intervention effect on change in depressive symptoms after 
adjusting for chemotherapy treatment status at baseline, F(1,54) = 5.360, p = .024, partial 
η2 =  0.090. Contrary to hypotheses, the change in depressive symptoms was positive; 
scores increased over time (by approximately three points on the CES-D) in the 
intervention group (M = .035, SE = .084) whereas scores decreased/were maintained 
(approximately half of a point decrease) among participants who did not complete the 
intervention (M = -.005, SE = .047), a mean difference of .042, 95% CI [.006, .079], p = 
.024. However, the assumption of homogeneity of variances was violated as assessed by 
Levene's test for equality of variances (p = .003). Therefore, the dependent variable, 
change in depressive symptoms following intent-to-treat principles, was re-examined 
more conservatively. Outliers (n = 1) beyond three, opposed to four, standard deviations 
(values less than .22) were excluded from a subsequent ANCOVA analysis. The model 
remained significant, F(1,53) = 4.275, p = .044, partial η2 =  0.075 and the change in 
depressive symptoms remained significantly positive in the intervention group (M = 
.024, SE = .064) whereas the change in depressive symptoms remained negative among 
those who did not complete the intervention (M = -.005, SE = .047), a mean difference of 
.032, 95% CI [.001, .062], p = .044 (see Figure 6). Although the Levine’s test for equality 
of variances remained significant after excluding the outlier (p = .022), Field (2013) 
suggests the Levene’s test is not the most reliable measure of the equal variances 
assumption. Instead Field (2013) recommends checking the assumption using a variance 
ratio by squaring each group standard deviation, dividing the largest standard deviation 
by the smallest, and referencing Figure 5 to determine if the quotient exceeds the critical 
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value. In this case, the largest squared standard deviation (.004; n = 23) divided by the 
smallest squared standard deviation (.002; n = 34) yielded a variance ratio of 2, which 
did not exceed the critical value of ~3 as determined using Figure 5. Thus, according to 
Field (2013) the homogeneity of variances assumption was not violated. Results are 
summarized in Table 10. 
Use of the intervention. Among those who completed the intervention (n = 25) 
and provided depression assessment at baseline and follow-up (n = 20), the regressions 
conducted to test the associations between intervention use (total listening time and total 
number of tracks listened to) and change in depressive symptoms did not emerge as 
significant. Results are summarized in Table 11. 
Loss to follow-up regression analysis using intent-to-treat principles yielded 
similar insignificant associations. Among those who completed the intervention (n = 25), 
the regressions conducted to test the associations between intervention use (total listening 
time and total number of tracks listened to) and change in depressive symptoms did not 
emerge as significant (Table 11). 
Hypothesis 2b. Participation. After adjusting for baseline individual differences 
in cortisol profiles and chemotherapy treatment status at baseline, the ANCOVA analysis 
demonstrated that the intervention did not demonstrate statistically significant association 
with change in any of the markers of cortisol (overall mean, bedtime mean, diurnal 
slope). However, the intercept from the within-subjects analysis emerged significant 
F(1,24) = 9.844, p = .004, partial η2 =  0.291, suggesting that there were significant 
baseline differences in diurnal cortisol slope between the two groups. There was 
homogeneity of variances, as assessed by Levene's test of homogeneity of variance for 
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each ANCOVA (p = .825, p = .572, p = .445, respectively). The results are presented in 
Table 12.  
Similarly, loss to follow-up ANCOVA analysis using intent-to-treat principles 
and adjusting for chemotherapy treatment status baseline did not yield statistically 
significant associations between the intervention and change in each marker of cortisol 
(overall mean, bedtime mean, diurnal slope). There was homogeneity of variances, as 
assessed by Levene's test of homogeneity of variance for each ANCOVA (p = .080, p = 
.239, p = .171, respectively). The results are also presented in Table 12. 
Use of the intervention. Among those who completed the intervention, none of the 
regression conducted to assess the association between total listening time and number of 
tracks listened to and change and markers of cortisol emerged as significant. The results 
are presented in Table 13. 
Similarly, loss to follow-up regression analyses using intent-to-treat principles 
yielded no statistically significant associations. Results are also presented in Table 13. 
Hypothesis 2c. Participation. After adjusting for baseline individual differences 
in LTL and chemotherapy treatment status at baseline, the ANCOVA revealed a 
statistically significant intervention effect on change in LTL, F(1,34) = 5.454, p = .026, 
partial η2 =  0.138. As demonstrated in Figure 7, for visual not statistical purposes, the 
slope of change in LTL was positive among those in the intervention group (M 
=.0000423, SE = .000725) whereas the slope of change was negative among those who 
did not complete the intervention (M = -.000327, SE = .000437), a mean difference of 
0.000470, 95% CI [0.000061, 0.000879], p = .026. In other words, LTL seemed to 
increase among those in the intervention group, whereas LTL appeared to decrease 
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among those who did not participate. Chemotherapy treatment at baseline also 
significantly contributed to the model F(1,34) = 4.914, p = .033, partial η2 =  0.126. 
Contrary to expectations, patients who were receiving chemotherapy treatment at 
baseline demonstrated an increase in LTL compared to those who did not (see Figure 8). 
There was homogeneity of variances, as assessed by Levene's test of homogeneity of 
variance (p = .615). The mean number of days from date of blood collection at baseline 
to follow-up was 139 (~4.6 months). Results are summarized in Table 14. 
Loss to follow-up ANCOVA analysis using intent-to-treat principles that adjusted 
for baseline differences in LTL and chemotherapy treatment status at baseline yielded 
statistically insignificant associations between the intervention and change in LTL; 
however, the statistical significance of chemotherapy at baseline persisted, F(1,53) = 
5.652, p = .021, partial η2 =  0.096. There was homogeneity of variances, as assessed by 
Levene's test of homogeneity of variance (p = .210). Results are also summarized in 
Table 14.  
Use of the intervention. Among those who completed the intervention, the 
regressions conducted to assess the association between both total listening time and total 
number of tracks listened to and change in TL yielded statistically insignificant results. 
Results are presented in Table 15. 
Similarly, loss to follow-up regression analyses using intent-to-treat principles 
yielded no statistically significant associations. Results are also presented in Table 15. 
Hypothesis 2d. Participation. Consistent with results that emerged following 
hypothesis 1a analyses, the Kaplan-Meier survival analysis using a log rank test revealed 
statistically significant differences in survival distributions calculated both from study 
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entry and date of diagnosis between those who participated in the intervention (n = 25) 
and those who did not (n = 42), χ2(1) = 5.536, p = .019 and χ2(1) = 6.033, p = .014, 
respectively. As demonstrated in Figure 9, contrary to hypotheses, participants that 
participated in the intervention on average had a shorter time to death in days calculated 
from study entry (M = 824.200, SD = 532.443) than those who did not (M = 944.810, 
DE = 400.392). Similarly, on average, patients that participated in the intervention had a 
shorter time to death in days calculated from date of diagnosis (M = 1450.920, SD = 
638.400) than those who did not (M = 1694.260, SD = 751.716; Figure 10). 
Use of the intervention. As stated in hypothesis 1a, sex (female) emerged as 
significantly associated with longer survival calculated from study entry and was entered 
as a covariate in the model (see Table 3).  
Among those who completed the intervention (n = 25), the Cox Proportional 
Hazards Regression models conducted to test the association between intervention use 
(total listening time and total number of tracks listened to) and survival calculated from 
study entry (after controlling for sex) and date of diagnosis did not yield statistically 
significant results. Results are presented in Table 16. 
Post-hoc analysis 
Aim 1. Hypothesis 1a. A score of  > 16 is indicative of clinical significant on the 
CES-D (Radloff, 1977). On average, patients reported experiencing nearly clinically 
significant levels of depressive symptoms at baseline (M = 15.5) and clinically significant 
levels at follow-up (M = 17.7). Consistent with previous reports that have suggested lung 
cancer patients experience some of the highest levels of depression (Linden et al., 2012), 
the average depression scores were higher in the current sample than the mean of 11 that 
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was reported by a different sample of breast cancer patients (N = 117; Hann et al. (1999), 
suggesting that the reported levels of depressive symptoms were not abnormally low in 
the current sample. Change in depressive symptoms ranged from -.16 and 3, however, 
and the average change was .025. In other words, from baseline to follow-up, regardless 
of intervention participation status, the overall change in depressive symptoms was less 
than one point on the CES-D.  
Baseline. The Kaplan-Meier survival analysis using a log rank test demonstrated 
statistically significant differences in survival distributions calculated from date of 
diagnosis between participants who endorsed experiencing clinically significant levels of 
depression (CES-D score > 16) and those who did not, χ2(1) = 3.832, p = .050. Consistent 
with primary analysis of hypothesis 1a, survival calculated from study entry did not 
emerge as significant, χ2(1) = 3.232, p = .072. As demonstrated in Figure 11, patients 
who endorsed experienced clinically significant depressive symptoms experienced earlier 
mortality (M = 23.9, SD = 6.375), than those who did not (M = 7.4, SD = 4.734). 
Hypothesis 1b. Baseline. After adjusting for age at study entry (Table 4), the 
overall model containing sub-clinical levels of depression emerged as significantly 
associated with bedtime mean cortisol, F(2, 24) =  4.265, p = .026; however, sub-clinical 
levels of depressive symptoms did not significantly contribute to the model (p = .519). 
Similarly, after adjusting for age at diagnosis (Table 4), the overall model containing sub-
clinical levels of depression emerged as significantly associated with bedtime mean 
cortisol, F(2, 24) =  3.698, p = .040, although sub-clinical levels of depressive symptoms 
did not significantly contribute to the model (p = .461). Contrary to hypothesis, neither 
model including clinical levels of depression emerged as significantly associated with 
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bedtime mean cortisol. Regarding diurnal slope, only sub-clinical levels of depression 
were significantly associated with a flatter slope, F(1, 26) =  5.073, p = .033. No 
regressions with overall mean cortisol emerged as significant. Results are presented in 
Table 17.  
Hypothesis 1c. Baseline. Contrary to hypothesis, after adjusting for age at 
diagnosis (Table 5), neither model containing sub-clinical nor clinical levels of 
depression emerged as significantly associated with LTL. Results are presented in Table 
18. 
Slope of change and intent-to-treat principles. The hierarchical linear regression 
conducted to assess the association between change in depressive symptoms and change 
in LTL remained significant when the interaction term between change in depressive 
symptoms and minority status was added to the model, F(4, 22) = 3.795, p = .017 and 
accounted for 41% of variance; however, the interaction term did not significantly 
contribute to the model (p = .436). Results are presented in Table 19. 
Aim 2. Hypothesis 2a. Participation. The ANCOVA used to assess the 
association between the intervention and change in depressive symptoms using intent-to-
treat principles including the interaction term between the intervention and chemotherapy 
treatment status at baseline yielded nearly significant results, F(1,53) = 3.142, p = .051, 
partial η2 =  0.106, although the interaction term was not significant. However, similar to 
primary analysis of hypothesis 2a, the assumption of homogeneity of variances was 
violated, as assessed by Levene's test for equality of variances (p = .003). Using the same 
procedures outlined for primary analysis of hypothesis 2a, a subsequent ANCOVA was 
conducted after excluding outliers (n = 1) beyond three standard deviations (values less 
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than 0.22). The model and the interaction term remained insignificant, and similar to 
hypothesis 2a, the assumption remained violated as assed by Levine’s test (p = .022). 
However, using the procedures outlined by Field (2013), the largest squared standard 
deviation (.004; n = 23) divided by the smallest squared standard deviation (.002; n = 34) 
yielded a variance ratio of 2, which did not exceed the critical value of ~3 as determined 
using Figure 5. Thus, according to Field (2013) the homogeneity of variances assumption 
was not violated. Results are summarized in Table 20.  
Use of the intervention. The median total listening time was 806 minutes and the 
median total number of tracks listened to was 82 yielding two groups: low (n = 12) and 
high (n = 13) use of the intervention. Neither of the independent samples t-tests 
conducted to test the association between median split total listening time and total 
number of tracks listened to yielded statistically significant differences in change in 
depressive symptoms following intent-to-treat principles, suggesting that there was not a 
dose-response relationship between use of the intervention and depressive symptoms. 
Results are presented in Table 21. 
Among the patients that participated in the intervention (n = 25), the average total 
amount of time that didactic and practice tracks were listened to were 1633.28 and 
1531.357 minutes, respectively, and average number of tracks listened to that were 
categorized as didactic and practice were 260 and 129.083, respectively. Of the 44 tracks 
recorded and provided to participants via the iPod, 33 of them were didactic (a total of 
208.30 minutes) and 11 were practice (a total of 180.85 minutes; Table 1). Neither of the 
linear regressions conducted to test the association of use of practice tracks on change in 
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depressive symptoms following intent-to-treat principles emerged as significant. Results 
are presented in Table 22. 
Twenty-three of the 25 patients who participated in the intervention listened to the 
“Awareness of the breath” practice track. The total number of minutes the track was 
listened to ranged from 11.10 (i.e., once) – 277.50 (M = 77.70, SE = 78.560), and the 
number of times the track was played ranged from 1 – 25 (M = 7.00, SE = 7.077). 
Neither regression conducted to test the association of use of the practice track 
“Awareness of the breath” emerged as a significant predictor of change in depressive 
symptoms following intent-to-treat principles. Results are also presented in Table 22. 
Hypothesis 2b. Participation. The independent-samples t-test revealed nearly 
statistically significant difference in diurnal cortisol slopes at baseline between patients 
who agreed to participate in the intervention than those who declined the intervention 
t(55) = 1.971, p = .054. As shown in Figure 12, patients who participated in the 
intervention demonstrated steeper diurnal cortisol slopes than those who declined the 
intervention.  
Hypothesis 2c. Participation. The ANCOVA used to assess the association 
between the intervention and change in LTL including the interaction term between the 
intervention and chemotherapy treatment status at baseline demonstrated a statistically 
significant effect of the interaction term, F(1,33) = 5.831, p = .021, partial η2 =  0.150, 
after adjusting for baseline differences in LTL and chemotherapy treatment status at 
baseline. As demonstrated for visual not statistical purposes, in Figure 13, it seems 
patients who received chemotherapy at baseline and participated in the intervention 
demonstrated an increase in LTL, whereas patients who were not receiving chemotherapy 
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at baseline and did not participate in the intervention evidenced a decrease in LTL. All 
other patients did not appear to evidence a change in LTL from baseline to follow-up; 
LTL appeared to have been maintained. Results are presented in Table 23. 
Change in LTL emerged as a significant predictor of survival calculated from date 
of study entry (P(Wald) < .01) and date of diagnosis (P(Wald) = .026) following the Cox 
Proportional Hazard regressions. Contrary to expectation, however, an increase in LTL 
predicted shorter survival in both models. For visual, not statistical purposes, change in 
LTL was median split to demonstrate significant differences in survival patterns from 
date of study entry (Figure 14) and date of diagnosis (Figure 15).  After adjusting for 
intervention participation, both models calculated from study entry (P(Wald) < .01) and 
date of diagnosis (P(Wald) = 0.17) remained significant, although the intervention did not 
significantly contribute to either model and LTL was not significant in the model 
including survival calculated from date of diagnosis. Consistent with findings from 
hypothesis 2a, participation in the intervention was associated with shorter survival. 
Results are presented in Table 24.  
The hierarchical linear regression examining the association between change in 
depressive symptoms and change in LTL with an interaction term between change in 
depressive symptoms and the intervention participation status, after adjusting for 
minority status, emerged as significant, F(4, 22) = 3.623, p = .021 and accounted for 
approximately 40% of variance, although the interaction term did not significantly 
contribute to the model. Results are presented in Table 25. However, as demonstrated for 
visual, not statistical purposes in Figure 16, there appear to be differences in the pattern 
of association between change in depressive symptoms and change in LTL between 
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intervention groups (participated versus not). The association between change in 
depressive symptoms and change in LTL was positive (as depressive symptoms 
increased, LTL also increased/lengthened) among those who participated in the group, 
whereas the association was negative (as depressive symptoms increased, LTL 
decreased/shortened) among those who did not.  
Hypothesis 2d. Use of the intervention. The Kaplan-Meier survival analysis using 
a log rank tests after median splitting total listening time and total number of tracks 
listened to yielded no statistically significant differences in survival distributions 
calculated both from either study entry (Time: χ2(1) = .566, p = .019; Tracks: χ2(1) = 
.329, p = .566) or date of diagnosis (Time: χ2(1) = .556, p = .456; Tracks: χ2(1) = .556, p 
= .456), suggesting that there was not a dose-response relationship between the 
intervention and survival. 
None of the Cox Proportional Hazard regressions conducted to test the association 
between use of practice tracks and survival emerged as significant. Results are presented 
in Table 26. 
None of the four Cox Proportional Hazard regressions conducted to test potential 
associations between use of the practice track “Awareness of the breath” and survival 
calculated from study entry or date of diagnosis emerged as a significant. Results are also 





In an attempt to integrate a dual emphasis on improving both quality and quantity 
of life among cancer patients, this dissertation explored the role of depressive symptoms 
and related biological markers of stress and cellular aging on survival as well as the 
potential benefits of a pilot MBI among a small sample of NSCLC patients. This 
dissertation approached elucidating the hypothesized association between depressive 
symptoms and survival from two angles exploring: 1) potential biological pathways and 
2) the potential benefits of an intervention as a means to improve psychological and 
clinical outcomes among a population facing high mortality. The importance of 
elucidating the biological underpinnings of the hypothesized depression-survival pathway 
in this population cannot be disregarded, as it provides one avenue to inform 
interventions to improve the poor survival rates that lung cancer patients face. As such, 
identifying feasible interventions that effectively improve psychological and clinical 
outcomes also remains a priority in lung cancer patients, a subset of the cancer population 
that remains highly underrepresented in the psycho-oncology literature.  
Although all cancer patients face considerable stress from the burden of treatment, 
shifts in social and vocational roles, and fear of death as well as a host of other 
challenges, lung cancer patients face unique and considerable burden given the low five- 
year overall survival rate that was recently estimated at 18% (Henningfield & Adjei, 
2017; Siegel et al., 2016). Not only do more than half of those diagnosed with lung
	
 83 
cancer die within the first year of diagnosis (Henningfield & Adjei, 2017; Siegel et al., 
2016), a stress-evoking statistic in and of itself, but cancer patients are four times more 
likely to experience depression than the non-medically ill populations (Lutgendorf & 
Andersen, 2015; Raison & Miller, 2003). Lung cancer patients in particular experience 
some of the highest prevalence rates of depression compared to any other type of cancer 
(Linden et al., 2012), which cannot be explained by disease severity (Brown et al., 2003). 
Thus, when faced with difficult mortality rates, stress may be inevitable, but depression is 
not, despite being highly prevalent. Fortunately, there are effective treatments for 
depression, providing one avenue for intervention that may subsequently result in 
improvements to both quality and quantity of life, given that depression has demonstrated 
prognostic value in cancer populations (Pinquart & Duberstein, 2010; Satin et al., 2009). 
The current lung cancer sample was recruited within a 120-mile radius of 
Louisville, KY, and can be described as mostly female, White, aged 50 – 60 with a high 
school education and an annual household income of less than $40,000. Consistent with 
the larger lung cancer population, 65% of which are diagnosed at a later stage (Siegel et 
al., 2014), the majority of patients from the current sample also received an initial 
diagnosis of stage III or IV (65.7%) within two years of study enrollment. Patients 
diagnosed at a later stage have a poorer prognosis, and as such, several study participants 
in the current study have since passed away – 46.3% of the overall current study sample, 
83.9% of which were initially diagnosed with a later stage. 




 While the intersection of mind and body has gained increasing attention in 
medical contexts, the biological underpinning of depression as it relates to shorter 
survival among cancer populations remains unknown. The majority of efforts to elucidate 
these pathways have primarily focused on the roles of the immune and the 
neuroendocrine systems. Although aberrant cortisol profiles have been associated with 
both depression and shorter survival among a number of cancer types (Cohen et al., 2012; 
Schrepf et al., 2015; Sephton et al., 2000), including lung (Sephton et al., 2013), much 
less attention has been given to the role of telomere biology, a system responsible for 
maintaining cellular integrity and stability, and is fundamental to cell proliferation 
(Blackburn et al., 2015). Despite mounting evidence demonstrating an association 
between shorter telomeres and stress (Shalev et al., 2013; Starkweather et al., 2014), 
depression (Vance et al., 2018), and shorter survival (Heaphy et al., 2013; Herrmann et 
al., 2018), there is a paucity of telomere biology in current biobehavioral cancer models. 
Thus, Aim 1 of the current study was to replicate the prognostic significance of 
depressive symptoms and to explore the role of two biomarkers – cortisol and leukocyte 
telomere length (LTL) – as they relate to the hypothesized depression-survival pathway. 
 Hypothesis 1a. Hypothesis 1a proposed that more depressive symptoms would 
predict shorter survival. Hypothesis 1a was partially supported.  
The primary analyses did not yield a significant association between depressive 
symptoms (assessed at multiple time points) and survival (calculated from two time 
points). However, post-hoc analysis revealed that, when the sample was split between 
those who reported experiencing clinically significant levels of depression (CES-D score 
> 16) and those who did not (CES-D score < 16), clinically significant levels of 
	
 85 
depression predicted shorter survival calculated from date of diagnosis, but not date of 
study entry. Although the observed inconsistency between survival from date of 
diagnosis and study entry was unexpected, it may be understood from the medical 
heterogeneity of the sample given the inclusion criterion of five years within diagnosis. 
The average time between dates of diagnosis and study entry was 704 days (SD = 5423; 
~1.9 years), and ranged from 38 – 2455, which reflects considerable variation. Despite 
this variability, these results highlight the need to consider severity, and specifically 
clinical significance, when examining the association between depression and survival in 
cancer samples. This is not to say that sub-clinical levels of depression are of 
unimportance. In contrast, patients with sub-clinical depression warrant equal attention as 
patients with clinical levels, as there is an opportunity to prevent worsening of symptoms 
to clinical levels and the subsequent greater risk of earlier mortality.  
These findings extend the growing literature in support of the prognostic 
significance of depression in cancer samples, and are clearly, of extreme clinical 
importance. These findings further support the need for on-going efforts to routinely 
screen all cancer patients for distress and mood symptoms and the need for trained 
clinical psychologists in oncology settings to effectively prevent and treat sub- and 
clinical levels of depression. Depression is a treatable condition and these findings further 
motivate efforts to adapt efficacious interventions for cancer patient populations as well 
as elucidate mechanisms driving the association between depression and shorter survival. 
Hypothesis 1b. Hypothesis 1b proposed that more depressive symptoms would 
be associated with greater cortisol dysregulation (higher overall mean and bedtime 
cortisol and flatter diurnal cortisol slopes). Hypothesis 1b was not supported. 
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Contrary to hypothesis 1b, depressive symptoms were not significantly associated 
with any markers of cortisol assessed at any of the different time points/using different 
methodologies (i.e., slope, intent-to-treat) upon primary analysis. Interestingly, only older 
age at study entry and at diagnosis was associated with elevated bedtime mean cortisol 
levels assessed at baseline. The direction of this association is not surprising given that 
the HPA-axis tends to function less efficiently with older age and higher bedtime mean 
cortisol is reflective of an unhealthier neuroendocrine system (see Figure 1). However, it 
is interesting that older age was only associated with bedtime mean, opposed to overall 
mean or diurnal cortisol slope, which are more robust markers of neuroendocrine-
mediated HPA-axis function. Nonetheless, of the two samples that combine to calculate 
the overall mean cortisol and diurnal slope (waking and bedtime), higher bedtime mean 
cortisol has previously emerged as a prognostic indicator and has been proposed as a 
driver of the HPA-dysregulation observed in cancer samples (Schrepf et al., 2015). 
 Post-hoc analyses examining sub-and clinical levels of depression only yielded a 
significant association between sub-clinical levels of depression and flatter diurnal 
cortisol slope. These results are surprising given the dearth of literature linking 
depression and hyperactivation/subsequent dysregulation of the HPA axis that worsens 
with increases in depression severity (Stetler & Miller, 2011). These results further 
support the notion provided under hypothesis 1a that sub-clinical levels of depression are 
equally worthy of attention by providers, as flattener diurnal cortisol profiles has been 
linked to shorter survival among lung cancer patients (Sephton et al., 2013). It is possible 
flattened diurnal cortisol slopes, indicative of a dysregulated HPA-axis, can be detected 
earlier, when symptoms are of sub-clinical levels among this population, enhancing the 
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overall clinical utility of diurnal cortisol as a biomarker for the convergence of worsening 
psychological and disease-related health. It should be noted, however, that power was 
limited by the small sub-sample sizes as a result of splitting the sample (sub-clinical: n = 
26 - 27; clinical: n = 27 – 28).  
Alternatively, these findings may have been further elucidated by the inclusion of 
distinct depressive specifiers (e.g., acute versus chronic; first episode versus recurrent) 
and subtypes (e.g., atypical and melancholic depression; Association (2013). Although 
depressive specifiers and subtypes were not assessed in the current study and extend the 
scope of the current dissertation, there is evidence to suggest that distinct depressive 
subtypes are differentially associated with aberrant cortisol profiles in non-medically ill 
populations (O’Keane, Frodl, & Dinan, 2012; Stetler & Miller, 2011). For example, 
melancholic depression, characterized by anhedonia, insomnia, loss of appetite and 
feelings of excessive guilt and worthlessness, is associated with greater (54% larger 
effect) elevations in cortisol than depressive presentations without melancholic features. 
Moreover, a quantitative review conducted by Stetler & Miller (2011) on depression and 
HPA-axis activation spanning four decades of research concluded that different 
depressive symptom clusters are associated with different patterns of HPA-axis activity. 
Taken together, although the CES-D has been shown to be a valid and reliable measure of 
depressive symptoms in cancer populations (Hann et al., 1998), it is clear that 
considerable variability is introduced by the term “depression,” and that much remains 
unknown about the distinct depressive specifiers and subtypes as they relate to nuanced 
differences in cortisol profiles both in and out of medical-ill populations. It is plausible to 
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hypothesize that variations in symptom clusters within the current sample could be 
contributing to insignificant results observed following analysis of hypothesis 1b.  
Hypothesis 1c. Hypothesis 1c proposed that more depressive symptoms would be 
associated with shorter LTL. Hypothesis 1c was supported. 
Regarding depressive symptoms and LTL assessed at baseline, although older age 
at diagnosis was significantly associated with shorter LTL, depressive symptoms did not 
yield statistical significance. Similar to other biomarkers, including cortisol, it is expected 
that older age would be associated with shorter LTL, as it is typically reflective of poorer 
biological functioning. Although chronological age is not synonymous with LTL, a 
marker of cellular aging (Blackburn et al., 2015), shorter LTL is suggestive of poorer 
cellular integrity and stability (Blackburn, 2001). Thus, all other factors held constant, it 
is expected that older individuals would have experienced a greater number of cell 
divisions and therefore, shorter LTL over the course of their life.  
Interestingly, contrary to hypotheses, after adjusting for age at diagnosis, neither 
model containing sub- nor clinical levels of depression were significantly associated with 
LTL. Similar to the potential explanation provided in hypothesis 1b, null results may be 
explained by limited power resulting from small sample sizes after splitting the sample 
(sub-clinical: n = 29; clinical: n = 28). Alternatively, given that the time point for 
assessment of depressive symptoms was arbitrary (at baseline, whenever patients were 
recruited and opted to enroll in the study), it is possible the detrimental effects of 
depression reported in the literature would not have affected LTL in the current sample, 
as LTL was also assessed at baseline (i.e., within the same week). Unlike changes in 
neuroendocrine functioning via the HPA-axis that can be observed relatively proximal to 
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a stressor (~within 20 - 30 minutes; Kirschbaum, Pirke, and Hellhammer (1993) through 
cortisol assessment, measurable LTL attrition is not conceptualized in the literature as an 
equally rapidly occurring process. Although it is believed that the temporal timeline 
between depression and subsequent telomere attrition has not yet been reported on in the 
literature, telomere attrition is conceptualized as a global marker of cellular aging. Thus, 
although the process of cell division, which leads to cumulative telomere attrition, occurs 
relatively quickly (within a day), measurable changes in telomere length may require 
greater time.  
Regarding change in symptoms, the hypothesized association between change in 
depressive symptoms and change in LTL was supported. Consistent with hypothesis 1c, 
as depressive symptoms increased, LTL decreased. As anticipated, despite a low sub-
sample (n = 11), minority status (non-White participants) emerged as a significant 
predictor of shorter LTL, although the interaction between minority status and change in 
depressive symptoms did not significantly contribute to the model. In other words, 
although minority status and change in depressive symptoms were both significantly 
associated with shorter LTL, the effects of a having an ethnic minority background on 
LTL was unrelatedly to depressive symptoms in the current sample.  
Overall, these findings support the mounting evidence demonstrating an 
association between depression and shorter LTL (Lindqvist et al., 2015) and extend the 
existing literature linking ethnic differences in LTL observed in non-medically ill 
populations (Geronimus et al., 2010; Geronimus et al., 2015; Weber et al., 2018) to lung 
cancer patients. Despite mounting evidence demonstrating a robust effect of stress on TL, 
there is paucity of telomere biology in current biobehavioral cancer models. TL has been 
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linked to both depression and cancer outcomes independently; however, this dissertation 
is one of the first investigations into the relationship between depression and TL in a lung 
cancer sample. 
 It is believed that this dissertation is also the first to demonstrate that minority 
status significantly predicted shorter LTL in a cancer sample. The fact that minority 
status was predictive of a decrease in LTL regardless of depressive symptoms is puzzling. 
Given that the majority of the literature discussing shorter LTL among ethnic minorities 
has postulated this disparity is a result of discrimination (Chae et al., 2014) and greater 
cumulative life stress, referred to as the “weathering hypothesis,” (Forde, Crookes, 
Suglia, & Demmer, 2019), it is intriguing that the relationship between ethnic minority 
status and LTL was not observed at baseline. These results suggest there may have been 
changes in other factor(s), other than depressive symptoms, over the three months 
between baseline and follow-up to explain the influence of ethnic minority status on 
decrease in LTL. Although it extends the scope of the current investigation, it is plausible 
to hypothesize that other stressors that are commonly reported among minority 
populations may have been exacerbated by cancer-related stressors to mediate or 
moderate the association between minority status and shorter LTL during this 3-month 
period. A rich area for exploration, future investigations should investigate the role of 
ethnic minority status on stress-related outcomes longitudinally across the cancer 
trajectory to elucidate stressors unique to patients with an ethnic minority background. 
Summary. Because hypothesis 1a was only partially supported and hypothesis 1b 
was not supported, hypothesis 1d and 1e – the role of cortisol markers and telomere 
length in the depression-survival relationship – were not tested. Thus, the potential 
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contribution of the circadian coordinated neuroendocrine system and telomere biology to 
the depression-survival relationship remain unclear and warrant further investigation. 
More broadly, although the current investigation was methodologically limited and 
exploratory rather than confirmatory in nature, the underlying biological mechanisms 
associated with the prognostic significance of depression in cancer remains unanswered 
and an important area of future inquiry. Nonetheless, the current investigation provided 
some important clues. First, the clinical significance, or severity, of depression appears to 
be an important factor in the depression-survival investigation. Despite limited sub-
sample sizes, only clinically significant levels of depression (CES-D score > 16) emerged 
as a significant predictor of survival. Second, despite considerably more evidence 
supporting the association between depression and markers of cortisol, LTL emerged as 
the only significant biomarker in the current investigation. Because cortisol is a hallmark 
of depression and has demonstrated robust associations with shorter survival across 
different cancers including lung, it should not be ignored in future investigations. 
However, the current analyses contribute greater support for future investigations into the 
role of telomere biology. Although telomere attrition has been linked to both depression 
and clinical outcomes in cancer samples, this dissertation is one of the first to integrate 
the two. Taken all together, in depth assessment of depression (i.e., severity, history, 
features, and subtypes), ethnic minority status, and the role of LTL may be important 
considerations for future investigations.  
Aim 2 Discussion: Mindfulness-based Interventions in Cancer Contexts 
 The need for feasible psychological care in cancer settings continues to become 
increasingly more apparent and pressing given the accumulating evidence to suggest 
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cancer patients experience high prevalence rates of distress, which is associated with 
poorer clinical outcomes. Despite relatively recent advancements in treatments, including 
immunotherapy, that have yielded promising results, cancer remains a life-threatening 
disease without a cure. In addition to facing this stark reality, cancer patients are faced 
with a plethora of other stressors at different points across the cancer trajectory, 
warranting stress-reduction strategies. As partially supported by hypothesis 1a, 
interventions that reduce stress and depression will not only improve quality, but also a 
patient’s quantity of life, and the evidence in support of MBSR as an efficacious 
treatment for reduction of depressive symptoms among cancer patient populations 
continues to grow (Huang et al., 2016; Zainal et al., 2013; Zhang, Wen, et al., 2015). 
Although there are some contradictory findings regarding depressive symptom reduction 
specifically (Bränström et al., 2012), MBSR interventions have evidenced strong support 
for stress-reduction more broadly among cancer populations (Ledesma & Kumano, 
2009), and no study to date has examined the effects of an MBSR intervention on 
survival among cancer patients. Nonetheless, the feasibility of interventions, including 
MBSR is a major priority given that attending weekly, in-person group sessions is 
challenging for many patients, particularly those experiencing greater burden and fewer 
resources (i.e., transportation and financial issues, limits to physical functioning, feeling 
overwhelmed with new appointments/obligations, cognitive changes, etc. (Lehto & 
Wyatt, 2013). As such, there is growing attention to the “e-health” movement in 
oncology settings and the healthcare system at large, which provides a host of services, 
including MBCR/(CR) (Lengacher et al., 2018; Zernicke et al., 2013), through a host of 
mobile, electronic formats. The most recent pilot iPad-based MBSR/(CR) intervention 
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conducted by Lengacher and colleagues (2018) demonstrated statistically significant 
improvements to somatic symptoms of depression (d = 0.85) among breast cancer 
survivors. Thus, Aim 2 of the current study was to explore the ameliorative role of an 
iPod-based MBSR intervention on depressive symptoms and related outcomes among 
lung cancer patients 
Hypothesis 2a. Hypothesis 2a proposed that participation in and use of the 
intervention would be associated with fewer depressive symptoms from baseline to 
follow-up. Hypothesis 2a was partially supported. 
After adjusting for baseline differences in depressive symptoms and 
chemotherapy treatment status at baseline since the intervention was optional and not 
randomized, participation in the intervention only emerged as a significant predictor of 
change in depressive symptoms following intent-to-treat principles outlined by (Lachin, 
2000). Following the outlined procedures, baseline values were used to replace missing 
values at follow-up, resulting in a slope of zero (i.e., no observed change). Contrary to 
hypotheses, change in depressive symptoms was positive (scores increased by 
approximately three points) in the intervention group whereas depressive symptoms were 
essentially maintained (scores decreased by approximately half of a point) among 
participants who did not complete the intervention (Figure 6). Interestingly, despite being 
only a three-point increase, the change in mean scores surpassed the clinical threshold 
(score of > 16 on the CES-D). In other words, among the intervention group, the average 
score at baseline fell in the sub-clinical range and elevated to a clinically meaningful 
level following the intervention, which is consistent with findings that emerged following 
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the analysis of hypothesis 1a. Thus, the hypothesized association emerged as significant, 
but not in the hypothesized direction.  
 Post-hoc analyses examining the interaction between chemotherapy treatment 
status at baseline and the intervention was not significant, suggesting that, although 
exploratory analyses revealed patients actively receiving chemotherapy treatment at study 
enrollment were significantly less likely to participate in the intervention, it was not a 
correlate of the association between the intervention and change in depressive symptoms 
in the current investigation. In other words, the stressors that typically accompany 
chemotherapy treatment could not statistically explain the outcomes following the 
intervention in the current sample. Importantly, however, only six patients actively in 
treatment at baseline (chemotherapy: n = 5; radiation: n = 1) participated in the 
intervention, providing extremely low power to measure and detect such associations. 
Further, post-hoc analysis among those who participated in the intervention, 
suggested greater use of the intervention was not associated with an increase in 
depressive symptoms, suggesting there was not a dose-response relationship between use 
of the intervention and an increase in depressive symptoms, although power was limited.  
While the results of the current analysis should be interpreted cautiously for a 
number of reasons, namely the limited sample size, the methodological design of the 
intervention (optional pilot), and the exploratory, rather than confirmatory nature of the 
analysis, the statistically significant associations that emerged following participation in 
the intervention only emerged following intent-to-treat principles. Although these 
replacement procedures are commonly used among populations with high attrition rates, 
such as medically ill populations, the use of such replacement procedures follows the 
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rationale that no change was observed, although it remains unknown if a change actually 
occurred. In other words, these procedures are not inaccurate based on the data collected 
(i.e., no observed change), but they do not ensure accuracy (i.e., change was not 
observed, but could have occurred). It is likely that the intent-to-treat principles yielded 
significance, whereas the analysis using non-replaced data did not, as a result of 
increased power given that the sample size nearly doubled (non-replaced: n = 31; intent-
to-treat: n = 59).  
Nonetheless, the results not only contradict hypothesis 2a, but they are clinically 
concerning. Despite evidence to suggest that MBSR/(CR) interventions in both in-person 
(Huang et al., 2016; Zainal et al., 2013; Zhang, Wen, et al., 2015) and mobile (Lengacher 
et al., 2018) formats reduce stress and depressive symptoms, the majority of this work 
was conducted among breast cancer patients, and more specifically, breast cancer 
survivors. While there are a number of shared stressors across all cancer patients, there 
are disease-specific differences, such as tumor location, treatments, and prognoses, as 
well as unique disease-specific stressors that differ across cancer types that could be 
contributing to the contradictory and unexpected findings in the current investigation. For 
example, breast and lung cancer patients may exist within unique social contexts. Breast 
cancer contexts tend to foster a sense of cohesion and societal support as evidenced by 
the widely known “pink ribbon” symbol, whereas lung cancer is typically coupled with 
smoking-related stigma (Chapple, Ziebland, & McPherson, 2004). This is not to suggest 
breast cancer patients do not experience significant distress or stigma or that the pink 
ribbon phenomenon is always beneficial, it is simply to acknowledge that cancer patients 
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have differing experiences specific to their disease that may have been underappreciated 
in the current investigation that are discussed further below.  
First, as suggested by the name, lung cancer patient’s tumor is located inside the 
lung, the organ responsible for breathing, which is a major focus/component of 
mindfulness-based practice (Kabat-Zinn, 1982). In meditative practice, and in many of 
the tracks, participants were encouraged to focus their attention to a focal point, which is 
not always, but often the breath. Post-hoc analyses revealed that the practice track titled,  
“Awareness of the breath,” which was listened to an average of seven times, was not 
associated with change in depressive symptoms (following intent-to-treat principles), 
suggesting explicit instruction to focus on the breath was no associated with an increase 
in depressive symptoms. Nonetheless, it is possible that without the added support of an 
in-person instructor, components of the intervention that are inherent to meditative 
practice predisposed risk for distress in this sub-sample of the cancer population. 
Second, a major difference in the time point in the cancer trajectory during which 
the intervention was administered could elucidate contradictory findings. Although 
survivorship presents a host of unique stressors (i.e., fear of recurrence), it is distinct 
psychologically from in the current sample, 24 of which were actively receiving 
treatment at study enrollment (chemotherapy: n = 24; radiation: n = 3), and were far from 
survivorship status. Because treatment is acutely stressful and is accompanied with a host 
of uncomfortable side effects, it is reasonable to assume that is an optimal time point to 
provide patients with stress reduction strategies. Alternatively, learning a new skill under 
acute stress can be ineffective (Joëls, Pu, Wiegert, Oitzl, & Krugers, 2006) and 
potentially overwhelming. Interestingly, chemotherapy treatment status at baseline 
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significantly differentiated the two groups (those who were actively receiving 
chemotherapy were more likely to decline the intervention), suggesting that stressors 
associated with active treatment were likely not responsible for increasing depressive 
symptoms in the current investigation. Nonetheless, because the intervention was not 
randomized and only six patients were actively receiving treatment at baseline 
(chemotherapy: n = 5; radiation: n = 1), it is difficult to discern if opting out of the 
intervention during active treatment was protective or if those were the individuals that 
would have benefited most.   
Additionally, it is not uncommon for participants to experience discomfort and an 
initial increase in distress during participation in an MBI given that the foundation of 
meditative practice is to approach (i.e., focus attention), rather than avoid internal 
experiences, which can be unpleasant (Dobkin & Zhao, 2011). Thus, while the 
underlying goal of meditative practice is not to increase distress, if done correctly, 
meditation increases awareness to existing distress, if distress is present. Like many 
psychological interventions, MBIs are often challenging in the short-term, but yield long-
term benefit. While the overarching goal of mindfulness-based practice is to simply 
increase awareness to inner experiences, which can also increase awareness of positive 
inner experiences, the results from the current investigation suggest this particular sample 
did not attain the intended longer-term stress-reduction benefits of the MBI. There are a 
number of potentially explanations for this, including possibilities already discussed; 
however, minimal instruction and consultation may have contributed to the poor 
outcomes as well. Participants were not instructed to listen to the tracks in any particular 
order; they were told to listen to tracks of their choice for 30 minutes per day, five days 
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per week (equating to 450 minutes over the 3-month period), introducing considerable 
variability in what the intervention experience might have been like for each participant. 
Post-hoc analyses revealed that surprisingly, intervention participants almost exclusively 
listened to practice, opposed to didactic tracks. Only two of 25 participants listened to a 
didactic track. Thus, it is plausible that by listening to almost exclusively practice tracks, 
participants missed key instruction and guidance surrounding typical experiences 
following increased awareness of inner experiences, such as the anticipation that greater 
contact with difficult emotions can be unpleasant. Counterintuitive to the finding (i.e., 
participation in the intervention increased depressive symptoms), in line with this 
theoretical position, it is also possible participants did not engage in the intervention 
enough to adequately master skills and attain benefit. Participants, on average, did not 
listen to the prescribed amount. Following the instruction of 30 minutes per day, five 
days per week over the course of three months, the prescribed listening amount was 1,800 
minutes, and on average, participants listened significantly less (mean = 1624, median = 
806). Thus, it is possible that upon experience of increased attention to existing 
discomfort, participants discontinued use of the intervention prematurely, resulting in the 
observed increase in depressive symptoms, without the long-term benefits observed after 
weeks (i.e., eight) of practice following a typical MBSR intervention.  
Further, this risk may have been moderated by minimal consultative support. 
Records indicated that only one participant attended the drop-in mindfulness-based 
cancer support group once over the 3-month intervention period. Therefore, the format of 
the pilot intervention essentially eliminated all interpersonal elements of MBSR. While 
the active components of MBSR and MBI’s are unknown, patients not only missed 
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opportunity for the benefits of social support that the group format facilitates (Lengacher 
et al., 2009), but participants in the current pilot MBI also did not have on-going access 
to an instructor, and therefore, lacked the opportunity to engage in on-going dialogue 
about their experiences. Although study personnel contacted participants twice over the 
course of the three-month intervention to check-in, provide reminders, and answer 
questions about the intervention, the degree and consistency of discussion regarding 
participants’ experiences was significantly less than what would have been achieved in a 
more traditional MBSR intervention.  
While the goal of feasibility seemed to be achieved by the current intervention, as 
evidenced by one third of the sample opting to participate and lack of attendance at the 
in-person support group, a primary difference between the current e-health intervention 
and previous studies involving mobile MBIs that yielded psychological benefit, in 
addition to differences in cancer sub-types, was lack of access to a trained instructor 
(Zernicke et al., 2013). Although a recent study involving an iPad-based MBSR/(CR) 
intervention that also lacked access to an in-person instructor led to improvements in 
depressive symptoms, study personnel contacted participants weekly, providing a more 
frequent avenue for consultation, and the sample was, again, among breast cancer 
survivors (Lengacher et al., 2018). Although it cannot be confirmed by the data, as there 
was no in-person MBSR comparison condition in the current investigation, it plausible to 
hypothesize that having access to a trained instructor, preferable a clinical psychologist, 




Taken all together, this finding should be interpreted cautiously given the 
possibility of selection effect, but considered, especially given the results that emerged 
following analysis of hypothesis 1a indicating clinical levels of depression predicted 
shorter survival in this sample. While it remains unknown which, if any, aspects of the 
intervention contributed to poor outcomes, there are a number of different factors that 
warrant greater consideration in future investigations. Differences between cancer types 
and the point in the cancer trajectory during which previous MBIs were administered 
may have been underappreciated in the current sample. Researchers and clinicians alike 
should consider the broader biopsychosocial perspective of the patient’s cancer 
experience to temper the generalizability of conclusions across populations. Lastly, these 
results further motivate efforts to dismantle active components of MBIs.  
Hypothesis 2b. Hypothesis 2b proposed that participation in and use of the 
intervention would be associated with improved diurnal cortisol rhythmicity from 
baseline to follow-up. Hypothesis 2b was not supported. 
Contrary to hypothesis 2b, the intervention did not change any of the markers of 
diurnal cortisol (including analyses following intent-to-treat principles). Additionally, 
consistent with hypothesis 1b, no theoretically derived indicators were significantly 
associated with changes in any of the markers of cortisol. Given the exploratory nature of 
the analysis and the minimal existent evidence to suggest MBSR is efficacious at 
improving diurnal cortisol rhythmicity among cancer patients, these null findings are not 
particularly surprising. Despite growing evidence to suggest that MBSR and other MBIs 
are efficacious at improving the physical health among non-medically ill populations 
(Grossman, Niemann, Schmidt, & Walach, 2004), the majority of studies examining the 
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effects of an MBI on cortisol among cancer patients have not yielded significance 
(Bränström et al., 2013; Lengacher et al., 2012). It is possible cancer patients’ 
neuroendocrine systems are less malleable to intervention as a result of tumor - and 
treatment-related effects. Alternatively, more extensive mindfulness-based training might 
be required to observe significant changes. Given Carlson and collogues’ findings that 
yielded statistically insignificant changes in cortisol profiles immediately following the 
intervention (2004), but significance at the one-year follow-up (2007), the latter is more 
likely. Interestingly, although the current investigation did not test mediation, in 
conjunction with findings from hypothesis 2a and 1b, it seems cortisol profiles were not a 
correlate or an underlying explanation for worsening depression among intervention 
participants in the current sample. 
Hypothesis 2c. Hypothesis 2c proposed that participation in and use of the 
intervention would be associated with maintenance of LTL (lack of a decrease) from 
baseline to follow-up. Hypothesis 2c was supported. 
After adjusting for chemotherapy treatment status at baseline, the intervention 
was significantly associated with a change in LTL. As hypothesized, the slope of change 
in LTL was positive among those in the intervention whereas the slope of change was 
negative among those who did not complete the intervention. As demonstrated in Figure 
7, the LTL increased among those in the intervention group, whereas LTL decrease 
among those who did not participate. Chemotherapy treatment status was also 
significantly associated with change in LTL. As shown in Figure 8, contrary to 
expectations, patients that were receiving chemotherapy treatment at baseline evidenced 
longer LTL compared to those who were not. Despite being consistent with the 
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hypothesized direction, the effect of the intervention was stronger than hypothesized (i.e., 
LTL was lengthened opposed to just maintained among the intervention group). 
Contradictory to what was expected, however, was that relatively proximal chemotherapy 
treatment was associated with an increase in LTL. Although these results technically 
support hypothesis 2c, they are somewhat puzzling given the results that emerged 
following analysis of hypothesis 2a, demonstrating that the intervention led to an increase 
in depressive symptoms. This is especially puzzling given that following analysis of 1c, a 
significant association emerged between change in depressive symptoms and change in 
the predicted direction LTL – as depressive symptoms increased, LTL decreased with 
and without adjusting for use of the intervention. 
To elucidate the complexity of these findings, post-hoc analyses examining the 
prognostic significance of LTL revealed that change in LTL predicted survival from both 
date of study entry and date of diagnosis. The results persisted after adjustment for 
participation in the intervention. However, contrary to expectations, increasing LTL 
predicted shorter survival from both date of study entry and date of diagnosis, suggesting 
that longer LTL may have been associated with poorer clinical outcomes in this lung 
cancer sample. Moreover, consistent with the results that emerged following analysis of 
hypothesis 2a, in the analysis demonstrating that longer LTL predicted shorter survival, 
after adjusting for participation in the intervention, results demonstrated that those who 
participated in the intervention died sooner. In other words, the intervention was 
associated with longer LTL, which predicted shorter survival, contrary to expectations. 
While these results suggest that the intervention was associated with an increase 
in depression and longer LTL, which unexpectedly predicted shorter survival, these 
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findings are inconsistent with results from hypothesis 1c (as depressive symptoms 
increased, LTL decreased/shortened after adjusting for minority status). Interestingly, the 
association between depression and LTL persisted after controlling for participation in 
the intervention. To elucidate these findings and clarify the bigger picture, despite 
restricted power, a regression re-assessing the association between depressive symptoms 
and change in LTL (hypothesis 1c) with the addition of the interaction term between 
change in depressive symptoms and the intervention was conducted. The model emerged 
as significant, although the interaction term did not significantly contribute to the model. 
Despite lack of statistical significance, as demonstrated for visual not statistical purposes 
in Figure 16, there appear to be differences in the pattern of association between change 
in depressive symptoms and change in LTL between intervention groups (participated 
versus not). The association between change in depressive symptoms and change in LTL 
was positive (as depressive symptoms increased, LTL also increased/lengthened) among 
those who participated in the group, whereas the association was negative (as depressive 
symptoms increased, LTL decreased/shortened) among those who did not. In contrast, as 
shown in Figure 17, excluding participation in the intervention, the pattern of findings are 
consistent with hypothesis 1c – the association between change in depressive symptoms 
and change in LTL is negative (as depressive symptoms increased, LTL 
decreased/shortened). Therefore, although the interaction was not statistically significant, 
it seems an increase in depressive symptoms was only associated with longer LTL among 
patients in the intervention group, providing a more cohesive picture among the current 
sample, as each predicted shorter survival and each “worsened” following the 
intervention. It is likely differential effects regarding minority status may have also 
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emerged after adjusting for intervention status as well with larger power, as only three 
individuals from ethnic minority backgrounds participated in the intervention.  
Importantly, these findings clarify the results that demonstrated patients who were 
receiving chemotherapy at baseline evidenced an increase in LTL. These findings 
cohesively support the post-hoc analysis that demonstrated a statistically significant 
interaction between intervention participation status and chemotherapy treatment status at 
baseline. As demonstrated in Figure 13, patients who received chemotherapy at baseline 
and participated in the intervention demonstrated an increase in LTL, whereas patients 
who were not receiving chemotherapy at baseline and did not participate in the 
intervention evidenced a decrease in LTL (all other patients evidenced no noticeable 
change), supporting the notion that the intervention was associated with worsening 
biological health among those who had recently undergone chemotherapy treatment. 
What remains unclear from the current investigation, however, is why increasing, 
opposed to shortening LTL, emerged as a marker of shorter survival, and was associated 
with an increase in depressive symptoms only among those in the intervention group. 
These findings are particularly perplexing given the substantial evidence to suggest that, 
in general, telomeres shorten faster under stressful conditions and shorter telomeres are 
indicative of poorer health. It is plausible, just as there appear to have been disease-
specific psychosocial considerations that were overlooked in the current intervention, that 
there may be underlying disease-specific biological differences occurring in the current 
NSCLC sample as well, especially given the complexity of cancer biology. As such, there 
are still a number of unknowns about telomere biology in tumor environments and what 
impact that has on the patient’s systemic biology.  
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Greater attention has been directed toward telomerase in cancer contexts, more 
recently, as it is the enzyme responsible for adding new DNA to the end of chromosomes 
effectively lengthening telomeres (Blackburn, 2011), and may be a missing piece to 
elucidating the current findings. Somewhat counter-intuitively, extremely short TLs that 
are near senescence are actually protective against cell division and uncontrollable cell 
growth, and therefore tumor progression, whereas continuous cell growth and advancing 
tumors is associated with reactivation of telomerase (Shay & Wright, 2011). Indeed, 
overexpression of telomerase has been observed in 90% of cancer cells (Kim et al., 
1994), and current hypotheses posit that as telomeres from cancer cells shorten rapidly, 
telomerase facilitates indefinite cell division in an attempt to re-stabilize telomeres, which 
ultimately leads to a state of “immortalization,” or unrest of cellular proliferation 
(Augustine et al., 2017). In other words, as the host’s body produces greater telomerase to 
rectify the excessively short TLs that may have conferred risk for the disease in the first 
place (Hou et al., 2012), it actually unlocks tumorigenesis. Importantly, telomere length 
in the current investigation was assessed peripherally via blood samples and telomerase 
was not assessed, so limited conclusions can be drawn. Nonetheless, it is plausible that 
the observed increase in LTL could be explained by an increase in telomerase, which 
may actually confer risk for shorter survival as it likely indicates greater cell proliferation 
both in and out of tumor environments, and therefore tumor growth.  
It should be acknowledged, however, that the alternative – depletion of 
telomerase in tumor microenvironments – appears to be equally problematic. 
Experiments have revealed the elimination of telomerase leads to eventual loss of 
telomere function, which also facilitates tumor progression (De Lange & Jacks, 1999). 
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Thus, it is likely more accurate to conceptualize the disruption of the delicate balance 
between cell division (telomere shortening) and telomerase (telomere lengthening) in the 
tumor microenvironment as harmful as it appears to activate tumorigenesis. However, the 
specific timing and mechanisms of this process remain unclear (Hackett & Greider, 
2002), and no literature on the longitudinal changes to peripheral LTL in cancer samples 
currently exists. Both gaps warrant greater attention to elucidate current findings, but 
also, to strengthen LTL’s utility as a feasible, easily obtainable clinical biomarker in 
cancer contexts. 
Consistent with the proposed theory, if longer telomeres are actually indicative of 
faster tumor growth and stress has been shown to tax telomere biology, then despite 
being counterintuitive to findings in non-medically ill populations, it is logical that 
worsening depression would be linked to longer telomeres in cancer populations, as 
demonstrated in the current sample. It is plausible that, consistent with the literature in 
non-medically ill populations, depressive symptoms shortened telomeres in the current 
sample, but instead of being biologically adaptive, greater distress potentially amplified 
the body’s production of telomerase indirectly, which ultimately supported 
tumorigenesis. To clarify, none of the proposed explanations discussed in the current 
section were tested in the current investigation, and should therefore, be considered on a 
theoretical level. Considerably more research examining the nuanced relationships 
between depression, LTL, telomerase, and medical factors known to influence tumor 
biology, including disease stage and treatments, from a longitudinal perspective is 
required to elucidate findings that emerged from the current investigation.  
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Most importantly, however, elucidating the elements of the intervention that 
contributed to poorer psychological and biological health should be prioritized. Although 
it is challenging to interpret the LTL findings in context of the broader literature, as there 
has only been one study that examined the effects of an MBI on TL among cancer 
patients, the pilot intervention led to statistically significant increases in LTL, which was 
unexpectedly associated with shorter survival. The only other study that examined the 
effects of an MBI on TL to date revealed that TL was maintained following an MBCR 
intervention compared to the control groups, whose TL decreased (Carlson et al., 2013). 
Importantly, however, as previously mentioned, this sample was among breast cancer 
survivors, who from a biological and psychosocial perspective, likely differ from NSCLC 
patients many of which were far from survivorship status. Although a number of potential 
explanations have been discussed under hypothesis 2a, findings from primary and post-
hoc analysis of hypothesis 2c, combine to suggest that active component(s) of the iPod-
based MBI were detrimental to the small sample of NSCLC patients included in the 
current investigation, demanding greater consideration from researchers and clinicians a 
like. 
Hypothesis 2d. Hypothesis 2d proposed that participation in and use of the 
intervention would be associated with longer survival. Hypothesis 2d was partially 
supported.  
As hypothesized, the intervention emerged as a significant predictor of survival 
calculated both from study entry and date of diagnosis; however, inconsistent with the 
hypothesis, participation in the intervention was associated with shorter survival (Figures 
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9 and 10). Thus, the hypothesized association emerged as significant, but not in the 
hypothesized direction, yielding partial support for hypothesis 2d.  
Similar to hypothesis 2a and 2c, among those who participated in the intervention, 
greater use of the intervention did not predict shorter survival, only participation in the 
intervention emerged as significant, suggesting that there was not a dose-response 
relationship and findings could be attributable to a selection effect. Additionally, post-hoc 
analyses demonstrated that use of practice tracks did not predict survival, and shorter 
survival could not be explained by use of the track “Awareness of the breath,” further 
suggesting that an aspect of the intervention, rather than the specific content of the 
intervention, contributed to poorer outcomes. As discussed at length under hypothesis 2a 
and 2c, there are a number of potential explanations hypothesizing why the pilot iPod 
intervention was unexpectedly related too poorer outcomes, although greater listening 
behavior, use of practice tracks, and use of the track with explicit focus on the breath, 
based on the available data, did not emerge as a likely explanation. However, conclusions 
surrounding listening behavior are restricted by the fact that participants largely did not 
listen to didactic tracks, which restricted power to make comparisons. Thus, as discussed 
under hypothesis 2a, it is possible lack of instruction regarding the order of tracks 
(didactic followed by or intermixed with practice) inadvertently facilitated an increase in 
awareness of distressing internal experiences, that without guidance, could have been 
interpreted by intervention participants as both distressing and concerning, leading them 
to terminate the intervention prior to fully gaining stress-reduction skills. Thus, it is more 
likely that limited instruction regarding track order, compiled by a virtual instructor void 
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of interpersonal dialogue contributed to poorer outcomes than the content of the 
intervention. 
As previously mentioned, although results from the current investigation should 
be interpreted cautiously given the aforementioned limitations to the study, namely that 
the design of the intervention was not randomized, results from the current hypothesis are 
clinically concerning and cannot be dismissed, especially in conjunction with the results 
that emerged following hypothesis 2a and 2c. While the current study should not be 
replicated at minimum without random assignment for ethical reasons, these findings will 
hopefully motivate efforts toward dismantling the active components of MBSR and MBIs 
to subsequently be tested among cancer patients, and sub-samples of the cancer patient 
population (i.e., lung cancer). Although the analysis from the current investigation was 
exploratory in nature, given the gravity of the results, the findings from the current 
dissertation should still be taken seriously in clinical contexts. The majority of published 
research on the effects of MBSR and MBIs among cancer patients has demonstrated 
benefit, or at least has not reported harm; thus, it is plausible to conclude that there was 
an underlying component inherent to the current intervention that was detrimental. It is 
still possible that the component of attention to the breath, which is common to 
meditation practice, led to an increase in depressive symptoms and related outcomes 
among this sample despite results that emerged following post-hoc analysis to suggest 
that greater use of the “Awareness of the breath,” track was not associated with greater 
depressive symptoms or shorter survival. However, the unspecified track order and 
limited access to a trained instructor are equally viable competing hypotheses. Indeed, it 
may have been a combination of the three. With greater power and a stronger 
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methodological design, it would have been helpful to explore the moderating role of a 
trained instructor on the potential association between increased attention to the breath 
and inner experiences and an increase in depressive symptoms and shorter survival. 
Summary. The evidence that emerged from analysis of Aim 2 hypotheses 
cumulatively and cohesively suggest that the intervention was associated with worsening 
psychological and physical health and shorter survival among a small sample of NSCLC 
patients. Contrary to the hypothesized and intended benefits of the pilot iPod-based MBI, 
the intervention yielded sobering negative associations. Because the intervention was not 
randomized, it is possible there were undetected differences between the two groups 
predisposing the intervention group to poorer outcomes. However, baseline differences 
were controlled for in each analysis and the initial exploratory analysis comparing the 
two groups demonstrated that chemotherapy treatment status at baseline was the only 
demographic/medical factor differentiating the two groups. Importantly, those who were 
receiving chemotherapy at study entry were actually less likely to participate in the 
intervention, suggesting results are likely best explained by an unidentified factor related 
to the intervention opposed to a biased sample. 
Although unintentional, these analyses inadvertently contributed to a gap in the 
mindfulness-based literature: absence of research on the harmful or negative of effects of 
MBIs (Irving, Dobkin, & Park, 2009). These results demonstrate that under specific 
conditions, MBIs may in fact confer risk and even be harmful. In accordance with Baer 
and colleagues’ (2019) extensive discussion surrounding the potential sources for harm in 
MBIs, including program/intervention, participant, and instructor/clinician factors, the 
current dissertation identifies a number of factors from each of these categories that may 
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have conferred risk for harm among the current sample. Unfortunately, although these 
factors cannot be compared, and therefore, confirmed as explanations in the current 
investigation, each one of these factors was discussed as a hypothetical explanation for 
the current findings (i.e., program/intervention: iPod-based; participant: lung cancer 
patients; instructor/clinician: optional and underutilized at the drop-in group). It is clear 
that Baer and colleagues’ (2019) discussion surrounding the potential for MBIs to induce 
harm should be taken seriously by researchers and clinicians a like.  
Conclusions 
 Taken all together, although results from the current investigation should be 
interpreted cautiously, the current dissertation provides a number of informative data 
points regarding depressive symptoms, telomere length, survival, and the use of an iPod-
based MBI among NSCLC patients (see Figure 2). 
1. Only clinical, not sub-clinical, levels of depression at baseline predicted shorter 
survival from both date of study entry and date of diagnosis (hypothesis 1a). 
2. All things held constant, ethnic minorities evidenced greater shortening of LTL 
(hypothesis 1c). 
3. The intervention was associated with an increase in depressive symptoms, an 
increase in LTL, and shorter survival from both date of study entry and date of 
diagnosis (hypothesis 2a, 2c, 2d). 
4. An increase in LTL was associated with shorter survival from both date of study 
entry and date of diagnosis (post-hoc hypothesis 2c/hypothesis 1e). 
5. Although an increase in depressive symptoms was initially associated with a 
decrease in LTL (hypothesis 1c), upon closer examination, it seems as depressive 
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symptoms increased, LTL only shortened among patients who did not participate 
in the intervention, whereas LTL lengthened among those who participated in the 
intervention (post-hoc hypothesis 2c/1c). 
Although mediations and moderation analyses extend the scope of the current 
dissertation, and the design of the study did not meet criteria for these analyses, these 
results point to longer LTL as a potential biological explanation for the depression-
survival relationship among lung cancer patients. Little is known about the longitudinal 
changes in LTL across the cancer trajectory and how it is dynamically influenced by 
telomerase, tumorigenesis, and psychological factors, such as worsening depression, but 
results from this dissertation further support the importance and complexity of telomere 
biology in cancer populations. Surprisingly, the less supported biomarker, TL, as 
compared to cortisol, emerged as the potential link between worsening depressive 
symptoms and shorter survival.  
Results from the current dissertation also highlight the importance of taking a 
humanistic approach to psycho-oncology by comprehensively considering the entire 
biopsychosocial perspective of the population of interest. In clinical research it is often 
both appropriate and efficient to generalize across sub-populations; however, it seems 
that generalizations cannot always be made across cancer sub-types (i.e., breast to lung), 
as there are unique factors differentiating their experience. Furthermore, it seems 
generalizations across patients at different points in the cancer trajectory may not have 
been appropriate as the majority of support for the intervention stemmed from research 
among breast cancer survivors. Although the specific factors of the population and the 
components of the intervention that contributed to poorer health on a psychological, 
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biological, and clinical level remain unclear, results from the current investigation that 
starkly contradict other findings in the literature demonstrate that active ingredients of the 
current intervention were under considered. While these results are unsettling and 
completely contradictory to a-priori hypotheses, they affirm the importance of 
conducting pilots and may caution against feasibility to the point of sacrificing efficacy 
of the intervention. Once again, although the underlying cause of risk cannot be 
confirmed, it is reasonable to speculate that patients facing mortality might require 
interpersonal support from a trained mental health professional, either in-person or 
virtually, throughout the MBI, as it can prompt greater attention to difficult inner 




 Although a number of limitations to the current dissertation have already been 
acknowledged, given the gravity of the findings, it is necessary to emphasize the 
limitations to the current investigation. First, the directionality between depression and 
biomarkers cannot be assumed since they were collected at roughly the same time point 
(e.g., baseline and follow-up). For this reason, the temporal precedence criteria discussed 
by Kraemer and colleagues (2008) for mediation and moderation statistical analysis was 
not met, limiting the conclusions that could be made in the current investigation. 
Although an increase in depressive symptoms was associated with change in LTL, and 
both were predictive of shorter survival, LTL could not be tested as a mechanism in the 
depression-survival pathway due to methodological limitations.  
As previously mentioned, other methodological limitations also exist. Although 
the overall sample size supported primary hypotheses, small sub-sample sizes (e.g., 
minority status, number of participants in the intervention, intervention listening 
behavior, etc.) limited power and the ability to statistically test differences in observed 
patterns and elucidate finings. Additionally, the pilot nature of the intervention (optional 
and not randomized) further limited the conclusive nature of its effects. Although there 
did not appear to be significant differences between those who opted to participate in the 
intervention versus those who did not, other than chemotherapy treatment status at 
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baseline, the intervention was not randomized, which further convolutes the striking and 
unexpected intervention findings.  
Lastly, there was considerable variation in the medical characteristics of the 
sample given that one of the inclusion criterions was a NSCLC diagnosis within five 
years of study entry. Interpretation of findings related to biomarkers (i.e., LTL) was 
limited by the medical heterogeneity of the sample. There was considerable variability in 
where each patient was in the cancer trajectory given that some were actively receiving 
treatment (chemotherapy: n = 24; radiation: n = 3) at study entry, whereas others were 




 Given the exploratory rather than confirmatory nature of the current dissertation, a 
number of questions remain unanswered and warrant future investigation. Regarding Aim 
1 and the mechanisms of the depression-survival pathway, future investigations should 
attempt to elucidate the role of factors and subtypes of depression as it relates to shorter 
survival. As discussed under hypothesis 1a, greater investigation into the severity, 
symptom clusters, history, and subtypes of depression could identity the patients at 
greatest risk and inform nuanced interventions to improve clinical outcomes. Moreover, 
in addition to testing LTL as a mediator of the depression-survival pathway, greater 
investigation into the longitudinal change in peripheral TL as relates to telomerase, 
tumorigenesis and distress/depression in current samples would increase the utility of 
LTL as potentially feasible clinical biomarker in cancer contexts. 
 Regarding Aim 2 and the clinically concerning results that emerged following the 
pilot iPod-based MBI, while future investigations should not aim to replicate the current 
investigation, dismantling studies should attempt to identify the active components of 
MBSR and MBIs to subsequently be tested among cancer patients and specific cancer 
types (e.g., lung) at different points in the cancer trajectory (e.g., prior to survivorship). 
Although other mobile studies without a group component have demonstrated efficacy in 
reducing depressive symptoms among cancer patients (Lengacher et al., 2018), the 
potential benefits of the group component should also be examined given the mounting 
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evidence demonstrating that social support yields many benefits among cancer patient 
populations (Uchino, 2004). The order and balance between didactics and practice 
content in e-health interventions should also be clarified and adapted accordingly. 
Additionally, future investigations should elucidate the role of a trained, easily accessible 




 In conclusion, a cancer diagnosis can be devastating, as it is followed by an 
arduous battle for survivorship that is, unfortunately, not always won. Typically, the 
primary goal is to extend life given that much of the distress that accompanies cancer 
stems from the very real, pressing threat of mortality. However, in consideration of this 
harsh reality, that survivorship may not be achieved, quality of life becomes highly 
valued. Said best by June Goodfield, and quoted by Siddhartha Mukherjee, in The 
Emperor of All Maladies: A Biography of Cancer, “Cancer begins and ends with people. 
In the midst of scientific abstraction, it is sometimes possible to forget this one basic fact” 
(p. 1). The shortcomings of the well intentioned current intervention may be best 
explained by this quote, as many of the proposed components that may have conferred 
risk could have potentially been avoided following greater consideration of the larger 
biopsychosocial perspective opposed to focus on scientific abstraction. Thus, identifying 
interventions that treat people, by enhancing both quality and quality of life remain an 
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A list of the Mindfulness-Based iPod Intervention Tracks. 
 
Didactic Tracks (minutes: seconds) Practice Tracks (minutes: seconds) 
1. Introduction (11:26) 1. Sitting Meditation Instructions (8:11) 
2. Foundation, Importance of 
Attitudes (3:54) 2. Awareness of the Breath (11:05) 
3. Non-judging (4:04) 3. 5 Minute Sitting Meditation (5:18) 
4. Patience (3:46) 4. 10 Minute Sitting Meditation (10:16) 
5. Beginner’s Mind (3:41) 5. 15 Minute Sitting Meditation (15:16) 
6. Trust (4:06) 6. 20 Minute Sitting Meditation (20:19) 
7. Non-Striving (6:19) 7. Extended Sitting Meditation (41:03) 
8. Acceptance (4:46) 8. Loving Kindness Meditation (5:40) 
9. Letting Go (6:53) 9. Informal Mindfulness Practice (3:17) 
10. The Present Moment (11:56) 10. Mountain Meditation (20:04) 
11. Wandering Mind (1) (7:53) 11. Body Scan Meditation (40:22) 
12. Wandering Mind (2) (9:17)  
13. Stress and Mindfulness (1) (7:45)  
14. Stress and Mindfulness (2) (7:08)  
15. Working with Difficult Emotions 
(7:22) 
 
16. Taking Care of Yourself (5:43)  
17. Social Support (9:05)  
18. Self Compassion (7:00)  
19. Accepting Emotions (8:52)  
20. Living with Cancer (1) (5:47)  
21. Living with Cancer (2) (5:52)  
22. Living with Cancer (3) (5:18)  
23. Cancer Teamwork (6:17)  
24. Caring and Sharing (8:37)  
25. I am not this Cancer (7:56)  
26. Waiting (11:35)  
27. Holding on and Letting Go (7:40)  
28. Acknowledgment (2:07)  
29. Taking Your Place (4:26)  
30. ‘Letting Go’ (3:29)  
31. ‘Wild Geese’ (2:18)  






Sample characteristics.  
 
 
Variable Frequency (n) Percent (%) Mean 
Sex    
Male 21 31.3  
Female 41 61.2  
* 5 7.5  
Age   61.5 
Race/Ethnicity    
Non-Hispanic White 39 58.2  
Black/African American 10 14.9  
Hispanic or Latino 1 1.5  
Asian/Asian American 1 1.5  
Other 1 1.5  
* 15 22.4  
Minority Status    
Yes 13 19.4  
No 39 58.2  
Annual Household Income    
>$15,000 - 39,999 36 53.7  
$40,000 - 79,999 15 22.4  
$80,000 – 149,999 7 10.5  
$150,000 - 249,999 1 1.5  
* 8 11.9  
Age at Diagnosis   59.6 
Disease Stage at Diagnosis    
I 15 22.4  
II 8 11.9  
III 28 41.8  
IV 16 23.9  
Early (I, II) 23 34.3  
Late (III, IV) 44 65.7  
Treatment Factors    
Chemotherapy at study entry    
Yes 21 31.3  
No 38 56.7  
* 8 11.9  
Radiation at study entry    
Yes 3 4.5  
No 57 85.1  
* 7 10.4  
Chemotherapy ever    
Yes 48 71.6  
No 12 17.9  
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* 7 10.4  
Radiation ever    
Yes 38 56.7  
No 22 32.8  
* 7 10.4  
Time since diagnosis (months)   23.5 
Predictors and Outcomes at Baseline    
Depression 59 88.1 15.5 
* 8 11.9  
Above clinical cut-off a 29  43.3 23.9 
Overall mean cortisol b 58 86.6 -2.17 
* 9 13.4  
Bedtime mean cortisol b 58 86.6 -2.83 
* 9 13.4  
Diurnal cortisol slope b 57 85.1 -0.05 
* 10 14.9  
TL at baseline 64 95.5 0.82 
* 3 4.5  
Notes. *Missing data. 
a The clinical cut off on the CES-D is 16. 




Table 3.    
Correlations between Theoretically-Derived Covariates and Independent and Dependent Variables 
(‘a’ and ‘d’ Hypotheses). 
 
  Correlations 
 10 11 12 13 14 
1. Disease stage -.066 .017 .094 -.252 -.262 
2. Age -.092 -.247 -.176 -.056 -.088 
3. Age at diagnosis -.074 -.205 -.146 -.056 -.194 
4. Sex -.060 .154 .053 .305* .209 
5. Chemotherapy treatment at baseline .325* -.057 -.066 -.183 -.200 
6. Ever received chemotherapy -.063 -.027 .018 .149 .109 
7. Radiation treatment at baseline .077 .265 .201 .002 .000 
8. Every received radiation -.044 -.175 .011 -.132 .091 
9. Smoking history  .109 .063 .045 -.265 -.069 
10. Depressive symptoms at baseline 1 - - - - 
11. Change in depressive symptoms - 1 - - - 
12. Intent-to-treat - - 1 -  
13. Survival from study entry - - - 1 - 
14. Survival from date of diagnosis - - - - 1 





Table 4.  
      
 
   
Correlations Between Theoretically-Derived Covariates and Independent and Dependent Variables 
(‘b’ Hypotheses). 
 
  Correlation 
 10 11 12 13 14 15 16 17 18 19 20 21 
1. Disease 
stage -.07 .02 .09 .19 -.14 -.05 .21 -.11 -.10 .04 .12 .06 
2. Age -.09 -.25 -.18 .26 -.18 -.08 .33* -.06 .01 .13 -.05 -.07 
3. Age at 
diagnosis -.07 -.21 -.15 .25 -.15 -.07 .31* -.06 .02 .13 -.04 -.06 
4. Sex -.06 .15 .05 -.08 -.12 -.04 -.11 .10 .08 -.06 -.07 -.06 
5. Chemo at 




-.06 -.03 .02 -.09 .03 .05 -.09 -.23 -.10 -.06 -.24 -.20 
7. Radiation 




-.04 -.18 .01 -.01 .01 .03 -.01 -.17 -.11 .03 -.13 -.09 
9. Smoking 









- 1 - - - - - - - - - - 
12. Intent-to-










- - - - 1 - - - - - - - 
15. Intent-to-








- - - - - - - 1 - - - - 
18. Intent-to-








- -  - - - - - - - 1 - 
21. Intent-to-
treat - - - - - - - - - - - 1 






Table 5.       
Correlations Between Theoretically-Derived Covariates and Independent and Dependent 
Variables (‘c’ Hypotheses). 
 Correlation 
 11 12 13 14 15 16 
1. Disease stage -.066 .017 .094 .117 -.037 .011 
2. Age -.092 -.247 -.176 -.295 -.070 -.024 
3. Age at diagnosis -.074 -.205 -.146 -.312* -.120 -.053 
4. Sex -.060 .154 .053 .136 .068 .087 
5. Chemo at baseline .325* -.057 -.066 -.018 .212 .249 
6. Ever received chemo -.063 -.027 .018 .246 .065 .100 
7. Radiation at baseline .077 .265 .201 -.049 -.134 -.146 
8. Ever received radiation -.044 -.175 .011 .062 .294 .193 
9. Smoking history .109 .063 .045 -.258 .126 .057 
10. Ethnic minority status .151 .251 .265 .003 -.332* .251 
11. Depressive symptoms at 
baseline 1 - - - - - 
12. Change in depressive 
symptoms - 1 - - - - 
13. Intent-to-treat - - 1 - - - 
14. Baseline LTL - - - 1 - - 
15. Change in LTL - - - - 1 - 
16. Intent-to-treat - - - - - 1 
Note. *r  > 0.3 and < 0.5 






Demographic and Medical Differences Between Intervention Groups (Exploratory Analysis). 
 
  
 Completed Intervention 
Did not 
Complete      
Intervention 
 
   
 M SD M SD t-test χ
2 U 
Demographics        
Age 61.0 9.5 61.7 8.4 .729   
Age at Diagnosis 59.2 9.6 59.8 8.6 .775   
Sex  - - - - - .798  
Minority Status  - - - - - .142  
Education † - - - - -  .301 
Income † - - - - -  .239 
Medical         
Disease Stage  - - - - -   
Treatment - - - - -   
Chemotherapy         
At baseline  - - - - - .050*  
Ever - - - - - .190  
Radiation         
At baseline - - - - - .764  
Ever - - - - - .085  
Months between diagnosis 
and study entry 626.7 389.9 749.5 616.0 .375 
  
Pack Years 46.7 36.2 37.5 24.4 .269   
Notes. *p  < .05      




Table 7.       
Associations Between Depressive Symptoms and Survival (Hypothesis 1a). 
 
Depressive Symptoms at Baseline on Survival from Study Entry 
Predictor B df p Hazard Ratio 95% CI 
Sex 0.669 1 .090 1.953 0.901 4.231 
Depression 0.023 1 .206 1.023 0.987 1.06 
Sex  0.654 1 .096 1.924 0.89 4.16 
Intervention -0.926 1 .017* 0.396 0.185 0.85 
Depression 0.025 1 .175 1.025 0.989 1.062 
Depressive Symptoms at Baseline on Survival from Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Depression 0.027 1 .139 1.027 0.991 1.064 
Intervention -0.905 1 .021* 0.405 0.188 0.87 
Depression 0.024 1 .180 1.024 0.989 1.061 
Change in Depressive Symptoms on Survival from Study Entry 
Predictor B df p Hazard Ratio 95% CI 
Sex 0.763 1 .154 2.145 0.752 6.121 
Depression 0.453 1 .869 1.573 0.007 338.148 
Sex  0.736 1 .185 2.088 0.736 1 
Intervention -1.12 1 .087 0.326 -1.12 1 
Depression -0.728 1 .810 0.483 -0.728 1 
Change in Depressive Symptoms on Survival from Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Depression 0.625 1 .798 1.869 0.015 226.456 
Intervention -0.781 1 .241 0.458 0.124 1.688 
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Depression -0.318 1 .904 0.727 0.004 128.856 
Change in Depressive Symptoms (intent-to-treat) on Survival from Study Entry 
Predictor B df p Hazard Ratio 95% CI 
Sex 0.686 1 .086 1.985 0.908 4.338 
Depression 1.085 1 .663 2.961 0.022 391.42 
Sex  0.684 1 0.09 1.982 0.899 4.371 
Intervention -0.915 1 0.021 0.4 0.184 0.871 
Depression -0.233 1 0.926 0.792 0.006 111.355 
Change in Depressive Symptoms (intent-to-treat) on Survival from Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Depression 1.5 1 .526 4.484 0.044 
Intervention -0.939 1 .020* 0.391 0.178 
Depression -0.026 1 .991 0.975 0.01 
Note. *p < .05 




Table 8.       
Depressive Symptoms Regressed on Markers of Diurnal Cortisol (Hypothesis 1b). 
Depressive Symptoms on Overall Mean Cortisol Assessed at Baseline 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.127 0.016 0.016 .356 .866 .356 
Depression 0.127 0.93 0.356       
Depressive Symptoms on Bedtime Mean Cortisol Assessed at Baseline 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.058 0.003 0.003 .675 .178 .675 
Depression 0.058 0.422 .675       
Model 2    0.354 0.125 0.122 .010 3.720 .031* 
Depression  0.100 0.764 .448       
Age 0.352 2.691 .010*       
Model 2    0.328 0.108 0.104 .017* 3.133 .052 
Depression 0.09 0.682 0.499       
Age at 
diagnosis 0.324 2.464 0.017       
Depressive Symptoms on Diurnal Cortisol Slope Assessed at Baseline 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.069 0.005 0.005 .615 .256 .615 




Change in Depressive Symptoms on Change in Overall Mean Cortisol  
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1     0.176 0.031 0.031 0.41 .706 .410 
Depression 0.176 0.84 0.410       
Model 2    0.328 0.108 0.077 0.193 1.270 .302 
Depression 0.283 1.281 .214       
Intervention -0.297 -1.344 .193       
Change in Depressive Symptoms on Change in Bedtime Mean Cortisol 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.231 0.053 0.053 0.278 1.237 .278 
Depression 0.231 1.112 0.278       
Model 2    0.362 0.131 0.078 0.185 .1580 .229 
Depression 0.338 1.55 0.136       
Intervention -0.298 -1.369 0.185       
Change in Depressive Symptoms on Change in Diurnal Cortisol Slope 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.209 0.044 0.044 .339 .957 .339 
Depression 0.209 0.978 .339       
Model 2    0.222 0.049 0.006 .730 .520 .602 
Depression 0.181 0.783 .443       
Intervention 0.081 0.350 .730       
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Change in Depressive Symptoms on Change in Overall Mean Cortisol (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.138 0.019 0.019 .316 1.024 .316 
Depression 0.138 1.012 .316       
Model 2    0.238 0.057 0.038 0.155 1.564 .219 
Depression 0.194 1.384 .172       
Intervention -0.202 -1.443 .155       
Change in Depressive Symptoms on Change in Bedtime Mean Cortisol (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.187 0.035 0.035 .172 1.916 .172 
Depression 0.187 1.384 .172       
Model 2    0.248 0.061 0.026 .231 1.700 .193 
Depression 0.234 1.672 .100       
Intervention -0.169 -1.211 .231       
Change in Depressive Symptoms on Change in Diurnal Cortisol Slope (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1     0.198 0.039 0.039 .151 2.122 .151 
Depression 0.198 1.457 .151       
Model 2    0.205 0.042 0.003 .693 1.123 .333 
Depression 0.182 1.278 .207       
Intervention 0.057 0.397 .693       




Table 9.       
Depressive Symptoms Regressed on LTL (Hypothesis 1c). 
Depressive Symptoms on LTL Assessed at Baseline 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.157 0.025 0.025 .242 1.398 .242 
Depression -0.157 -1.182 .242       
Model 2    0.356 0.127 0.102 .015 3.915 .026* 
Depression -0.191 -1.495 .141       
Age at 
diagnosis -0.321 -2.509 .015*       
Depressive Symptoms on Change in LTL 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.058 0.003 0.003 .675 1.988 .171 
Depression -0.271 -1.41 .171       
Model 2    0.354 0.125 0.122 .010* 4.914 .016* 
Depression  -0.418 -2.318 .029*       
Minority 
Status 0.488 2.708 .012*       
Model 3    0.626 0.391 0.101 .063 4.930 .009** 
Depression -0.508 -2.875 .009**       
Minority 
Status 0.453 2.639 .015*       
Intervention 0.335 1.952 .063       
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Change in Depressive Symptoms on Change in LTL (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.102 0.01 0.01 .449 .582 .449 
Depression -0.102 -0.763 .449       
Model 2    0.228 0.052 0.042 .130 1.481 .237 
Depression -0.159 -1.155 .253       
Intervention 0.211 1.538 .130       
Note. *p < .05, **p < .01       
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Table 10.       
Association Between the Intervention and Change in Depressive Symptoms (Hypothesis 2a). 
 
Change in Depressive Symptoms 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 0.002 1 0.002 0.264 .612 0.010 
Chemotherapy 0.001 1 0.001 0.145 .706 0.006 
Intervention 0.018 1 0.018 2.314 .140 0.082 
Change in Depressive Symptoms (intent-to-treat) 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 0.001 1 0.001 0.269 .606 0.005 
Chemotherapy 0.002 1 0.002 0.367 .547 0.007 
Intervention 0.023 1 0.023 5.36 .024* 0.09 
Baseline differences 
(intercept) 0.002 1 0.002 0.641 .427 0.002 
Chemotherapy 0.003 1 0.003 1.139 .291 0.003 
Intervention 0.013 1 0.013 4.275 .044* 0.013 
Note. *p < .05, **p < .01      
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Table 11.       
Use of the Intervention Regressed on Change in Depressive Symptoms (Hypothesis 2a). 
Total Listening Time on Change in Depressive Symptoms 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.196 0.038 0.038 .407 .719 .407 
Intervention -0.196 -0.848 .407       
Total Number of Tracks on Change in Depressive Symptoms  
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.206 0.043 0.043 .383 .800 .383 
Intervention -0.206 -0.894 .383       
Total Listening Time on Change in Depressive Symptoms (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.313 0.098 0.098 .128 2.494 .128 
Intervention 0.313 0.098 .098       
Total Number of Tracks on Change in Depressive Symptoms (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.318 0.101 0.101 0.121 2.587 .121 
Intervention 0.318 0.101 0.101       
Note. *p < .05       
	
 166 
Table 12.       
Association Between the Intervention and Change in Markers of Diurnal Cortisol 
(Hypothesis 2b). 
 
Change in Overall Mean Cortisol 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 4.70E-05 1 4.70E-05 1.505 .231 0.057 
Chemotherapy 1.14E-05 1 1.14E-05 0.364 .552 0.014 
Intervention 3.46E-05 1 3.46E-05 1.108 .303 0.042 
Change in Bedtime Mean Cortisol 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 1.86E-05 1 1.86E-05 0.32 .576 0.013 
Chemotherapy 1.23E-06 1 1.23E-06 0.021 .886 0.001 
Intervention 1.37E-05 1 1.37E-05 0.236 .631 0.009 
Change in Diurnal Cortisol Slope 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 4.49E-06 1 4.49E-06 9.844 .004** 0.291 
Chemotherapy 1.32E-06 1 1.32E-06 2.903 .101 0.108 
Intervention 2.40E-08 1 2.40E-08 0.053 .821 0.002 
Change in Overall Mean Cortisol (intent-to-treat) 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 2.33E-05 1 2.33E-05 1.398 .243 0.027 
Chemotherapy 1.22E-05 1 1.22E-05 0.732 .396 0.014 
Intervention 3.24E-05 1 3.24E-05 1.946 .169 0.037 
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Change in Bedtime Mean Cortisol (intent-to-treat) 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 2.42E-05 1 2.42E-05 0.786 .379 0.015 
Chemotherapy 4.14E-07 1 4.14E-07 0.013 .908 0 
Intervention 2.60E-05 1 2.60E-05 0.844 .363 0.016 
Change in Diurnal Cortisol Slope (intent-to-treat) 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 1.13E-06 1 1.13E-06 3.58 .064 0.067 
Chemotherapy 6.81E-07 1 6.81E-07 2.16 .148 0.041 
Intervention 1.21E-07 1 1.21E-07 0.384 .539 0.008 
Note. *p < .05, **p < .01      
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Table 13.       
Use of the Intervention Regressed on Change in Markers of Diurnal Cortisol (Hypothesis 2b). 
Total Listening Time on Change in Overall Mean Cortisol 
Variable β T p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.01 0 0 .970 .001 .970 
Intervention 0.01 0.038 .970       
Total Number of Tracks on Change in Overall Mean Cortisol 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.018 0 0 .945 .005 .945 
Intervention -0.018 -0.07 .945       
Total Listening Time on Change in Bedtime Mean Cortisol 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.026 0.001 0.001 .921 .010 .921 
Intervention 0.026 0.101 .921       
Total Number of Tracks on Change in Bedtime Mean Cortisol 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.020 0 0 .940 .006 .940 
Intervention 0.02 0.076 .940       
Total Listening Time on Change in Diurnal Cortisol Slope 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.093 0.009 0.009 .731 .123 .731 
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Intervention 0.093 0.351 .731       
Total Number of Tracks on Change in Diurnal Cortisol Slope 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.104 0.011 0.011 0.702 .152 .702 
Intervention 0.104 0.39 .702       
Total Listening Time on Change in Overall Mean Cortisol (intent-to-treat) 
Variable β T p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.02 0 0 .929 .008 .929 
Intervention -0.02 -0.09 .929       
Total Number of Tracks on Change in Overall Mean Cortisol (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.05 0.003 0.003 .819 .053 .819 
Intervention -0.05 -0.231 .819       
Total Listening Time on Change in Bedtime Mean Cortisol (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.015 0 0 .946 .005 .946 
Intervention -0.015 -0.069 .946       
Total Number of Tracks on Change in Bedtime Mean Cortisol (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.031 0.001 0.001 .890 .002 .890 
Intervention -0.031 -0.14 .890       
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Total Listening Time on Change in Diurnal Cortisol Slope (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.071 0.005 0.005 .747 .107 .747 
Intervention 0.071 0.327 .747       
Total Number of Tracks on Change in Diurnal Cortisol Slope (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.081 0.007 0.007 .007 .140 .712 
Intervention 0.081 0.374 .712       
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Table 14.       
Association Between the Intervention and Change in LTL (Hypothesis 2c). 
 
Change in LTL 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 9.01E-10 1 9.01E-10 0.003 .960 0 
Chemotherapy 1.75E-06 1 1.75E-06 4.915 .033* 0.126 
Intervention 1.95E-06 1 1.95E-06 5.454 .026* 0.138 
Change in LTL (intent-to-treat) 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 2.94E-08 1 2.94E-08 0.106 .746 0.002 
Chemotherapy 1.57E-06 1 1.57E-06 5.652 .021* 0.096 
Intervention 7.75E-07 1 7.75E-07 2.791 .101 0.05 
Note. *p < .05      
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Table 15.       
Use of the Intervention Regressed on Change in LTL (Hypothesis 2c). 
Total Listening Time on Change in LTL 
Variable β T p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.167 0.028 0.028 .446 .603 .446 
Intervention -0.167 -0.776 .446       
Total Number of Tracks on Change in LTL 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.134 0.018 0.018 .543 .383 .543 
Intervention -0.134 -0.619 .543       
Total Listening Time on Change in LTL (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.156 0.024 0.024 .466 .551 .466 
Intervention -0.156 -0.742 .466       
Total Number of Tracks on Change in LTL (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.13 0.017 0.017 .546 .376 .546 
Intervention -0.13 -0.613 .546       
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Table 16.       
Association Between Use of the Intervention and Survival from Date of Study Entry and Date of 
Diagnosis (Hypothesis 2d). 
 
Total Listening Time on Survival from Study Entry 
Predictor B df p Hazard Ratio 95% CI 
Intervention 0 1 .107 1 1 1 
Sex 0.525 1 .179 1.69 0.787 3.632 
Total Number of Tracks on Survival from Study Entry 
Predictor B df p Hazard Ratio 95% CI 
Intervention 0.001 1 .210 1.001 0.999 1.003 
Sex 0.57 1 .177 1.768 0.773 4.043 
Total Listening Time on Survival from Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Intervention 0 1 .094 1 1 1 
Total Number of Tracks on Survival from Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Intervention 0.001 1 .179 1.001 0.999 1.003 
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Table 17.       
Sub- and Clinical Levels of Depressive Symptoms Regressed on Markers of Diurnal Cortisol (Post-
hoc, Hypothesis 1b). 
Depressive Symptoms on Overall Mean Cortisol Assessed at Baseline 
 β t p R R2 ΔR2 p(ΔR2) F p 
Model 1          
Sub-
clinical 0.01 0.049 .961 0.01 0 0 .961 .002 .961 
Clinical -0.258 -1.362 .185 0.258 0.067 0.067 .185 1.854 .185 
Depressive Symptoms on Bedtime Mean Cortisol Assessed at Baseline 
 β t p R R2 ΔR2 p(ΔR2) F p 
Model 1          
Sub-
clinical 0.239 1.229 .23 0.239 0.057 1.512 .230 1.512 .230 
Clinical -0.342 -1.858 .074 0.342 0.117 3.453 .074 3.453 .074 
Model 2          
Sub-
clinical 0.119 0.655 .519 0.512 0.262 6.676 .016 4.265 .026* 
Age 0.469 2.584 .016*       
Clinical -0.309 -1.627 .116 0.375 0.141 0.69 .414 2.051 .150 
Age 0.158 0.831 .414       
Model 1          
Sub-
clinical 0.239 1.229 .230 0.239 0.057 0.057 .230 1.512 .230 
Clinical -0.342 -1.858 .074 0.342 0.117 0.117 .074 3.453 .074 
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Model 2          
Sub-
clinical 0.138 0.75 .461 0.485 0.236 0.179 .026* 3.698 .040* 
Age at 
diagnosis 0.435 2.368 .026*       
Clinical -0.316 -1.663 .109 0.365 0.133 0.016 .503 1.922 .167 
Age at 
diagnosis 0.129 0.68 .503       
Depressive Symptoms on Diurnal Cortisol Slope Assessed at Baseline 
 β t p R R2 ΔR2 p(ΔR2) F p 
Model 1          
Sub-
clinical 0.411 2.252 .033* 0.411 0.169 0.169 .033 5.073 .033* 
Clinical -0.366 -2.002 .056 0.366 0.134 0.134 .056 4.009 .056 
Note. *p < .05       
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Table 18.       
Sub- and Clinical Levels of Depressive Symptoms Regressed on LTL (Post-hoc, Hypothesis 1c). 
Depressive Symptoms on LTL Assessed at Baseline 
 β t p R R2 ΔR2 p(ΔR2) F p 
Model 1          
Sub-
clinical -0.268 -1.443 .161 0.268 0.072 0.072 .161 2.081 .161 
Clinical 0.132 0.68 .503 0.132 0.017 0.017 .503 .462 .503 
Model 2          
Sub-
clinical -0.193 -1.051 .303 0.413 0.17 0.099 .091 2.666 .088 
Age -0.323 -1.758 .091       
Clinical 0.075 0.382 .706 0.283 0.08 0.062 .205 1.085 .353 
Age -0.256 -1.302 .205       
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Table 19.       
Change in Depressive Symptoms Regressed on Change in LTL Including an Interaction Between 
Change in Depressive Symptoms and Minority Status (Post-hoc, Hypothesis 1c). 
 
Depressive Symptoms on LTL Assessed at Baseline 
 β t p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.271 0.074 0.074 .171 1.988 .171 
Depression -0.271 -1.41 .171       
Model 2    0.539 0.291 0.217 .012 4.914 .016* 
Depression -0.418 -2.318 .029       
Minority Status 0.488 2.708 .012       
Model 3    0.626 0.391 0.101 .063 .4930 .009* 
Depression -0.508 -2.875 .009       
Minority Status 0.453 2.639 .015       
Intervention 0.335 1.952 .063       
Model 4    0.639 0.408 0.017 .436 2.795 .017* 
Depression -0.856 -1.81 .084       
Minority Status 0.485 2.73 .012*       




0.357 0.794 .436       
Note. *p < .05 
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Table 20.       
Association Between the Intervention and Change in Depressive Symptoms Including an 
Interaction Between the Intervention and Chemotherapy (Post-hoc, Hypothesis 2a). 
 
Change in Depressive Symptoms (intent-to-treat) 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 0.001 1 0.001 0.219 .642 0.004 
Chemotherapy 0.001 1 0.001 0.149 .701 0.003 
Intervention 0.028 2 0.014 3.142 .051 0.106 
Intervention x 




Association Between Low Versus High (Median Split) Use of the Intervention and Depressive 
Symptoms (Post-hoc, Hypothesis 2a). 
         Total Track Time    Total Number of Tracks 
 Low High      Low    High  
 M SD M SD t-test M SD M SD t-test 
Depression (intent-
to-treat) 0.052 0.100 0.011 0.068 .233 0.052 0.100 0.011 0.068 .291 
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Table 22.       
Use of the Intervention (Practice Tracks and “Awareness of the Breath” Track) Regressed on Change 
in Depressive Symptoms (Post-hoc, Hypothesis 2a). 
 
Total Practice Track Listening Time on Change in Depressive Symptoms (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Intervention -0.535 -2.002 .073 0.535 0.286 0.286 .073 4.007 .073 
Total Number of Practice Tracks on Change in Depressive Symptoms (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Intervention -0.551 -2.089 .063 0.551 0.304 0.304 .063 4.364 .063 
Total Listening Time of the “Awareness of the Breath” Track on Change in Depressive Symptoms 
(intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Intervention -0.327 -1.583 .128 0.327 0.107 0.107 .128 2.507 .128 
Total Number of Times the “Awareness of the Breath” Track Listened to on Change in Depressive 
Symptoms (intent-to-treat) 
Variable β t p R R2 ΔR2 p(ΔR2) F p 
Intervention -0.327 -1.583 .128 0.327 0.107 0.107 .128 2.507 .128 
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Table 23.       
Association Between the Intervention and Change in LTL Including an Interaction Between 
the Intervention and Chemotherapy (Post-hoc, Hypothesis 2c). 
 
Change in LTL 
Source SS df MS F p Partial η2 
Baseline differences 
(intercept) 1.68E-07 1 1.68E-07 0.537 .469 0.016 
Chemotherapy 1.91E-06 1 1.91E-06 6.104 .019* 0.156 
Intervention 1.55E-07 2 7.73E-08 0.248 .782 0.015 
Intervention x 
Chemotherapy 1.82E-06 1 1.82E-06 5.831 .021* 0.150 
Note. *p < .05      
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Table 24.       
Change in LTL Regressed on Survival (Post-hoc, Hypothesis 2c/Hypothesis 1e). 
 
Survival Analysis from Study Entry: Change in LTL  
Predictor B df p Hazard Ratio 95% CI 
Model  1 .002**    
LTL 959.435 1 .001** - 1.92E+166 - 
Model  2 002**    
LTL 731.339 1 .017* . 9.27E+56 . 
Intervention -1.178 1 .075 0.308 0.084 1.128 
Survival Analysis from Diagnosis: Change in LTL 
Predictor B df p Hazard Ratio 95% CI 
Model  1 .026*    
LTL 695.08 1 .018* 7.40E+301 1.00E+52 - 
Model  2 .017*    
LTL 496.454 1 .103 4.05E+215 0 . 
Intervention -1.085 1 .100 0.338 0.093 1.231 
Note. *p < .05, **p < .01.       
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Table 25.       
Change in Depressive Symptoms Regressed on Change in LTL Including an Interaction Between 
Change in Depressive Symptoms and the Intervention (Post-hoc, Hypothesis 2c). 
 
Variable β T p R R2 ΔR2 p(ΔR2) F p 
Model 1    0.271 0.074 0.074 0.171 1.988 .171 
Depression -0.271 -1.41 .171       
Model 2    0.455 0.207 0.133 0.056 3.133 .062* 
Depression -0.387 -2.029 .054       
Intervention 0.383 2.009 .056       
Model 3    0.626 0.391 0.184 0.015 4.93 .009** 
Depression -0.508 -2.875 .009**       
Intervention 0.335 1.952 .063       
Minority 
Status 0.453 2.639 .015*       
Model 4    0.63 0.397 0.006 0.65 3.623 .021* 
Depression -0.474 -2.438 .023*       
Intervention 0.325 1.847 .078       
Minority 
Status 0.43 2.374 .027*       
Depression x 
Intervention 0.084 0.46 .650       
Note. *p < .05, **p < .01 
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Table 26.       
Use of the Intervention (Practice Tracks and “Awareness of the Breath” Track) 
Regressed on Survival (Post-hoc, Hypothesis 2d). 
 
Total Practice Track Listening Time on Survival from Study Entry 
Predictor B df p Hazard Ratio 95% CI 
Model  1 .759    
Intervention 0 1 0.757 1 0.999 1.001 
Total Number of Practice Tracks Listened to on Survival from Study Entry 
Predictor B df p Hazard Ratio 95% CI 
Model  1 .762    
Intervention 0.001 1 0.76 1.001 0.993 1.009 
Total Practice Track Listening Time on Survival from Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Model  1 .965    
Intervention 0 1 0.965 1 0.999 1.001 
Total Number of Practice Tracks Listened to on Survival from Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Model  1 .974    
Intervention 0 1 0.974 1 0.992 1.008 
Total Time Listening to “Awareness of the Breath” Track on Survival from Study Entry 
Predictor B df p Hazard Ratio 95% CI 
Model  1 .787    
Intervention -0.001 1 0.79 0.999 0.993 1.006 
Total Number of Times Listened to “Awareness of the Breath” Track on Survival from 
Study Entry 
Predictor B df p Hazard Ratio 95% CI 
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Model  1 .787    
Intervention -0.01 1 0.79 0.99 0.922 1.064 
Total Time Listening to “Awareness of the Breath” Track on Survival from Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Model  1 .925    
Intervention 0 1 0.926 1 0.993 1.006 
Total Number of Times Listened to “Awareness of the Breath” Track on Survival from 
Diagnosis 
Predictor B df p Hazard Ratio 95% CI 
Model  1 .925    





















Figure 1. The yellow line depicts a “normal” diurnal cortisol profile. The red line is a visual 
representation of cortisol slope calculated from waking and bedtime samples. Steeper slopes 
have been linked to favorable health outcomes, whereas flatter slopes are considered aberrant 




.Figure 2. The proposed study model, aims, and hypotheses. The shaded arrows represent the 
primary associations that will be examined, whereas the unshaded arrows represent the 
relationships that will be explored contingent on the associations that emerge following the 










Figure 4. Change in depressive symptoms regressed on change in LTL by ethnicity 







Figure 5. Critical values used to determine variance ratio cut-offs for assessment of the 


















Figure 9. Kaplan-Meier curves depicting all-cause mortality for each of the intervention 




Figure 10. Kaplan-Meier curves depicting all-cause mortality for each of the intervention 





Figure 11. Kaplan-Meier curves depicting all-cause mortality for sub- and clinical levels 




Figure 12. Diurnal cortisol slope at baseline by intervention participation status (post-






Figure 13. Change in LTL by intervention participation status and chemotherapy 





Figure 14. Kaplan-Meier curves depicting all-cause mortality for low versus high 




Figure 15. Kaplan-Meier curves depicting all-cause mortality for low versus high 





Figure 16. Change in depressive symptoms regressed on change in LTL by intervention 
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disabilities, Autism, severe mental illness, ADHD, Selective Mutism. Administer 
assessments to determine placement into Gifted and Talented programs. Consult with 
external agencies and conduct collateral interviews and assessments as needed. Prepare 





Title of Project: Depressive Symptoms and Survival Among Lung Cancer 
Patients: Biomarkers and Potential Benefits of an iPod- and 
Mindfulness-based Intervention 
Funding:   Kentucky Lung Cancer Research Grant 
Dissertation Chair:   Sandra Sephton, Ph.D. 
Committee Members: Elizabeth Cash, Ph.D. Paul Salmon, Ph.D., Benjamin Mast, 
Ph.D., and Tamara Newton, Ph.D.  
Study aims: To test the prognostic significance of depressive symptoms 
and the role of two biomarkers – cortisol and leukocyte 
telomere length – as they relate to the depression-survival 
pathway; and to explore the ameliorative role of an iPod- 
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and mindfulness-based intervention on depressive 
symptoms and related outcomes among lung cancer 




July 2015 – Current  Graduate Student Research Assistant 
    Mindfulness and Biobehavioral Health Research Lab 
    Department of Psychological and Brain Sciences 
    University of Louisville, Louisville, KY 
Primary Mentor: Sandra E. Sephton, Ph.D. 
 
EXPERIENCE WITH SPECIFIC PROJECTS 
 
Title of Project: Are you F.O.M.O. prone? 
Study aims: Pilot an online study exploring the relationships between social 
media use, the F.O.M.O. (fear of missing out) phenomenon, 
mental health outcomes, and individual risk and protective 
factors. 
Duties: Designed study, proposed hypotheses, and prepared IRB 
materials; managed data collection; supervised undergraduate 
research assistants. 
 
Title of Project: A Dyadic Mindfulness Intervention for College Students and 
their Roommates – Mechanisms and Health Effects 
Study aims: Pilot a Koru iPod-based intervention; explore neural, cognitive 
and circadian pathways between mindfulness practice and health 
outcomes; explore the dyadic effects of a Koru iPod-based 
intervention among college roommates. 
Duties: Prepared and analyzed cognitive (memory and attention) e-Prime 
tasks and data; assisted with recruitment; collaboratively 
facilitated neural data collection via functional magnetic 
resonance imaging (fMRI); facilitated follow-up feedback 
sessions 
 
Title of Project: Mindfulness-based Stress Reduction for Parkinson’s Disease 
(PD) Patients and Caregivers 
Study aims: Test feasibility and efficacy of an MBSR intervention among PD 
patients and their caregiving partners on a host of health factors; 
examine shared dyadic stress and health effects.  
Duties: Assisted with analytic strategy, analysis and interpretation of 
findings; disseminate findings through presentation and 
manuscript preparation. 
 
Title of Project: Understanding the Prognostic Significance of Circadian 
Disruption in Lung Cancer  
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Study aims: Explore biobehavioral pathways of psychosocial and circadian 
effects on lung cancer progression; pilot an iPod- and 
mindfulness-based intervention.  
Duties: Collaborated with physicians to recruit patients; collected, 
organized, and analyzed psychosocial, circadian, and 
psychoneuroimmune data; managed study database; supervised 
undergraduate research assistants; prepared presentations and 
publications to disseminate findings; managed IRB compliance; 
prepared and shipped biological samples. 
 
Title of Project: A Meditation-based Intervention to Reduce Stress in 
Undergraduates 
Study aims: Pilot an iPod-based mindfulness meditation intervention among 
university undergraduates; explore the effects of mindfulness 
meditation on psychosocial and biological indicators of stress and 
health outcomes. 
Duties: Assisted with data analysis and interpretation of findings; 
disseminated findings. 
  
Title of Project: The Role of Mindfulness in Predicting Perceived Stress, Health 
and Positive Adaptation in College Undergraduates 
Study aims: Assess the relationship between stress, cortisol, and health in 
college undergraduates; evaluate ameliorative role of 
mindfulness. 
Duties: Interpreted and disseminated findings.  
 
Title of Project: Distress and Quality of Life in Head and Neck Cancer 
Study aims: Explore behavioral and biological pathways by which depression 
may influence cancer survival; examine treatment 
adherence/interruption and the role of tumor response to 
treatment in the depression-survival relation. 
Duties: Assisted in the interpretation of findings and preparation of 
publications. 
 
Title of Project: Stress, Coping, and Sleep in Breast Cancer 
Study aims: Examine the relationships between stress, coping, and circadian 
disruption among women with breast cancer. 
Duties: Assisted in interpretation and dissemination of findings. 
 
Title of Project: Effects of Stress in Women with Cancer 
Study aims: Examine role of stress on disease progression among women 
with ovarian or endometrial cancer. 
Duties: Generated hypotheses; planned and conducted data analysis; 
interpreted and disseminated findings; prepared publication 
materials; maintained IRB compliance 
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Title of Project: Psychosocial Effects in Lung Cancer Outcomes 
Study aims: Elucidate effects of psychosocial factors on medical and health 
outcomes among lung cancer patients; examine prognostic 
significance of psychosocial factors as mediated by medical 
adherence, health behaviors, and neuroendocrine function. 
Duties: Conducted data analysis; conceptualized findings; disseminated 
findings 
 
2014 – 2015     Post baccalaureate Study Coordinator 
      Mood and Memory Laboratory 
      Department of Psychiatry 
      University of Wisconsin, Madison, Madison, WI 
      Faculty Mentor: Heather Abercrombie, Ph.D. 
 
2012 – 2014     Research Assistant 
      Mood and Memory Laboratory 
      Department of Psychiatry 
      University of Wisconsin, Madison, Madison, WI 
      Faculty Mentor: Heather Abercrombie, Ph.D. 
 
Title of Project: Depression, Adversity, and Stress Hormones Study 
Study aims: Examine neurocognitive effects of cortisol in women with 
depression and/or early life adversity to inform pharmacologic 
treatment for depression subtypes. 
Duties: Oversaw integrity of NIMH and NARSAD-funded data 
collection and procedures; organized data analysis operations 
among collaborating groups (i.e. medical physics, genetics, and 
neuroscience); collected genetic, hormonal, cognitive and 
neuroimaging data; conducted clinical phone screen interviews 
and fMRI-scanning sessions; followed-up on safety and 
eligibility concerns with MRI technicians and study physicians; 
determined eligibility of participants; created recruitment 
materials targeted for depressed and diverse individuals; tracked 
study-related materials purchased with department funds. 
  
Title of Project: Memory for Emotional Pictures 
Study aims: Pilot stimuli to be used in the fMRI scanner for the parent study, 
Depression Adversity and Stress Hormones study among 
undergraduate students. 
Duties: Assisted with recruitment; scheduled and tracked participants; 
independently conducted study sessions; collected and managed 
cognitive data; developed standardized study procedures. 
 







Title of Project: Associations Between Positive and Negative Self-views, 
Depressive Symptoms, and Telomere Length in Non-small Cell 
Lung Cancer 
 
Effective Dates: 07/01/2017 – 06/30/2018 
 
Role: Author (PI: Sandra E. Sephton, Ph.D.) 
 





Aims: Explore how negative and positive self-views relate to depressive 
symptoms and how relationships between negative and positive 
self-views, as well as depressive symptoms, relate to telomere 





Title of Project: Circadian Disruption in Lung Cancer – Mechanisms & 
Prognostic Significance 
 
Role: Graduate Research Assistant (PI: Sandra E. Sephton, Ph.D.) 
 




Aims: Describe psychoneuroimmune pathways by which stress and 
circadian disruption affect lung cancer-related health outcomes 




PEER-REVIEWED JOURNAL ARTICLES 
 
1. Hicks, A., Siwik, C., Phillips, K., Zimmaro, L.A., Salmon, P., Burke, N.,  … & 
Sephton, S.E. (2019). Dispositional mindfulness is associated with lower basal 
sympathetic arousal and less psychological stress. International Journal of Stress 
Management.   
2. Zimmaro, L. A., Sephton, S. E., Siwik, C. J., Phillips, K. M., Rebholz, W. N., 
Kraemer, H. C., ... & Cash, E. D. (2018). Depressive symptoms predict head and 
neck cancer survival: Examining plausible behavioral and biological 
pathways. Cancer, 124(5), 1053-1060. 
3. Siwik, C., Hicks, A., Phillips, K., Rebholz, W. N., Zimmaro, L. A., Weissbecker, 
I., … & Sephton, S. E. (2017). Impact of coping strategies on perceived stress, 
depression, and cortisol profiles among gynecologic cancer patients. Journal of 
health psychology. 
4. Rebholz, W.N., Cash, E., Zimmaro, L.A., Bayley-Veloso, R., Phillips, K., Siwik, 
C., Chagpar, A.B., Dhabhar, F.S., Spiegel, D., Saltsman-Bell, B.N., & Sephton, 
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S.E. (2016). Distress and quality of life in an ethnically diverse sample awaiting 
breast cancer surgery. Journal of Health Psychology. 
5. Zimmaro, L.A., Salmon, P., Naidu, H., Rowe, J., Phillips, K., Rebholz, W.N., 
Giese-Davis, J., Cash, E., Dreeben, S.J., Bayley-Veloso, R., Jablonski, M.E., 
Hicks, A., Siwik, C., & Sephton, S.E. (2016). Association of dispositional 
mindfulness with stress, cortisol, and well-being among university undergraduate 
students. Mindfulness, 7(4), 874-885. 
 
MANUSCRIPTS UNDER REVIEW 
 
1. Hicks, A., Phillips, K., Siwik, C., Salmon, P., Litvan, I, Jablonski, M.E., Filoteo, 
J.V., Kayser, K., Sephton, S.E. (under review, 2018). The role of innate 
mindfulness in stress-health pathway among Parkinson’s disease patients and 
caregiving partners. Submitted to Quality of Life Research Journal. 
2. Siwik, C.J., Zimmaro, L., Blevins, T., Salmon, P., Kloecker, G., Cash, E., 
Phillips, K., Bayley-Veloso, R., Barve, S., & Sephton, S.E. (under review, 2019). 
Factors related to cancer patients’ willingness to participate in an iPod- and 
mindfulness-based intervention. Submitted to Annals of Behavioral Medicine. 
3. Bayley-Veloso, R, Szabo, Y., Cash, E., Zimmaro, L., Siwik, C., Kloecker, G., 
Salmon, P., van der Gryp., K., and Sephton, S.E. (under review, 2019). The role 
of trauma in the health-related quality of life of lung cancer patients. Submitted as 
a brief report to Journal of Psychosocial Oncology. 
 
MANUSCRIPTS IN PROGRESS 
 
1. Phillips, K., Siwik, C.J., Hicks, A., Salmon, P., Litvan, I, Jablonski, M.E., 
Filoteo, J.V., Kayser, K., Sephton, S.E. Baseline differences between Parkinson’s 
disease patients and their caregiving partners: Examination of non-independence 
among members of a dyad. Manuscript in preparation. Submitting to Movement 
Disorders. 
2. Siwik, C.J., Hicks, A., Phillips, K., Salmon, P., Litvan, I, Jablonski, M.E., 
Filoteo, J.V., Kayser, K., Sephton, S.E. An MBSR intervention for Parkinson’s 
disease patients and caregiving partners: Effects on distress, social support, 
cortisol, and inflammation. Manuscript in preparation. Submitting to Mindfulness. 
3. Siwik, C.J., Phillips, K., Zimmaro, L., Salmon, P., Kathleen van der Gryp & 
Sephton, S.E. The relationship between shame, guilt, and depressive symptoms 
and the ameliorative role of self-compassion among lung cancer patients. 
Manuscript in preparation. Submitting to Journal of Clinical Oncology. 
4. Siwik, C.J., Fischbach, A., Phillips, K. & Sephton, S.E. Hashtag F.O.M.O.: 
Understanding the relationship between mental health, social media use, and the 
fear of missing out phenomenon. Manuscript in Preparation. 
5. Rebholz, W., Cash, L., Weissbecker, I., Siwik, C.J., Phillips, K., Bayley-Veloso, 
R., van der Gryp, K., Sephton, S. Prognostic value of allostatic load in 
gynecologic cancer survival. Manuscript in preparation. 
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PUBLISHED ABSTRACTS  
 
1. Siwik, C.J., Phillips, K., Zimmaro, L., Cash, E., Hicks, A. & Sephton, S.E. 
(2019). The relationship between shame, guilt, and depressive symptoms and the 
ameliorative role of self-compassion among lung cancer patients. Psychosomatic 
Medicine, 81(3), A-94. 
2. Hicks, A., Salmon, P., Rebholz, W., Phillips, K., Siwik, C., Zimmaro, L., Cash, 
E., van der Gryp, K., & Sephton, S.E. (2018). The role of self-compassion in a 
stress-health pathway. Psychosomatic Medicine, 80(3), A76-A77. 
3. Phillips, K., Siwik, C., Hicks, A., Salmon, P., Cash, E., Litvan, I., Filoteo, J.V., 
van der Gryp, K., & Sephton, S.E. (2018). Exploration of dyadic associations of 
anxiety and diurnal cortisol among Parkinson’s disease patient/caregiver dyads. 
Psychosomatic Medicine, 80(3), A28-A29. 
4. Phillips, K., Siwik, C., Segerstrom, S., Zimmaro, L., Rebholz, W., Cash, E., 
Hicks, A., van der Gryp, K., & Sephton, S.E. (2018). Associations between daily 
affect, intrusive thoughts, and cortisol levels among lung cancer patients. 
Psychosomatic Medicine, 80(3), A83. 
5. Sephton, S.E., Hicks, A., Phillips, K., Siwk, C., Albert, C., Zimmaro, L., van der 
Gryp, K., & Salmon, P. (2018). A brief i-Pod-based mindfulness intervention for 
undergraduates: Effects on psychological and physiological outcomes. 
Psychosomatic Medicine, 80(3), A67. 
6. Siwik, C., Segerstrom, S., Phillips, K., Cash, E., Rebholz, W., Zimmaro, L., 
Hicks, A., van der Gryp, K., & Sephton, S.E. (2018). Associations of 
actigraphically measured daytime sedentariness and nighttime restfulness with 
waking and bedtime salivary cortisol levels. Psychosomatic Medicine, 80(3), 
A101. 
7. Siwik, C., Phillips, K., Salmon, P., Litvan, I., Filoteo, J.V., Rebholz, W., Cash, 
E., Hicks, A., van der Gryp, K., & Sephton, S.E. (2018). An MBSR intervention 
for Parkinson’s disease patients and caregiving partners: Effects on distress, social 
support, cortisol, and inflammation. Psychosomatic Medicine, 80(3), A128. 
8. van der Gryp, K., Siwik, C., Zimmaro, L., Phillips, K., Rebholz, W., Cash, E., 
Hicks, A., & Sephton, S.E. (2018). Lung cancer-related distress is associated with 
elevated mean diurnal cortisol levels. Psychosomatic Medicine, 80(3), A32. 
9. Cash, E., Rebholz, W., Albert, C., Fields, O., Zimmaro, L., Siwik, C., Phillips, K., 
Kloecker, G., & Sephton, S.E. (2017). Associations between the prognostic 
indicators rest/activity rhythm and diurnal cortisol profiles in patients with lung 
cancer. Brain, Behavior, and Immunity, 66, e31-e32. 
10. Phillips, K., Salmon, P., Siwik, C., Rebholz, W., Cash, E., Litvan, I., Filoteo, 
J.V., Kayser, K., & Sephton, S.E. (2017). A dyadic MBSR intervention for 
Parkinson’s disease patients/caregivers: Effects on distress, cortisol, and 
inflammation. Brain, Behavior, and Immunity, 66, e19-e20. 
11. Rebholz, W.N., Cash, E., Siwik, C., Phillips, K., Albert, C., Zimmaro, L., 
Dhabhar, F.S., Barve, S., & Sephton, S.E. (2017). Pro-inflammatory, chemotactic, 
and anti-inflammatory cytokine responses associate with HPA, but not SNS, 
function in lung cancer patients. Brain, Behavior, and Immunity, 66, e24. 
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12. Siwik, C., Rebholz, W., Phillips, K., Cash, E., Dhabhar, F.S., Barve, S., Zimmaro, 
L., & Sephton, S.E. (2017). Sense of coherence in lung cancer patients: 
Association with  
coping, immune function, and fatigue. Brain, Behavior, and Immunity, 66, e25. 
13. Zimmaro, L.A., Segerstrom, S., Cash, E., Siwik, C., Phillips, K., Rebholz, W., & 
Sephton, S.E. (2017). Moderating role of mindfulness on daily affect and cortisol 
in lung cancer patients. Psychosomatic Medicine, 79(4), A52-A52. 
14. Hicks, A.M., Salmon, P., Phillips, K., Zimmaro, L., Siwik, C., Bayley-Veloso, R., 
Cash, E., & Sephton, S.E. (2016). The role of mindfulness in stress and 
depression of undergraduate students. Psychosomatic Medicine, 78(3), A101-
A102. 
15. Phillips, K., Bayley-Veloso, R., Zimmaro, L.A., Siwik, C., Hicks, A.M., Cash, E., 
Salmon, P., & Sephton, S.E. (2016). Living situation and quality of life among 
cancer patients. Psychosomatic Medicine, 78(3), A73-A73. 
16. Siwik, C.J., Phillips, K., Zimmaro, L.A., Bayley-Veloso, R., Hicks, A., Cash, E., 
Salmon, P., & Sephton, S.E. (2016). Psychological and physiological effects of 
problem-focused and emotional approach to coping styles in gynecological cancer 
patients. Psychosomatic Medicine, 78(3), A60. 
 
CONFERENCE PRESENTATIONS (*Oral Presentation) 
 
1. Siwik, C.J., Phillips, K., Zimmaro, L., Cash, E., Hicks, A. & Sephton, S.E. (2019, 
March). The Relationship Between Shame, Guilt, and Depressive Symptoms and 
the Ameliorative Role of Self-compassion Among Lung Cancer Patients. 
American Psychosomatic Society 77th Annual Scientific Meeting, Vancouver, 
BC, Canada. 
2. *Hicks, A., Salmon, P., Rebholz, W., Phillips, K., Siwik, C., Zimmaro, L.A., 
Cash, E., van der Gryp., K., & Sephton, S. E. (2018, March). The Role of Self-
Compassion in a Stress-Health Pathway. Oral Session on Psychological 
Wellbeing, American Psychosomatic Society 76th Annual Scientific Meeting, 
Louisville, KY. 
3. *Phillips, K., Siwik, C., Salmon, P., Litvan, I., Filoteo, J.V., Rebholz, W., Cash, 
E., Hicks, A., van der Gryp, K. & Sephton, S.E. (2018, March). MBSR 
Intervention for Parkinson's Disease Patients and Caregiving Partners: Effects 
on Distress, Social Support, Cortisol, and Inflammation. Oral Session on 
Inflammation, American Psychosomatic Society 76th Annual Scientific Meeting, 
Louisville, KY. 
4. *Phillips, K., Salmon, P., Siwik, C., Rebholz, W., Cash, E., Litvan, I., Filoteo, 
J.V., Kayser, K., & Sephton, S.E. (2018, March). Associations Between Daily 
Affect, Intrusive Thoughts, and Cortisol Levels Among Lung Cancer Patients. 
Oral Session on Cancer, American Psychosomatic Society 76th Annual Scientific 
Meeting, Louisville, KY. 
5. Phillips, K., Siwik, C., Hicks, A., Salmon, P., Cash, E., Litvan, I., Filoteo, J.V., 
van der Gryp, K., & Sephton S.E. (2018, March). Exploration of dyadic 
associations of anxiety and diurnal cortisol among Parkinson’s disease 
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patient/caregiver dyads. American Psychosomatic Society 76th Annual Scientific 
Meeting, Louisville, KY. 
6. Sephton, S.E., Hicks, A., Phillips, K., Siwik, C., Albert, C., Zimmaro, L., van der 
Gryp, K.A. & Salmon, P. (2018, March). A brief iPod-based mindfulness 
intervention for undergraduates: Effects on psychological and physiological 
outcomes. American Psychosomatic Society 76th Annual Scientific Meeting, 
Louisville, KY. 
7. *Siwik, C. J., Segerstrom, S., Phillips, K., Cash, E., Rebholz, W., Zimmaro, L., 
Hicks, A., van der Gryp, K., & Sephton, S.E. (2018, March). Associations of 
Actigraphically Measured Daytime Sedentariness, Nighttime Restfulness, and 
Rest-Activity Rhythms with Daily Waking and Bedtime Salivary Cortisol Levels. 
Oral Session on Sleep, American Psychosomatic Society 76th Annual Scientific 
Meeting, Louisville, KY. 
8. van der Gryp, K., Siwik, C., Zimmaro, L., Phillips, K., Rebholz, W., Cash, E., 
Hicks, A., & Sephton, S.E. (2018, March). Lung Cancer-related Distress is 
Associated with Elevated Mean Diurnal Cortisol Levels. American 
Psychosomatic Society 76th Annual Scientific Meeting, Louisville, KY. 
9. Phillips, K., Siwik, C., Hicks, A., Salmon, P., Cash, E., Litvan, I., Filoteo, J.V., 
van der Gryp, K., & Sephton S.E. (2017, October). Exploration of dyadic 
associations of anxiety and diurnal cortisol among Parkinson’s disease 
patient/caregiver dyads. American Psychosomatic Society Mid-Year Meeting – 
“Emotions in Social Relationships: Implications for Health and Disease,” 
Berkeley, CA. 
10. Siwik, C., Phillips, K., Salmon, P., Litvan, I., Filoteo, V., Rebholz, W., Cash, E., 
Hicks, A., van der Gryp, K., & Sephton, S.E. (2017, October). An MBSR 
intervention for Parkinson’s disease patients and caregiving partners: Effects on 
distress, social support, cortisol and inflammation. American Psychosomatic 
Society Mid-Year Meeting – “Emotions in Social Relationships: Implications for 
Health and Disease,” Berkeley, CA. 
11. Cash, E., Rebholz, W., Albert, C., Fields, O., Zimmaro, L., Siwik, C., Phillips, K., 
Kloecker, G., & Sephton, S.E. (2017, June). Associations between the prognostic 
indicators rest/activity rhythm and diurnal cortisol profiles in patients with lung 
cancer. PsychoNeuroImmunology Research Society 24th Annual Scientific 
Meeting, Galveston, TX. 
12. *Phillips, K., Salmon, P., Siwik, C., Rebholz, W., Cash, E., Litvan, I., Filoteo, 
J.V., Kayser, K., & Sephton, S.E. (2017, June). A dyadic MBSR intervention for 
Parkinson’s disease patients/caregivers: Effects on distress, cortisol, and 
inflammation. Oral Session on Inflammation and Relationships Through the 
Lifespan, PsychoNeuroImmunology Research Society 24th Annual Scientific 
Meeting, Galveston, TX. 
13. Rebholz, W.N., Cash, E., Siwik, C., Phillips, K., Albert, C., Zimmaro, L., 
Dhabhar, F.S., Barve, S., & Sephton, S.E. (2017, June). Pro-inflammatory, 
chemotactic, and anti-inflammatory cytokine responses associate with HPA, but 
not SNS, function in lung cancer patients. PsychoNeuroImmunology Research 
Society 24th Annual Scientific Meeting, Galveston, TX. 
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14. Siwik, C., Rebholz, W., Phillips, K., Cash, E., Dhabhar, F.S., Barve, S., Zimmaro, 
L., & Sephton, S.E. (2017, June). Sense of coherence in lung cancer patients: 
Association with coping, immune function, and fatigue. PsychoNeuroImmunology 
Research Society 24th Annual Scientific Meeting, Galveston, TX. 
15. Zimmaro, L.A., Segerstrom, S., Cash, E., Siwik, C., Phillips, K., Rebholz, W., & 
Sephton, S.E. (2017, March). Moderating Role of Mindfulness on Daily Affect and 
Cortisol in Lung Cancer Patients. American Psychosomatic Society 75th Annual 
Scientific Meeting, Sevilla, Spain. 
16. Hicks, A., Salmon, P., Phillips, K., Zimmaro, L., Siwik, C., Bayley-Veloso, R., 
Albert, C., Fields, O., Cash, E., & Sephton, S.E. (2016, March). The role of 
mindfulness in stress and depressive symptoms of undergraduate students. 
American Psychosomatic Society 74th Annual Scientific Meeting, Denver, CO.  
17. Phillips, K., Bayley-Veloso, R., Zimmaro, L.A., Siwik, C., Hicks, A.M., Cash, E., 
Salmon, P., & Sephton, S.E. (2016, March). Does living situation affect stress and 
health outcomes among cancer patients?  American Psychosomatic Society 74th 
Annual Scientific Meeting, Denver, CO.  
18. Siwik, C., Phillips, K., Zimmaro, L.A., Bayley-Veloso, R., Hicks, A., Cash, E., 
Salmon, P., & Sephton, S.E. (2016, March). Psychological and physiological 
effects of problem-focused and emotional approach to coping styles in 
gynecological cancer patients. American Psychosomatic Society 74th Annual 
Scientific Meeting, Denver, CO. 
19. Siwik, C., Hoks, R.M., Walsh, E., & Abercrombie, H.C. (2014, May). Memory 
Formation: Moments Matter. University of Wisconsin, Madison Undergraduate 
Honors Symposium, Madison, WI. 
20. *Siwik, C. (2012, May). Emotional Memory: Effects of Valence, Modality, and 
Distraction. University of Wisconsin, Madison Experimental Psychology 
Symposium, Madison, WI.  
 
LAB AND DATA ANALYTIC SKILLS 
 
fMRI 




Experience in collecting, preparing, processing, and preserving human saliva samples. 
Proficient in cortisol data cleaning and reduction. 
 
Immunology and Cellular Aging 
Experience in processing and preserving serum and plasma human blood samples. 
Experience preparing and preserving whole blood samples for stimulated analysis. 
 
Circadian Rhythms 
Experience in initializing and downloading MicroMini Motionlogger Actiwatches. 
 
Data Analysis 
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Experience conducting univariate and multivariate analyses, structural equation 
modeling, and survival analyses. Experience using the following statistical software: 
SPSS, AMOS. Experience in REDCap and Qualtrics data capture systems. 
 
HONORS, AWARDS & SCHOLARSHIPS 
 
March 2018  Selected to Present Orally at a Session on Sleep 
American Psychosomatic Society 76th Annual Scientific 
Meeting, Louisville, KY 
 
Fall 2017  Graduate Network in Arts and Sciences Research Fund 
Award 
    University of Louisville, Louisville, KY 
 
Summer 2017 Graduate Student Council Travel Award 
    University of Louisville, Louisville, KY 
 
Spring 2016   Research Presentation Selected for Citation Poster 
Award 
    American Psychosomatic Society, Denver, CO 
 
Spring 2016   Graduate Student Council Travel Award 
    University of Louisville, Louisville, KY 
 
Spring 2016 Graduate Network in Arts and Sciences Research Fund 
Award 
    University of Louisville, Louisville, KY 
 
Spring 2013   Dean’s List 
    College of Arts and Sciences 
    University of Wisconsin, Madison, Madison, WI 
 
Fall 2012    UW Alumni Association Study Abroad Scholarship 
    University of Wisconsin, Madison, Madison, WI 
 
MULTICULTURAL AND DIVERSITY TRAINING 
 
Fall 2015, 2018  Safe Zone Training 
    LGBT Center 
    University of Louisville, Louisville, KY 
 
This two-part workshop was designed to provide university community members the 
tools and resources needed to understand LGBTQ+ students and colleagues, and how to 
appropriately create a welcoming, affirming environment for all. Provided valuable 
information on how to advocate for individuals who identify as LGBTQ+ and 
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psychoeducation on common misconceptions, defining terms, and outlining risk factors 
for mental health disparities.  
 
May 2017   Operation Immersion 
    Wendell H. Ford, Regional Training Center, Greenville, 
KY 
 
Attended a four-day/night intensive training for healthcare providers to become immersed 
in military culture and explore issues unique to service members, veterans, and their 
families. Hosted by the Kentucky Army National Guard, this immersion required 
overnight stay in barrack-like quarters to simulate day-to-day military culture. Education 
activities geared toward behavioral health for active military and veterans accounted for a 
significant portion of the day. 
 
Jan. 2017   White Allies Training  
    Multicultural Center 
    University of Louisville, Louisville, KY 
 
Individuals from primarily white backgrounds gathered together to recognize the need for 
and brainstorm actions to be taken to protect and minimize discrimination against 
minorities, both on campus and in the greater Louisville community. 
 
Dec. 2016 Tier One Training: The Impact of Deployment on 
Service Members and Their Families 
    Center for Deployment Psychology  
Star Behavioral Health Providers 
Indiana Family and Social Services Administration, New 
Albany, IN 
 
A one-day training geared toward training of civilian behavioral health providers in 
military specific culture, the deployment cycle, and treatments that focus on the needs of 
the military population. 
 
Jan. 2016   Diversity Workshop 
    College of Arts and Sciences 
    University of Louisville, Louisville, KY 
 
This workshop provided opportunity for graduate students and faculty members to gather, 
discuss, and think critically about diversity in the classroom. Topics included power 




CLINICAL TEACHING EXPERIENCE 
 
Current   Co-Instructor 
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    Intellectual and Cognitive Assessment 
    University of Louisville, Louisville, KY 
 
Taught clinical psychology graduate students how to conduct intellectual assessments. 
Supervised graduate students’ first administration of WAIS-IV and WISC-V. Provided 
extensive and corrective feedback on administration, scoring, and report writing. 
 
Summer 2017, 2018  Co-Instructor 
    Interview Skills 
    University of Louisville, Louisville, KY 
 
Taught clinical psychology graduate students introductory material to interviewing and 
clinical and multicultural competence. Provided direct supervision of graduate students’ 
first therapy intake interview.  
 
Spring 2018   Co-Instructor 
    Intellectual and Cognitive Assessment 
    University of Louisville, Louisville, KY 
 
Taught clinical psychology graduate students how to conduct intellectual assessments. 
Supervised graduate students’ first administration of WAIS-IV and WISC-V. Provided 
extensive and corrective feedback on administration, scoring, and report writing. 
 
RESEARCH TEACHING EXPERIENCE 
 
Sept. 2018 - Current  Graduate Student Mentor 
    Undergraduate Honors Thesis 
“Hashtag F.O.M.O.: Understanding the Relationships 
Between Mental Health, Social Media Use, and the Fear of 
Mission Out Phenomenon” 
Psychological and Brain Sciences 
    University of Louisville, Louisville, KY 
Student: Abigail Fischbach 
 
I am currently mentoring an undergraduate student through the yearlong process of 
designing, analyzing, drafting, and defending an honors thesis.  
 
Summer 2018   Graduate Student Mentor 
    NCI R25 Cancer Education Program 
“Factors Related to Cancer Patients’ Willingness to 
Participate in an iPod-based MBSR Intervention” 
School of Medicine 
    University of Louisville, Louisville, KY 
Student: Tessa Blevins 
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Mentored an undergraduate student through a National Cancer Institute (NCI)-funded 10-
week summer program. Demonstrated the scientific process and assisted with the steps 
required to design and present a poster at a local conference.  
 
Sept. 2017 – May 2018 Graduate Student Mentor 
    Undergraduate Honors Thesis 
“Mindfulness, Psychological Distress, and Cognitive 
Functioning Among University Students” 
Psychological and Brain Sciences 
    University of Louisville, Louisville, KY 
Student: Samantha Melton 
 
Mentored an undergraduate student through the yearlong process of designing, analyzing, 
drafting, and defending an honors thesis.  
 
ACADEMIC TEACHING EXPERIENCE 
 
Summer 2018   Lecturer 
Topic: Stress, Health, and Resilience: Optimizing Quality 
and Quantity of Life 
    Course: Undergraduate Human Development 
    University of Louisville, Louisville, KY 
 
Spring 2017   Lecturer 
    Topic: Pain, the Brain, and Culture 
    Course: Graduate Cultural Neuroscience 
    University of Louisville, Louisville, KY 
 
Spring 2017   Graduate Teaching Assistant 
    Course: Physiological Psychology 
    University of Louisville, Louisville, KY 
 
Oct. 2016   Lecturer 
    Topic: Sensorimotor Function 
    Course: Physiological Psychology 
    University of Louisville, Louisville, KY 
 
September 2016  Lecturer 
    Topic: Neural Anatomy 
    Course: Physiological Psychology 
    University of Louisville, Louisville, KY 
 
Fall 2016   Graduate Teaching Assistant 
    Courses: Physiological Psychology; Personality 
    University of Louisville, Louisville, KY 
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Summer 2016   Graduate Teaching Assistant 
Courses: Physiological Psychology; Intro to Neuroscience; 
Abnormal Psychology 
    University of Louisville, Louisville, KY 
 
2015 - 2016   Graduate Teaching Assistant Academy 
    School of Interdisciplinary and Graduate Studies 
    University of Louisville, Louisville, KY 
 
Participated in a yearlong teaching academy designed to assist graduate teaching 
assistants develop knowledge, skills, and excellence in the classroom. Partook in 
interactive workshops with faculty mentors selected for their expertise in teaching. 
Learned scholarly and conceptual frameworks for understanding “today’s” students, 
practical teaching strategies, and scholarship of teaching and learning.  
 
Spring 2016   Graduate Teaching Assistant 
    Courses: Personality Psychology; Abnormal Psychology 
    University of Louisville, Louisville, KY 
 
Fall 2015   Graduate Teaching Assistant 
    Courses: Abnormal Psychology 
    University of Louisville, Louisville, KY 
 
PROFESSIONAL ACTIVITIES, LEADERSHIP & SERVICE 
 
2018 – Current  Graduate Student Cohort Liaison 
    Psychological and Brain Sciences 
    University of Louisville, Louisville, KY 
 
Serve as a representative of the 4th year Clinical Psychology Doctoral Student cohort. 
Communicate with peers regarding program-wide issues and ensure concerns are 
effectively communicated to faculty. 
 
Jan. 2019   Abstract Reviewer 
    National Conference of Undergraduate Research (NCUR) 
    Kennesaw State University, Kennesaw, GA 
 
May – Aug. 2018  Graduate Student Advocate 
    Diversity Recruitment and Retention Committee  
    Psychological and Brain Sciences 
    University of Louisville, Louisville, KY 
 
Serve as a graduate student advocate for greater inclusion of underrepresented minorities 
in the doctoral psychology programs at the University of Louisville and in higher 
education more broadly. Collaborate with faculty and graduate peers to discuss goals, 
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outline strategies, and formalize plans to increase and improve recruitment and retention 
of diverse students and faculty within our department.  
 
 
Aug. 2016 – Aug. 2018 Graduate Student Ambassador 
    School of Interdisciplinary and Graduate Studies 
    University of Louisville, Louisville, KY 
 
Assisted the graduate school with recruitment and retention efforts. Provided other 
graduate students with networking and professional development opportunities and skills. 
Assisted with the organization and implementation of graduate student orientations and 
graduation ceremonies. 
 
Aug. 2017 – May 2018 Colloquium Development and Community Liaison 
Clinical Psychology Professional Development Series 
    Department of Psychological and Brain Sciences 
    Noble H. Kelley Psychological Services Center 
    University of Louisville, Louisville, KY 
 
Communicated with behavioral health professionals in the Louisville community to 
coordinate the colloquium series for the 2017-2018 academic year. Attendance that is 
required by all clinical psychology doctoral students, the colloquium series is designed to 
expand on student and faculty knowledge of community resources and facilitate 
professional development. Collected and organized APA-accredited materials including 
presentation aims, CVs, and assessment measures in order to provide faculty with 
continued education credits.  
 
Oct. 2017   Ad-Hoc Reviewer 
    Journal of Health Psychology 
 
April 2017   Poster Judge 
    Kentucky Psychological Association  
    Spring Academic Conference 
    Spalding University, Louisville, KY 
 
Nov. 2016   Abstract Reviewer 
American Psychosomatic Society 75th Annual Scientific 
Meeting 
Sevilla, Spain 
     
Fall 2016   Co-facilitator 
    20 Minutes of Mindfulness 
    Health Promotions Office 
    Campus Health Services 
    University of Louisville, Louisville, KY 
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Co-facilitated a university-wide initiative aimed at decreasing stress and improving 
coping and health among undergraduate students through brief mindfulness-based 
intervention. 
 
April 2016   Poster Judge 
    Kentucky Psychological Association 
    Spring Academic Conference 
    Georgetown College, Georgetown, KY 
 
Sept. 2015   Psychological Services Center Representative 
    Community Outreach at Health and Wellness Fair 
    Baptist Church, Louisville, KY 
 
Spring 2012   Volunteer Tutor 
    Schools of Hope, Madison, WI 
 
Volunteered for the community initiative aimed at reducing the academic achievement 
gap between students of color and their white peers. Paired one-on-one with students to 
ensure adequate preparation for successful completion of academic requirements. Created 
weekly lesson plans and interactive games to improve literacy and math skills of 
bilingual students ranging from 5 – 11 in age. Portrayed academic role model 
characteristics. 
 
COMMUNITY & OTHER PRESENTATIONS 
 
1. Siwik, C. J. & Mier-Chairez, J. (2018, June). Stress and Coping. Summer Health 
Professions Education Program (SHPEP). University of Louisville, Louisville, 
KY. 
2. Siwik, C. J. (2018, April). Stress, Health, and Resilience: Optimizing Quality and 
Quantity of Life. Oral Session, Clinical Psychology Department Faculty Meeting. 
University of Louisville, Louisville, KY. 
3. Siwik, C. J., Segerstrom, S., Phillips, K., Cash, E., Rebholz, W., Zimmaro, L., 
Hicks, A., van der Gryp, K., & Sephton, S.E. (2018, April). Associations of 
Actigraphically Measured Daytime Sedentariness, Nighttime Restfulness, and 
Rest-Activity Rhythms with Daily Waking and Bedtime Salivary Cortisol Levels. 
Oral Session, Graduate Student Brown Bag Series. University of Louisville, 
Louisville, KY. 
4. Siwik, C. & Phillips, K. (2018, April).  Implementing Self-compassion Skills 
Among Veteran Women. Athena’s Sisters – Support group for women veterans, 
Louisville, KY. 
5. Siwik, C. & Phillips, K. (2017, September). Coping with Symptoms of Anxiety 
and  
Depression in the Context of Chronic Illness. Better Breathers Club – Support 
group for individuals with chronic lung disease, University of Louisville School 
of Medicine, Louisville, KY. 
 




Feb. 2017   Writing a Literature Review Workshop 
    School of Interdisciplinary & Graduate Studies 
    University of Louisville, Louisville, KY 
 
Spring 2016   Entrepreneurship Academy 
    School of Interdisciplinary and Graduate Studies 
    University of Louisville, Louisville, KY 
 
Participated in a semester-long academy aimed to teach entrepreneurial thinking and 
skills. Session topics included entrepreneurial thinking, the business model canvas, 
learning to launch, and social entrepreneurship.  
 
May 2016   Mindfulness Counseling Meeting 
    Earth and Spirits Center, Louisville, KY 
 
Attended a mindfulness-based practice and discussion among other mental health 
professionals regarding personal and professional meditation practice. 
 
March 2016   Resilient Families Training Program 
Hotel Louisville, Louisville, KY 
    Facilitator: Dr. Barbara Burns, Ph.D. 
     
Attended a workshop on the Resilient Families Project to learn how science on resilience 
has informed new approaches to supporting the well being of children from families 
facing trauma, stress, and adversity. 
 
Fall 2015   Mindfulness-based Stress Reduction (MBSR) Program 
    Earth and Spirits Center, Louisville, KY 
 
Attended a comprehensive 8-week MBSR program to actively learn by doing. The 
program facilitated integration of meditation practice, observation of group-based 
meditation to inform clinical application. 
 
Nov. 2015 Understanding the Gut Brain: Stress, Appetite, 
Digestion and Mood Workshop 
    Institute for Brain Potential, Lexington, KY 
Facilitator: Dr. Merrily Kuhn, RN, Ph.D., ND 
 
Attended a daylong seminar on the enteric nervous system and its pivotal role in 
regulating inflammation, stress, metabolism, appetite and mood. The workshop 
elucidated the mind-body connection by discussing the effects of stress on digestive and 
gastrointestinal disorders. 
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PROFESSIONAL AFFILIATIONS AND HONOR SOCIETIES 
 
2016 – 2018   American Psychosomatic Society 
 
2014 – 2018   Psi Chi, The International Honor Society in Psychology  
 
2017 – 2018   Kentucky Psychological Association 
 
2017 – 2018   American Psychological Association
